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Background:  As the population ages and cancer survival improves, the incidence of multiple 
primary cancers (MPC) is increasing. Several studies have documented poorer health outcomes 
among adults with MPC compared to single-cancer survivors. However, there is a paucity of 
research focused on understanding factors linking MPC to poor health outcomes and identifying 
individual (e.g., personality, sociodemographic, clinical) factors that increase risk. 
Purpose:  The purpose of this study was to test a psychobehavioral stress-response model to 
identify factors associated with MPC health outcomes. We aimed to: 1) test the hypothesized 
model, examining linear relations among six latent variables: perceived stress, psychological 
response, behavioral response, financial toxicity, social health, and physical health; 2) explore 
associations between individual characteristics and upstream latent variables; and 3) describe 
self-management behaviors of MPC survivors. 
Methods:  This cross-sectional study included MPC survivors recruited through a regional 
tumor registry whose first cancers (stages I-III) were diagnosed within 1-10 years. Data were 
collected via 1) a battery of validated questionnaires to measure latent variables and covariates; 
2) tumor registry records; and 3) medical records. Structural equation modeling was performed
to fit and modify the measurement model, specify the full SEM, and identify significant 
covariates. Descriptive statistics were conducted to characterize self-management. 
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Results:  211 participants completed questionnaires. Data fit a four-factor modified 
measurement model linking self-management, distress, financial toxicity, and functional health. 
Overweight BMI, graduate education, less neuroticism, and increased social support predicted 
better self-management. Poorer self-management, greater neuroticism, and lower social 
support predicted increased distress. Greater distress predicted financial toxicity. Greater 
distress and financial toxicity predicted poorer functional health. Scores for positive self-
management were generally high; obesity rates were above published norms. 
Conclusions:  MPC survivors with higher risk BMI, less education, greater neuroticism, and 
lower social support should be considered at risk for poorer self-management and negative 
health outcomes. Self-management behaviors and distress are potentially modifiable 
intervention targets to reduce financial toxicity and improve functional health. Future research 
should evaluate the model with a focus on developing the science of MPC self-management 
and financial toxicity and include longitudinal assessments to identify critical times of increased 
vulnerability during MPC survivorship. 
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1.0 PROPOSAL INTRODUCTION 
1.1 SPECIFIC AIMS 
As the cancer survivor population ages and cancer survival improves (American Cancer 
Society, 2017; Bluethmann, Mariotto, & Rowland, 2016; Jemal et al., 2017), the incidence of 
subsequent primary cancer diagnoses in cancer survivors is increasing. Affecting approximately 
3 million Americans, nearly one in five cancers diagnosed in the United States occurs in an 
individual with a previous cancer diagnosis (Morton, Onel, Curtis, Hungate, & Armstrong, 2014). 
These multiple primary cancers (MPC), ≥2 histologically distinct primary cancer diagnoses that 
have been ruled out as being metastatic disease (Begg, 1999), are a leading cause of morbidity 
and mortality among cancer survivors. Previous large sample studies have established that 
MPC survivors, compared to single cancer survivors and healthy (no cancer) controls, have 
increased risk for poor health outcomes including psychological distress, risky health behaviors, 
and negative physical health outcomes (Andrykowski, 2012; Burris & Andrykowski, 2011; 
Dowling et al., 2013; Gotay, Ransom, & Pagano, 2007; Thong et al., 2013).  
Lazarus and Folkman classically defined perceived stress as the perception that one’s 
demands exceed his or her coping resources (Lazarus & Folkman, 1984). Cancer patients face 
demands throughout the cancer continuum that may be perceived as exceeding their coping 
resources (e.g., cancer diagnosis, treatment, and/or persistent symptoms). Resulting perceived 
stress can produce a cascade of psychological, behavioral, and biologic responses that 
negatively impact health outcomes (Bode, Hahn, Devellis, & Cella, 2010). The proposed 
conceptual model for this study (see Figure 1) is informed by biobehavioral frameworks, which 
have contributed to research identifying pathways linking stress to poor outcomes (Andersen, 
Kiecolt-Glaser, & Glaser, 1994; Andersen et al., 2008; Bower & Lamkin, 2013; Cohen, Kessler, 
& Underwood Gordon, 1995; Sherwood et al., 2008). This study will be the first to apply this 
type of framework to MPC research, providing opportunities to 1) guide early identification of 
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MPC survivors most vulnerable to persistent stress and 2) identify important pathways (i.e., 
possible intervention points) that contribute to the cascade of negative health outcomes 
observed in this patient population (Grady & Gough, 2014; Grey, Knafl, & McCorkle, 2006; 
Grey, Schulman-Green, Knafl, & Reynolds, 2015). 
Our preliminary work, building on early MPC literature, has demonstrated that, compared 
to single cancer survivors, adults with MPC generally experience higher levels of stress (Gotay 
et al., 2007), report poorer psychological well-being (Andrykowski, 2012; Belcher et al., 2017; 
Belcher, Hausmann, Cohen, Donovan, & Schlenk, 2016; Burris & Andrykowski, 2011; Gotay et 
al., 2007; Thong et al., 2013), engage in more negative health behaviors (Burris & Andrykowski, 
2011), and are at increased risk for poor health outcomes (Andrykowski, 2012; Belcher et al., 
2015; Dowling et al., 2013; Gotay et al., 2007; Thong et al., 2013). Our work also complements 
previous findings that MPC survivors live with cancer as a chronic illness (Belcher et al., 2017; 
Gotay et al., 2007; Thong et al., 2013). Importantly, prolonged perceived stress has been shown 
Figure 1. Conceptual model. This figure depicts the cascade of 
psychological, behavioral, and biologic responses to perceived 
stress that can negatively impact health outcomes in adults with 
multiple primary cancers. Biologic responses and pathways will 
be investigated in future study. 
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to increase susceptibility to negative physical health outcomes (Cohen et al., 1995; Cohen, n.d.; 
G. E. Miller, Cohen, & Ritchey, 2002; O’Connor et al., 2009). However, little is known about the 
characteristics that put individual MPC survivors at risk for prolonged perceived stress or the 
psychological and behavioral pathways that could serve as targets for self-management 
interventions to improve health outcomes in MPC survivors. 
This proposed conceptual model is informed by several biobehavioral frameworks, which 
have contributed to research identifying pathways linking stress to poor health outcomes 
(Andersen et al., 1994; Andersen et al., 2008; Bower & Lamkin, 2013; Cohen et al., 1995; 
Sherwood et al., 2008). However, these models have not yet been applied to MPC research. 
Important weaknesses in MPC survivorship research to date include: 1) a lack of attention to 
who among the many survivors of MPC are at increased risk for poor health outcomes; 2) 
inattention to consistent, valid perceived stress measurement; and 3) an almost exclusive focus 
on negative behavioral responses without attention to positive behavioral responses (i.e., self-
management). Robust self-management literature in chronic illness (Grady & Gough, 2014; 
Grey et al., 2015; Lorig & Holman, 2003) and general cancer (Chen et al., 2015; Hammer et al., 
2015; McCorkle et al., 2011; Miller, Bowen, Croyle, & Rowland, 2009; Risendal et al., 2015) 
supports the premise that identification of characteristics of MPC survivors most at risk of poor 
health outcomes and factors that promote positive self-management behavioral responses will 
advance MPC science toward early risk identification and interruption of negative stress 
response pathways. It has been demonstrated in the literature that MPC survivors are at 
increased risk for poor health outcomes compared to their single cancer counterparts. This 
study will advance the science to begin to elucidate who among MPC survivors is at greatest 
risk and why.   
My long-term goal is to develop a program of cancer survivorship research focused on 
the development of strategic self-management interventions to interrupt biobehavioral stress 
response pathways in at-risk survivors of MPC. The overarching purpose of this dissertation 
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study, and the first step in my program of research, is to test the proposed conceptual model to 
better understand the components that impact health outcomes in persons with a history of 
MPC diagnoses. This study aims to answer the following research question: Does the 
proposed conceptual model explain poor health outcomes in persons with MPC? Our central 
hypothesis is that survivors of MPC are exposed to a wide range of cancer- and treatment-
related stressors that are associated with persistent perceived stress and result in a cascade of 
psychological (e.g., depression, anxiety), behavioral (i.e., lack of positive self-management and 
risky behaviors), and biologic responses that are associated with poor health outcomes (i.e., 
physical, financial, and social). The rationale underlying the proposed research is that positive 
self-management behaviors have the potential to interrupt these negative pathways and to 
reduce negative impact after an MPC diagnosis. By elucidating mechanisms and identifying 
characteristics of MPC survivors with high risk for poor health outcomes, findings from this study 
will provide the basis for future studies that will include development of targeted self-
management interventions, interventions to trigger appropriate screening in high risk MPC 
patients, and incorporate important biological pathways known to impact health outcomes. 
Specifically, in a cross-sectional sample of n=440 adults with a history of multiple (i.e., 
two or more) primary cancers, we will pursue the following specific aims: 
Aim 1: Determine whether the proposed conceptual model fits data collected from MPC 
survivors. 
Aim 1a:  Evaluate whether the proposed overall model adequately explains variation in 
health outcomes among adults with MPC. 
Aim 1b: Evaluate whether post-hoc model modifications based on previous cancer 
literature and sample data improve model fit and parsimony. 
Exploratory Aim 2: Identify additional individual characteristics (i.e., clinical, personal, and 
sociodemographic) that contribute to improved model fit.  
Exploratory Aim 3:  Describe the self-management behaviors used by MPC survivors. 
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1.2  BACKGROUND, SIGNIFICANCE, AND INNOVATION 
1.2.1 Background 
The National Academy of Medicine, the American Cancer Society, cancer survivorship 
advocates, clinicians, and scientists have called for an increased focus on addressing the health 
and psychosocial needs of cancer survivors (American Cancer Society, 2016; Klein et al., 2014; 
Miller et al., 2016; Mullan, 1985, 2016; National Academy of Sciences, 2006), and survivors of 
MPC represent a growing, understudied, and at-risk group in critical need of additional research. 
The current number of cancer survivors living in the United States, 15.5 million, is 
projected to increase to 26.1 million by 2040, and the cancer survivor population is aging 
(American Cancer Society, 2017; Bluethmann et al., 2016; Jemal et al., 2017). With improved 
survival and increased age, however, comes the risk of developing a wide range of late effects 
of cancer and cancer treatment including the development of second cancers. As compared to 
those in the general population without a cancer diagnosis, cancer survivors face a 14% higher 
risk of developing a new primary cancer (Fraumeni, Curtis, Edwards, & Tucker, 2006). The 
observed increased risk is likely attributable to complex interactions among risk factors, 
including factors ranging from age at, and site of, first diagnosis, carcinogenic effects of cancer 
treatment, and genetic susceptibility (most pronounced in childhood survivors) to cumulative 
environmental exposures and lifestyle factors (e.g., smoking, alcohol use) in adult survivors 
(American Cancer Society, 2016; Fraumeni et al., 2006; Morton et al., 2014). Cancers 
specifically linked to the risk of subsequent cancer diagnoses include Hodgkin’s lymphoma, 
non-Hodgkin’s lymphoma, select solid tumors (i.e., prostate, testicular, ovarian, breast, and 
cervical), and childhood cancers (American Cancer Society, 2012; Meadows et al, 2009). The 
National Cancer Institute reports that one in five cancers diagnosed in the United States will 
occur in someone who has a previous cancer diagnosis, and MPCs are a major cause of 
morbidity and mortality in cancer survivors (De Gonzalez et al., 2011; Morton et al., 2014; 
National Cancer Institute, n.d.-a). 
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Diagnoses, disease- and treatment-related effects, and care transition points (e.g., 
transition to survivorship, recurrence, and end of life) commonly result in varying levels of 
distress for cancer patients (National Comprehensive Cancer Network, 2015); 20-47% of cancer 
patients with new and recurrent cancer diagnoses experience significant distress (Holland et al, 
2013). Literature from various countries estimates mood disorders are experienced by 30-40% 
of cancer patients in acute care settings experience (Mitchell, Lancet 2011), and 10.3-14.9% of 
individuals with cancer experience anxiety and depression, respectively (Holland et al, 2013; 
Jacobsen & Andrykowski, 2015). These rates are critically important, as distress has been 
linked to cancer therapy nonadherence, increased difficulty in treatment decision making, poorer 
quality of life (QOL), poorer adherence to cancer surveillance screening recommendations, and 
poorer health behaviors (Holland et al, 2013). However, most cancer research related to 
psychological distress has been conducted irrespective to number of cancer diagnoses.  
There is a robust body of literature documenting associations between stress and 
negative health outcomes (Cohen, Tyrrell, & Smith, 1991; Kiecolt-Glaser, Marucha, Malarkey, 
Mercado, & Glaser, 1995; Matthews & Gump, 2002; Pace, Hu, & Miller, 2007; Pyykkönen et al., 
2010; Sandberg et al., 2000). In cancer specifically, distress is known to be associated with 
cancer diagnosis, treatment, and persistent symptoms (Holland et al., 2013; Jacobsen & 
Andrykowski, 2015; Mitchell et al., 2011; National Comprehensive Cancer Network, 2015). We 
posit that negative psychobehavioral and biologic responses may be more severe in those with 
MPC, influencing the negative outcomes previously described in the literature. Importantly, 
findings are indicative of chronic illness in MPC survivors, and prolonged stress has been 
shown to decrease immune cell sensitivity to cortisol and increase pro-inflammatory cytokines 
and susceptibility to poor health outcomes (Cohen et al., 1995; Cohen, n.d.; Miller et al., 2002; 
O’Connor et al., 2009). The importance of biological response pathways is recognized and will 
be a source of inquiry for future research studies. 
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Self-management was first described as the work of living with a chronic illness (e.g., 
medical management, behavioral management, and emotional management) (Corbin & 
Strauss, 1988). MPC survivors live with cancer as a chronic illness (Belcher et al., 2017; Gotay 
et al., 2007; Thong et al., 2013). As cancer conceptualization has shifted from acute to chronic 
disease management, responsibility for day-to-day management has been gradually shifting 
from providers to individuals (Barlow, Wright, Sheasby, Turner, & Hainsworth, 2002; Green 
McDonald, O’Connell, & Lutgendorf, 2013; Klein et al., 2014; McCorkle et al., 2011). Thus, it is 
becoming ever more critical to determine trends in self-management, determine associations 
between self-management and other key variables, and eventually optimize individuals’ ability to 
effectively manage health in the MPC survivor population. 
No prior work has examined how MPC survivors self-manage their health. The proposed 
study directly addresses a National Institute of Nursing Research (NINR) priority to advance 
self-management science and dissemination of results for clinical translation (Grady & Gough, 
2014). By assessing self-management behaviors, incorporating recommended common data 
elements for self-management research, and evaluating associations between self-
management and health outcomes in MPC survivors, the proposed study will address public 
health and clinical priorities of self-management in chronic disease as identified by the 
Department of Health and Human Services, the National Academy of Medicine, the NINR, 
Oncology Nursing Society, and the American Cancer Society (Grady & Gough, 2014; Knobf et 
al., 2015; National Cancer Survivorship Resource Center, n.d.). Additionally, tailored self-
management interventions have been shown to provide positive benefit in varying ethnic, 
geographic, and age groups, making this research promising in its applicability to diverse 
populations of MPC survivors (Grady & Gough, 2014). 
The proposed research study, the first step in a planned program of research, is critically 
important to advance the state of the science in the growing population of vulnerable survivors 
of MPC. The proposed study will contribute to the field of cancer survivorship research by being 
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the first to identify associations among key pathways that lead to health outcomes and by 
identifying the behaviors MPC survivors use to manage their health. Findings from this study will 
assist clinicians and researchers in identifying MPC survivors at greatest risk for poor outcomes 
and will identify modifiable targets for future intervention development. Timely, targeted self-
management interventions guided by the findings from this study could reduce long-term health 
problems experienced by this population. Future studies will also examine biological pathways 
to further elucidate mechanisms resulting in poor health outcomes. The long-term research goal 
is to create an innovative program of research focused on the development of strategic self-
management interventions to interrupt stress response pathways and optimize wellness in 
survivors of MPC. 
1.2.2 Significance 
The proposed study is significant and timely because it will address gaps in MPC literature and 
add to the currently limited knowledge regarding risk factors for poor health outcomes in the 
rapidly expanding MPC survivor population. Additionally, the healthcare system is requiring 
increasing levels of disease self-management, making the previously undescribed self-
management variable key in understanding psychobehavioral mechanisms in the MPC survivor 
population. Clinically, this research has the potential to guide early identification of MPC 
survivors most vulnerable to prolonged stress and the associated cascade of negative health 
outcomes, providing a potential health promotion opportunity early on in a person’s illness 
trajectory. Identified risk and protective factors for MPC survivors can then be used by 
researchers to as behavioral targets to pave the way for future, targeted intervention work.  
1.2.3 Innovation 
We argue that both the current conceptualization of cancer survivorship and practices that 
traditionally do not include the potential impact of MPC (e.g., often excluding MPC survivors 
from clinical trials), is doing a disservice to MPC survivors and has resulted in a dearth of 
knowledge that impacts over one million people in the United States.  
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Previous MPC studies have lacked theoretical underpinnings to guide their research. 
This study is innovative because it will be the first study to employ a biobehavioral stress 
response framework and the first to begin to describe mechanisms underlying poor health 
outcomes in adult MPC survivors. This cross-sectional study will establish the groundwork for 
future longitudinal studies using this framework to investigate novel 1) biological pathways 
resulting in poor health outcomes and 2) temporal associations among variables. We will be the 
first to recruit a sample of MPC survivors to identify clinical, personal, and sociodemographic 
characteristics associated with perceived stress, paving the way for early identification of at-risk 
patients and potential targets for future interventions. Assessing self-management behaviors 
among MPC survivors is novel and provides information on whether interventions to promote 
self-management could be a potential avenue for optimizing health among MPC survivors.  
1.3 PRELIMINARY STUDIES 
1.3.1 State of the science (manuscript #1 in 3.1) 
The first major step in establishing the state of the science for MPC survivors included a review 
and synthesis of the literature to determine the relationship between MPC diagnoses and 
psychological distress in adult cancer survivors (S.M. Belcher et al., 2016). We hypothesized 
that, compared to single cancer survivors, persons with MPC diagnoses would report higher 
psychological distress. Effect size (ES) values were calculated using Cohen's d. Across the five 
studies included in this study, we found that MPC survivors, when compared with single cancer 
survivors, had lower global QOL (d = 0.32–0.37), poorer emotional role function and stress (d = 
0.08–0.20), greater and more frequent distress (d = 0.11–0.37), and greater anxiety symptoms 
(d = 0.15). Differences between MPC survivors and single cancer survivors were more variable 
for depressive symptoms (d = 0.01–0.22), and no statistically significant differences between 
MPC and single cancer groups were identified for sleep or suicidal ideation. Supporting our 
original hypothesis, effect sizes reflect small but potentially significant higher psychological 
distress in survivors of MPC compared with survivors of a single cancer.  
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1.3.2 Expansion of conceptual model 
As the proposed conceptual model expanded (Figure 1), subsequent MPC literature searches 
included the addition of the following key model concepts: perceived stress; behavioral 
responses, health behaviors, self-management, risk behaviors; physical health outcomes; 
financial toxicity; social health/social role function. Only one additional article (Dowling et al., 
2013) was identified. In this study, MPC was found to be a consistent predictor of disease 
burden, including physical function limitations and lost productivity. 
1.3.2.1 Financial toxicity. We used WRITE Symptoms® data to conduct an exploratory 
analysis to compare measures of QOL, including well-being, social support, and financial 
vulnerability, between women with recurrent ovarian cancer with and without more than one 
additional cancer diagnosis (Belcher et al., 2015).  
Methods. Design: A secondary analysis of data from a completed three-arm randomized 
controlled trial (RCT) of a Web-based symptom management study of women with recurrent 
ovarian cancer. Sample: Participants (N= 497) were women ≥18 years old with a diagnosis of 
recurrent ovarian, fallopian tube, or primary peritoneal cancer, experiencing ≥3 symptoms 
associated with cancer or cancer treatment. Setting: Participants were recruited from 53 GOG 
sites across the country. Within 28 days of signing informed consent, participants completed 
baseline questionnaires via the web-based WRITE Symptoms Questionnaire System. 
Measures: Multiple dimensions of QOL were assessed using the FACT-O (well-being), ISEL-12 
(social support), and sociodemographic survey (financial vulnerability, as measured by a single 
item asking women to rate difficulty paying for basic needs). A single item from the Charlson 
Comorbidity self-report was used to identify women who had been diagnosed with a second 
cancer (other than ovarian) within the past 3 years. Analysis: t-tests and chi-square analyses 
were used to compare QOL between groups.  
Results. Sixty-four women (12.9%) reported a cancer diagnosis in addition to ovarian 
cancer. Well-being subscales and social support did not significantly differ between the two 
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groups (p=.15-.85 and p=.39, respectively). However, a higher proportion of women diagnosed 
with a second cancer (51%) reported more difficulty paying for basic needs than did those who 
had not been diagnosed with a second cancer (36%), p=.02. Additionally, women with second 
cancers were more likely to report incomes <$60,000 per year (68% vs. 50%, p=.01).  
Implications of findings to the proposed dissertation study. This preliminary, 
exploratory study led to further exploration of financial vulnerability and toxicity in the literature, 
ultimately resulting in inclusion of measures of financial toxicity in the proposed conceptual 
model. 
1.3.3 Conceptualization of key model concepts (manuscript #2 in Appendix F) 
We conducted a study to describe relationships among key model concepts (see Manuscript 1 
in Appendix E), specifically evaluating whether survivorship of multiple primary cancers (MPC) 
is associated with psychological distress, health behaviors, and benefit finding (Belcher et al., 
2016). 
Methods. Design: Secondary analysis of the 2010 LIVESTRONG cross-sectional 
survey. Sample: 238 MPC and 3,295 single cancer survivors. Setting: Online survey. Main 
Research Variables: MPC versus single cancer; psychological distress, health behavior (healthy 
lifestyle and positive healthcare utilization), and benefit finding scores. Analyses: Chi-square 
tests of independence and t-tests for comparisons between persons with MPC versus single 
cancers. Multivariate linear and logistical regression models, adjusted for covariates, were 
conducted to determine associations between variables.  
Results. Survivors of MPC, compared to single cancer survivors, were significantly older 
(p<.001), less likely to have a spouse/partner (p=.03), further out from original cancer diagnosis 
(p<.001), less likely to be employed full-time (p<.001), and differed by type of cancer diagnoses 
(p<.001) and cancer survivorship stage (p<.001). MPC was associated with significantly higher 
psychological distress (p=.021) and healthcare utilization (p=.003) but not healthy lifestyle 
(p=.914) or benefit finding (p=.263).  
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Conclusions. Relative to those with single cancers, MPC survivors in this sample 
reported higher psychological distress and were more likely to receive recommended cancer 
screenings. Additional research is needed to understand mechanisms of psychological distress 
in MPC survivors. Implications for Nursing: Targeted distress screening in MPC survivors may 
allow for early identification and interventions to ameliorate distress and reduce negative 
downstream health effects. Knowledge Translation: Nurses should assess for previous cancer 
histories and recognize that survivorship experiences may differ between MPC and single 
cancer survivors. MPC survivors have increased psychological distress risk and may have 
needs related to living with cancer as a chronic illness. Further study of psychological distress 
mechanisms in MPC survivors is warranted. 
Implications of findings to the proposed dissertation study. This descriptive 
secondary analysis reaffirmed findings of psychological distress for MPC survivors in a large, 
mixed-cancer survivor population and allowed for clearer conceptualization of the MPC 
population and key model concepts, including MPC as a chronic illness. 
1.3.4 Methodological influences 
Additional collaborative analyses have been conducted to inform this study including exploration 
of the influence of individual characteristics on key model concepts (Belcher, Sereika, Mattos, 
Hagan, & Donovan, 2017), relationships between psychological responses and physical health 
(Sherwood et al., 2016), and decision making related to mode of survey administration (Hagan, 
Belcher, & Donovan, 2017). 
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1.3.5 MPC science 
1.3.5.1 Summary of literature. Across studies, when compared to single cancer survivors, 
MPC survivors report poorer health outcomes including: higher levels of psychological distress 
(general and cancer-specific) (Andrykowski, 2012; Belcher et al., 2017; Belcher et al., 2016; 
Burris & Andrykowski, 2011; Gotay et al., 2007; Thong et al., 2013); more risky health behaviors 
including physical inactivity, smoking, and alcohol use (Burris & Andrykowski, 2011); increased 
symptom burden including diarrhea, fatigue, and pain (Thong et al., 2013); poorer physical 
function (Andrykowski, 2012; Burris & Andrykowski, 2011; Dowling et al., 2013; Gotay et al., 
2007; Thong et al., 2013); more financial hardship and lost productivity (Belcher et al., 2015; 
Dowling et al., 2013); higher numbers of comorbidities (Andrykowski, 2012; Gotay et al., 2007; 
Thong et al., 2013); and interference with social activities (Thong et al., 2013).  
1.3.5.2 Gaps in the science and future directions. While previous studies add to the science 
by including samples from various geographical regions representing a broad range of cancer 
diagnoses, this study will address the following critical gaps to advance MPC science:  
1. Atheoretical. No studies to date have identified theoretical models to guide scientific
inquiry in this area, leading to a lack of conceptual clarity for scientific advancement. 
2. Study design. Previous MPC research has been devoted to comparing groups of
cancer survivors based upon the number of cancer diagnoses (e.g., no cancer controls versus 1 
primary cancer versus ≥2 primary cancer diagnoses). Differences among groups have now 
been established, and the time is right to look within MPC survivor groups to identify a) the 
factors that put particular MPC survivors at risk for poor health outcomes and b) potential 
mechanisms that link exposure to the chronic stresses of MPC with negative health outcomes. 
3. Negative behavioral responses. While one previous study evaluated dietary intake
and physical activity in this patient population (Burris & Andrykowski, 2011), no studies have 
formally evaluated positive behavioral responses (self-management) among survivors of MPC. 
Positive self-management behaviors are important to understand in this population, as they 
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have potential to interrupt negative pathways and restore optimal wellness in the context of 
chronic illness, such as occurs with MPC diagnosis.  
4. Inconsistent use of valid and reliable measures. We will avoid measurement pitfalls
and limitations of previous MPC studies by using valid and reliable instruments (Redeker et al., 
2015).  
5. Reliable clinical data. Previous overreliance on self-reported clinical data will be
avoided by incorporating cancer registry disease classifications and confirming MPC diagnoses 
via systematic medical record review using standard definitions of MPC (Begg, 1999; Johnson 
et al., 2007; Koubkova, Hrstka, Dobes, Vojtesek, & Vyzula, 2014). 
6. Variable inclusion criteria. Previous study samples differed by inclusion criteria,
particularly by age at diagnosis and by cancer type. We will address this gap by removing 
potential developmental influences on outcomes by including only survivors of cancers 
diagnosed during adulthood and by excluding noninvasive skin cancer cases, which have been 
shown to not differ from general noncancer populations in regard to psychosocial issues 
(Holfeld, Hogan, Eldemire, & Lane, 1990).  
7. Diversity. Previous studies have largely lacked racial and ethnic diversity. While
recognizing the limitations of the planned recruitment frame for diversity of race and ethnicity, 
processes will be put in place to oversample for minority groups when possible.  
1.4 RESEARCH DESIGN AND METHODS 
1.4.1 Design 
We will implement a cross-sectional design using a self-administered, mixed-mode survey of 
valid and reliable patient reported outcomes with survivors of two primary cancer diagnoses, or 
multiple primary cancers. A cross-sectional survey design is feasible and will allow for testing of 
associations/correlations among variables in the theoretical model (Fowler, 2014; Groves et al., 
2009). Identified patterns of association will be tested for temporal ordering in future longitudinal 
study. 
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1.4.2 Sample 
1.4.2.1 Sampling design. Stratified systematic sampling with oversampling for minorities will be 
used to select our study sample. 
1.4.2.2 Sampling frame and elements. The UPMC Cancer Network Registry (1990 – current) 
will serve as our sampling frame. The sampling unit will be the registry participant ID number, 
and MPC survivors will be the sampling elements. 
1.4.2.3 Inclusion criteria. 1) history of two or more primary cancers, as defined by Surveillance, 
Epidemiology, and End Results (SEER) Program coding rules (Johnson et al., 2007), both 
diagnosed in adulthood [≥18 years old]; 2) first diagnosis is consistent with one of the 7 most 
prevalent first cancers experienced by male/female MPC survivors (American Cancer Society, 
2009), including: breast, prostate, colorectal, urinary 
bladder, uterine, melanoma, kidney/renal pelvis, 
lung/bronchus, oral cavity/pharynx, thyroid, and ovary 
(see Figure 2); 3) stage I-III cancers; 4) between 1 and 
10 years following active treatment/no evidence of 
disease; and 5) able to read and complete 
questionnaires in English.  
1.4.2.4 Exclusion criteria. 1) non-melanoma skin 
cancers; 2) in situ cancers; 3) stage IV cancers; and 4) 
history of recurrence. 
1.4.2.5 Sampling plan. Gotay and colleagues have 
been the only research team to our knowledge to 
specifically recruit a sample of adults with MPC from a 
state tumor registry (Gotay et al., 2007). They reported the following recruitment results: 1) 
27.7% were unable to be contacted due to out of date contact information or being deceased, 2) 
physicians requested that 1.2% of potential participants not be contacted, and 3) 56% of those 
Figure 2. Cancer sites of study 
inclusion. Estimated survivors who 
have been diagnosed with more than 
one cancer, by site of first primary. 
Diagnoses in red box indicate top 7 
cancers for men and women which 
will be included in this study. Image: 
(American Cancer Society, 2009).  
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contacted via mail returned completed surveys. Balancing cost, feasibility, and analytic power, 
we plan to send initial invitations to 1,440 MPC survivors (see detailed sampling plan below). 
Based on conservative estimates from the Gotay study, we expect that we will be able to reach 
approximately 60% of potential MPC participants, leaving approximately 864 potential 
responders. Targeting rates of participation similar to those in the Gotay study (approximately 
50%), we would have an estimated 432 respondents in this proposed study (rounded up to 440 
to allow for equal recruitment attempts among groups of cancer diagnosis sites).  
1.4.3 Recruitment and data collection procedures 
Cancer Registry personnel will assist in identifying potential study participants from the 
Cancer or Cancer-like Blood Disorder Registry (UPCI protocol #03-038). Personnel from the 
UMPC Network Cancer Registry will first match registry participants meeting the study's criteria 
to the UPCI protocol 03-038 patients. For living patients in common between these data sets, 
our research team will be provided with the names and mailing addresses for the matching 
patients in order to conduct the recruitment mailings ourselves. All MPC survivors in the registry 
meeting inclusion criteria will be considered in the sampling frame. Based on July 2016 Registry 
data, we expect that all non-white and Hispanic MPC survivors (n=323) will be invited to 
participate. The remaining 1,117 potential white participants will be randomly sampled from the 
larger sampling frame. UPMC physician champions who are content experts in the cancers 
being targeted are being enlisted to introduce the study to prospective participants via a 
standardized invitation letter facilitated by the study team in collaboration with the Cancer 
Registry. In response to the invitation, individuals can select their mode of survey delivery 
(pencil/paper or online) by returning an enclosed postage-paid card, calling the study line, or 
emailing the PI. Participant follow-up contacts will occur up to four times over a 6-week period 
based on Dillman’s Tailored Design Method (see study flow chart in Figure 3). Additional 
participant contact details are provided in the Research Participant Risk and Protection human 
subjects section of this document. 
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1.4.3.1 Dillman’s Tailored Design Method. Dillman’s Tailored Design Method (Dillman, Smyth, 
& Christian, 2014) will be followed to maximize recruitment and response. This method, based 
on social exchange theory, embeds processes and procedures to increase survey requests and 
Figure 3. Study flow chart. This figure illustrates the planned study flow. Study protocol allows for +/- 3 
days adjustment to timeline to conduct study procedures. 
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motivation to complete the survey. This is achieved by establishing trust, increasing perceived 
benefits of survey completion, and decreasing expected cost of participation. We will establish 
trust in the following ways: 1) UPMC disease-based specialists will introduce and provide written 
endorsement of the study; 2) stressing the importance of the knowledge to be gained about 
MPC survivors in this study; and 3) ensuring participants’ privacy. By providing study 
background in the survey, demonstrating respect for individuals, compensating participants with 
a $5 gift card in recognition of participants’ time and expertise as survivors, and providing social 
validation of the persistent cancer-related influences experienced by MPC survivors, we will 
increase participants’ perceived benefit of survey completion. Decreasing expected costs to 
participants will be achieved in the following ways: allowing convenient participation, only 
including necessary measures and using sort forms when possible, minimizing the amount of 
private information requested, and avoiding authoritative language. 
1.4.3.2 Data collection. Mixed-mode data collection was chosen for the proposed study in 
order to maximize response rates and data quality (de Leeuw & Berzelak, 2016; Dillman & 
Edwards, 2016). Surveys will be administered both via Computer Assisted Self-Interviewing via 
Qualtrics (University of Pittsburgh Computing Services and Systems Development, n.d.) and 
pencil/paper, based on respondent preference. Participants will complete a one-time battery of 
patient reported outcomes that will include valid measures of key model concepts (see Table 1). 
To ensure accuracy (Abraham et al., 2009; Bergmann et al., 1998; Bergmann, Byers, 
Freedman, & Mokdad, 1998; Inoue et al., 2011; Yoshinaga, Sasaki, & Tsugane, 2001) and to 
decrease participant burden, clinical data will be extracted from the medical record using a 
standardized data extraction form. All data collected via pencil/paper mode and medical record 
extraction will be entered into a separate Qualtrics-based electronic database by the study PI 
and undergraduate student research assistant personnel via direct data entry, allowing for 
simple data merging into the final comprehensive dataset. Quality assurance for direct data 
entry variables (Agency for Healthcare Research and Quality, 2014) will be ensured by using 
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built in Qualtrics validation features (e.g., limiting characters and ranges allowed for entered 
variables, such as only allowing 5 characters for zip code variables) and conducting accuracy 
audits of every 10th paper survey entered into the database; if errors are uncovered, audit 
frequency will be increased. Additionally, the PI is currently exploring options for collecting and 
banking biological samples for future analyses. 
1.4.4 Measures 
A paper copy of the survey battery administered to study participants is included in Appendix A. 
The online version of the survey was designed to closely mirror the paper copy format. 
Variables, levels of measurement, measures, and psychometric properties are presented in 
Table 1. 
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Table 1. 
Dissertation Study Concepts, Measures, Levels of Measurement, and Psychometric Properties 
Concept Level Self-Report Measures, Description, and Psychometric Properties 
Perceived Stress 
Perceived 
Stress, Global 
Highly Ordinal* The Perceived Stress Scale (PSS) is a 10-item measure of globally perceived 
stress that uses 5-point Likert scale items. Higher scores (0-40) indicate more 
stress. Extensive reliability and validity (concurrent and predictive) (Cohen, 
Kamarck, & Mermelstein, 1983) has been demonstrated and confirmed in various 
populations. Cronbach’s ! ranges from .86 to .92 in women following breast cancer 
surgery and demonstrated a two-factor solution of positive versus stress items with 
stability over 12-month intervals (Golden-Kreutz, Browne, Frierson, & Andersen, 
2004). 
Perceived 
Stress, Cancer-
Specific 
Highly Ordinal* The Impact of Event Scale-Revised (IES-R)(Weiss, 2007; Weiss & Marmar, 1997) 
is 22-item Likert-scale measure of event-specific post-traumatic stress adapted from 
Hurowitz and colleagues’ earlier Impact of Event Scale. (Weiss & Marmar, 1997) 
The IES-R includes subscales for intrusion, avoidance, and hyperarousal (verified 
by factor analyses; correlated with HADS subscales). It has been used specifically 
to assess how distressed patients have felt in the past 7 days about a range of 
cancer-related difficulties and demonstrated extensive reliability and validity in 
various cancer patient populations, including post-treatment survivors (Cronbach’s ! 
= .77 - .96; 3-day test-retest reliability r = .97) (Salsman, Schalet, Andrykowski, & 
Cella, 2015; Vodermaier, Linden, & Siu, 2009). 
Perceived 
Stress, Cancer-
Worry 
Highly Ordinal* The Assessment of Survivor Concerns (ASC) (Gotay & Pagano, 2007; Hershman 
et al., 2013; Thewes et al., 2012) is a 5-item Likert-scale instrument to measure 
fears about cancer recurrence and health in mixed population cancer survivors. The 
item responses range from 1 (not at all) to 4 (very much), with higher scores 
indicating higher worry. The instrument was developed based on work with previous 
cancer survivors and has undergone extensive validation work with mixed cancer 
survivor populations. The 3-item cancer-specific worry subscale to be used in this 
study has demonstrated high internal consistency (Cronbach’s ! = .93); it measures 
worry about cancer recurrence, new cancer diagnoses, and future diagnostic 
testing.  
Psychological Responses 
Depressive 
Symptomatol-
ogy 
Highly Ordinal* The Personal Health Questionnaire Depression Scale (PHQ-8), (Kroenke, 
Spitzer, & Williams, 2001; Kroenke et al., 2009; Ory et al., 2013) an adaptation of 
the valid and reliable PHQ-9 depression scale with omission of the suicidal ideation 
item, is an 8-item clinically validated measure of depressive symptoms. The PHQ-8 
is preferred over PHQ-9 when measures are self-administered. Participants are 
asked how often over the last 2 weeks they have been bothered by different 
problems. Higher scores (0-24) indicate more severe depression. Cronbach’s ! 
ranges from .80 to .86 in mixed cancer populations and individuals with chronic 
disorders. To decrease participant burden, individuals who score 0 on the first two 
items of this measure will be instructed to skip the remaining items in the measures, 
as the PHQ-2, which taps into depressed mood and anhedonia, has been shown to 
be an effective screen for depression in validity and sensitivity studies (American 
Psychlogical Association, 2017; Kurt Kroenke, Spitzer, & Williams, 2003). 
Anxiety Highly Ordinal* The Generalized Anxiety Disorder 7-item scale (GAD-7) (Kroenke, Spitzer, 
Williams, Monahan, & Lowe, 2007; Löwe et al., 2008; Spitzer, Kroenke, Williams, & 
Lo, 2006) is a clinically validated measure of generalized anxiety. Participants are 
asked how often over the last 2 weeks they have been bothered by a list of 
problems. A cut point of 10 was established to optimize sensitivity and specificity 
(89% and 82%, respectively), with higher scores indicative of greater anxiety. 
Confirmatory factor analyses confirmed a 1-factor structure and equitability for 
gender and age for use in the general population to detect various types of anxiety 
(Cronbach’s ! = .89 - .92; intra-class correlation [ICC] = .83 for test-retest reliability). 
Criterion validity was also established. To decrease participant burden, individuals 
who score 0 on the first two items of this measure will be instructed to skip the 
remaining items in the measure, as the GAD-2 is recommended as an “ultra short” 
diagnostic instrument for generalized anxiety disorder. A positive GAD-2 result is a 
score ≥3, while a positive GAD-7 result is a score ≥8. 
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Table 1 (continued). 
Behavioral Responses 
Positive Self-
Management  
Highly Ordinal* The Health Education Impact Questionnaire (hei-Q) (Deakin University, 2016; 
Elsworth, Nolte, & Osborne, 2015; Osborne, Batterham, & Livingston, 2011; 
Osborne, Elsworth, & Whitfield, 2007) is a 40-item scale used internationally to 
assess 8 domains (factor structure validated) of self-management in chronic illness, 
including cancer: health directed activities (Cronbach’s ! = .80); positive and active 
engagement in life (Cronbach’s ! = .86); emotional distress (Cronbach’s ! = .89); 
self-monitoring and insight (Cronbach’s ! = .70); constructive attitudes and 
approaches (Cronbach’s ! = .81); skill and technique acquisition (Cronbach’s ! = 
.81); social integration and support (Cronbach’s ! = .86); and health service 
navigation (Cronbach’s ! = .82). Internal consistency (≥.8) and discriminant validity 
have been established across sex, age, education, and ethnic background groups. 
Risky 
Behaviors: 
Alcohol Use 
Highly Ordinal* †The PROMIS Alcohol Use Short Form 7a (Gibbons et al., 2016; Patient-Reported 
Outcomes Measurement Information System, 2014; Pilkonis et al., 2016) assesses 
drinking patterns, cue-based drinking, cravings to drink, and efforts to control 
drinking indicative of problematic drinking at the moderate and low severity levels for 
adults with chronic illness. Participants are first asked if they have consumed any 
alcohol in the previous 30 days and, if yes, respond to 7 items scored on a 5-point 
Likert scale, with higher scores indicating more risky alcohol use behavior. 
Risky 
Behaviors: 
Tobacco Use by 
Cancer Patients 
Highly Ordinal* The Cancer Patient Tobacco Use Questionnaire (C-TUQ),(Land et al., 2016; 
Land et al., 2016; National Cancer Institute, 2016) developed by joint National 
Cancer Institute and the American Association for Cancer Research task force, was 
created to assess tobacco use in cancer patients and survivors. The instrument 
includes both 4 core constructions and extension items to assess domains of 
smoking history and current use, use relative to cancer diagnosis and treatment, 
other tobacco product use, cessation, and second-hand exposure. Expert review 
panels and iterative cognitive interviews were conducted during instrument 
development. 
Health Outcomes:  Global Health, Physical Health, Financial Toxicities, Social Role Function 
Global Health 
Global Health Highly Ordinal* † The PROMIS SF v1.1 – Global Health, is a 10-item measure intended to 
measure general, self-reported health. It includes 10 global health items from the 5 
core PROMIS domains and has been tested in broad clinical samples, including 
adults with cancer. Previous research (Hays et al., 2009) has demonstrated 
construct validity of items, and found two underlying domains reflected during factor 
analysis: mental and physical health (Cronbach’s ! = .81 and .86, respectively). 
Items are scored on a 5-point Likert scale with higher scores indicating better global 
health.  
This instrument is recommended by NINR as a common data element for self-
management research (Moore et al., 2016) and will be analyzed for descriptive 
purposes, not as part of measurement model. 
Physical Health 
Physical 
Function 
Highly Ordinal* † The PROMIS Physical Function Short Form 20a (Patient-Reported Outcomes 
Measurement Information System, 2015; Rose et al., 2014; Schalet et al., 2016) 
measures capability rather than actual performance of physical activities, including 
dexterity, walking or mobility, neck/back, and instrumental activities of daily living. 
PROMIS recommends using the 20a short form if variability is expected and various 
subdomain information is desired, thus the 20a was selected for this study. Higher 
scores indicate better physical function. Validity over time was established in adults 
with chronic illness, including cancer. Field testing and criterion testing was 
consistent, irrespective of health, age, and disease group/number of chronic 
conditions. 
Treatment-
Related 
Symptoms and 
Interference 
Highly Ordinal* The MD Anderson Symptom Inventory (MDASI) (Aktas, Walsh, & Kirkova, 2015; 
Cleeland et al., 2000; Cleeland, 2016) is a multi-symptom patient-reported outcome 
measure for clinical and research use. It is used to both assess symptom severity 
and interference with daily living. The 21-item core bank of symptoms consists of 
those symptoms that are most frequent and/or severe in cancer patients and yielded 
2 symptom factors and interference scales (Cronbach’s ! = .85 - .87; .82 - .87; and 
.91 - .94, respectively). The core accounted for 64% of symptom distress variance in 
principal factor analysis. Sensitivity to disease severity performance status (ECOG) 
and treatment status was confirmed. 
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Table 1 (continued). 
Comorbidity Ratio The Charlson Comorbidity Index (CCI) was originally developed in 1987 
(Charlson, Pompei, Ales, & MacKenzie, 1987) as a weighted sum measure of 
chronic disease burden used to predict long term prognosis and outcomes and 
remains a population instrument for comorbidity risk adjustment. The brief 10-item 
self-report form selected for this study (short form) has been demonstrated to 
predict 1-year mortality in racially diverse populations and performed well compared 
to ICD-9 generated CCI scores (Chaudhry, Jin, & Meltzer, 2005). 
Financial Toxicity 
Financial 
Toxicity 
Highly Ordinal* The 11-item COmprehensive Score for financial Toxicity (COST-FACIT, version 
1) tool (De Souza et al., 2016; De Souza et al., 2014) was developed using a step-
wise approach to provide a patient reported outcome measure of financial toxicity
(1-factor latent variable) in patients with cancer. Item responses are scored on a
Likert scale of not at all to very much (0-4), with lower scores indicating worse
financial toxicity. Internal consistency (Cronbach’s ! = .92), test-retest reliability
(ICC = .80, 95% CI = .57 - .92), convergent validity (POMS Pearson correlation =
.26, p<.001; household income Pearson correlation = .28, P<.001), divergent validity
(Marlowe-Crowne Social Desirability Scale Pearson correlation = .11, p=.11), and
correlation with health-related quality of life (FACT-G Pearson correlation = .42,
p<.001; EORTC-QOL Pearson correlation = .33, P<.001) have been validated in
samples of adults with advanced cancer.
Economic 
Hardship 
Highly Ordinal* The Economic Hardship questionnaire (Barrera, Caples, & Tein, 2001), a 17-item 
measure of perceived economic hardship, is based off of four measures of 
subjective hardship: financial strain (Vinokur, Price, & Caplan, 1996); inability to 
make ends meet (Conger & Elder Jr., 1994; Pearlin, Menaghan, Lieberman, & 
Mullan, 1981); not enough money for necessities (Conger & Elder Jr., 1994; Pearlin 
et al., 1981); and economic adjustments/cutbacks (Conger & Elder Jr., 1994). This 
scale has demonstrated factor structure, internal structure congruence, and validity 
in urban families across gender, language (English and Spanish), and ethnicities 
(African American, European American, and Mexican American), in 4 different 
domains: financial strain; inability to make ends meet; not enough money for 
necessities; and economic cutbacks and adjustments (Cronbach’s ! = .70 - .85). 
The first 3 domain items are rated on a 5-point Likert-type scale and mean subscale 
scores are created. Economic Adjustments and Cutbacks are assessed with 9 
items, such as added another job, received government assistance, and sold 
possessions because money was needed. Participants indicate whether these 
events have occurred in the past month. This subscale score is the total number of 
events that occurred (0– 9). 
Social Role Function 
Social function, a part of social health with implications for impact on physical health, is broken down into ability to and 
satisfaction with participation.(Bode et al., 2010) Both instruments are scored on a never (5) to always (1) Likert scale. 
Social Role 
Function, Ability 
Highly Ordinal* † The PROMIS - Ability to Participate in Social Roles and Activities Short Form 
8a (Bode et al., 2010; Hahn et al., 2014) is a short form intended to assess 
perceived ability to participate in usual social roles and activities. Higher scores 
represent better abilities. 
Social Role 
Participation, 
Satisfaction 
Highly Ordinal* † The PROMIS – Satisfaction with Participation in Social Roles Short Form 8a 
(Bode et al., 2010; Hahn et al., 2014, 2016) is a short form intended to assess 
perceived satisfaction with participation in usual social roles and activities. 
Responsiveness to change was demonstrated in a sample of adults with chronic 
illness. 
Personal, Demographic, and Clinical Characteristics 
Personal 
Personality:  
Neuroticism and 
Conscientious-
ness 
Highly Ordinal* The 50-item International Personality Item Pool (IPIP)(Goldberg, 1999; Goldberg 
et al., 2006; Socha, Cooper, & McCord, 2010) includes 10 items each for five 
personality factors, including extroversion/introversion, agreeableness, 
conscientiousness, emotional stability-neuroticism, and intellect. The present study 
is measuring only subscales for Neuroticism (Cronbach’s ! = .86) and 
Conscientiousness (Cronbach’s ! = .85), as they have previously been linked to 
self-management. Respondents are asked to rate present behaviors on a 1 (very 
inaccurate) to 5 (very accurate) scale. 
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Table 1 (continued). 
Self-Regulation Highly Ordinal* The 9-item Index of Self-Regulation (Fleury, 1998; Yeom, Choi, Belyea, & Fleury, 
2011) is intended to measure someone’s level of self-regulation for physical activity. 
Psychometric testing has demonstrated Cronbach’s ! of .81-.96, adequate test-
retest reliability (coefficient = .73), and concurrent validity with relevant concepts.  
This instrument is recommended by NINR as a common data element for self-
management research (Moore et al., 2016). 
Self-Efficacy Highly Ordinal* The 6-item Self-Efficacy for Managing Chronic Disease instrument asks 
participants to rate how confident they are in various activities (0-10), with higher 
scores indicating more confidence. The instrument has demonstrated internal 
consistency (Cronbach’s ! = .91) in subjects with chronic disease (Lorig, Sobel, 
Ritter, Laurent, & Hobbs, 2001). 
This instrument is recommended by NINR as a common data element for self-
management research (Moore et al., 2016). 
Sociodemographic 
Social Support Highly Ordinal* The Interpersonal Support Evaluation List Short Version (ISEL-12) (Brookings & 
Bolton, 1988; Cohen, Mermelstein, Karmark, & Hoberman, 1985) is a 12-item 
questionnaire designed to assesses perceived social support. Respondents are 
asked to respond to a list of statements on a 1 (definitely false) to 4 (definitely true) 
Likert scale. Scores are summed. Cronbach’s ! of .90 has been found in women 
with breast cancer (Cohen, 2008). 
Education,  
Age,  
Gender,  
Marital Status, 
Income 
Ordinal, 
Ratio, 
Nominal, 
Nominal, 
Ordinal 
An adapted, face-valid standardized socio-demographic questionnaire developed in 
the University of Pittsburgh School of Nursing will be administered to capture 
demographic characteristics. 
Clinical 
Clinical 
Characteristics 
Nominal, 
Interval, 
Ordinal 
A face-valid standardized medical record review form will be used to extract and 
record important clinical characteristics such as cancer diagnoses, stages at 
diagnoses, age at initial and subsequent diagnoses, time since diagnoses and 
treatments, cancer treatment history, and BMI. 
Exploratory 
MPC 
Experience  
Nominal 
Ordinal 
Descriptive 
The items in this section were generated by the PI, based on the literature, to 
explore the experience of having multiple primary cancers. Items asks patients to 
identify their current stage of survivorship (item adapted from the 2010 
LIVESTRONG survey), compare challenges/stressors between 1st and 2nd cancer 
experiences, and enter what they think providers should know about what it’s like to 
have more than on cancer. 
Health Care 
Utilization 
Ratio The Stanford Patient Education Center measure, Health Care Utilization, (Lorig et 
al., 1996; Ritter et al., 2001) is a 4-item questionnaire that asks respondents about 
their health care utilization in the previous 6 months. Utilization includes physician 
and emergency department visits and times and nights hospitalized. Test-retest 
reliability for each item ranged from .76 to .97. in subjects with chronic disease. 
Notes. Pretesting pilot work determined that the total survey completion time estimate = 30-45 minutes. Prior team 
research (Hagan et al., 2017) has demonstrated that participants find the estimated time of survey completion to be 
acceptable.  
 
*Likert-scaled items from a multi-item scale are ordinal. The mean or sum score of these items will be highly ordinal but 
approximate an interval scaled variable.  
 
†Patient-Reported Outcomes Measurement Information System (PROMIS) measures were developed as an NIH 
Roadmap project to provide clinicians and researchers access to efficient, precise, valid, responsive measures of health 
status. They have undergone rigorous psychometric testing, were designed for universal relevancy, and may be used in 
the general population and for those who have chronic conditions. Population-based reference values have been 
estimated for use in cancer by respondent age and disease stage (Cella et al., 2010; Cook et al., 2016; DeWalt, 
Rothrock, Yount, & Stone, 2007; Jensen et al., 2017; Northwestern University, 2016). 
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1.4.5 Data analysis plan 
As described in Table 1, individual constructs have been theoretically defined and 
operationalized. The proposed conceptual model (Figure 1) will guide data analyses. Collected 
data will be exported to a database for analyses. 
1.4.5.1 Descriptive statistics. Descriptive and exploratory analyses will first be performed 
using IBM® SPSS® software, version 25 (IBM Corp., Armonk, NY) to identify any data anomalies 
(e.g., missing data or outliers that may be a result of data entry error or invalid participant 
responses) that might invalidate findings of the primary aim analyses to be conducted. To 
confirm external validity, sample characteristics will be compared to what is currently known in 
existing MPC literature. For continuous variables, appropriate descriptive statistics including 
graphical representation will be computed to describe sample characteristics and determine 
observed variable distributions. For categorical variables, we will examine frequency 
distributions to ensure adequate category size; categories will be meaningfully collapsed as 
possible if inadequate category sizes are observed. Pairwise correlations will be calculated to 
summarize bivariate associations between variables.  
For the variables previously described in Table 1, we will report frequency counts and 
percentages for categorical variables. For the central tendency and dispersion for categorical 
variables, mode and range will be reported for nominal variables, and median and interquartile 
range (IQR) will be reported for ordinal variables. For continuous variables, we will describe 
central tendency as means and dispersion as standard deviations for normally distributed data 
and medians and IQRs or semi-quartile ranges (SQR) for non-normal data distributions.  
1.4.5.2 Data screening procedures. Statistical assumptions for planned analyses will be 
checked for violations (e.g., independence, normality, homoscedasticity, multivariate normality, 
and linearity) prior to performing any primary aim analyses. Measured variables will be screened 
for univariate outliers by z-scores for continuous type variables with absolute values >3.29 and 
lopsided distributions (i.e., small categories <10%) for categorical variables suggesting 
25 
univariate outliers. Univariate and bivariate data exploration with graphical plots will be 
conducted to determine outliers, potentially influential cases, and linearity of relationships 
among variables. Mahalanobis distance will be used to assess for multivariate outliers. 
Correlations (i.e., determinant of the covariance matrix); variance inflation factors (VIF); 
tolerance; and Belsley, Kuh, and Welch (BKW) diagnostics (Mason, 1987) will be used to 
assess for multicollinearity.  
Data transformations or more statistically robust measures will be used in such 
instances of assumption violations. Robust maximum likelihood estimation methods are 
available and will be employed to fit all models if multivariate normality assumptions are 
questionable. We will also examine correlations between potential covariates/confounders and 
outcome variables and psychometric properties of multi-item scales. Cronbach’s coefficient 
alpha will be used to estimate internal consistency of multi-item scales. All tests will be two-
tailed, with statistical significance criterion set at p<.05. 
Because our primary multivariate analytic technique, SEM, is based on covariances, 
parameter estimates and "2 tests of fit are sensitive to sample size and require larger samples 
(Tabachnick & Fidell, 2013). We will assess for representativeness of population due to 
dropouts/exclusions and amount and patterns of missing data. SEM allows for data missing 
completely at random (MCAR) and missing at random (MAR) through full information maximum 
likelihood (FIML) methods (Enders & Bandalos, 2001). 
1.4.5.3 Data analysis procedures. SEM, using Mplus, version 8 (Muthén & Muthén, 2017) will 
be conducted to analyze structural linear relations between latent constructs and considering 
the loadings of measured variables and their reliabilities in the proposed multivariate model 
using results from the primary data collection. The following SEM testing plan is based on 
standard procedures (Tabachnick & Fidell, 2013). 
Aim 1a. The first step will be to fit the full measurement model to identify any issues with 
measurement. The hypothesized full structural equation model is presented in Figure 4. The 
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independence model will be conducted first to test whether all variables are uncorrelated (this is 
anticipated to be easily rejected, allowing us support to move on to the next phase). Next, we 
will test the hypothesized model using appropriate test statistics and fit indices. Evaluation of 
model fit has been described as a “gestalt process” (Little, 2013); model fit (Little, 2013) will be 
evaluated based on theory and 1) statistical rationale using exact, or statistical, fit ["2 statistic] 
and 2) modeling rationale, which incorporate a) absolute fit, or the measured distance between 
the hypothesized model and the perfect fitting model [root mean square error of approximation 
(RMSEA)] and b) relative fit, or index of the percent improvement from the null to the saturated 
or perfect model (comparative fit indices [CFI] and Tucker Lewis Index [TLI]). Taking statistical 
rationale into consideration, which are influenced by sample size, the following modeling 
rationale cutoffs will be considered and interpreted as acceptable when evaluating model fit in 
this study: 1) RMSEA and associated 90% confidence intervals are ≤.05 and 2) CFI ≥.90 (Little, 
2013). 
 Aim 1b. Post-hoc model modifications will be conducted to attempt to improve model fit 
and parsimony. Model paths may be added or removed based on "2 difference tests and path 
coefficient significance testing results. The Wald test will be used to determine if there are any 
parameters that could be deleted from the model without impacting model fit. In a model that fits 
the data well, we would anticipate that the paths should all be significant and model modification 
indices should be small. The final model will be presented with significant coefficients in 
standardized form. 
Aim 2. Pending determination of model adequacy, specific aspects of the model will be 
tested for secondary aims. Paths will be added to explore the relationships among the clinical, 
personal, and sociodemographic characteristics and the latent variable of perceived stress. 
Models will be compared using "2 difference testing (Tabachnick & Fidell, 2013). 
Exploratory Aim 3. Descriptive and exploratory analyses will be conducted to 
characterize self-management behaviors, as measured by the hei-Q.  
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1.4.5.4 Sample size justification. Based on cost and feasibility of this dissertation study, we 
have budgeted for a target sample of 440 MPC survivors returning completed surveys. To fit the 
full structural equation model, as displayed in Figure 4, will use data from 21 measured 
variables yielding 21 variances and 210 covariances to estimate and test 57 parameters. As 
specified, with 172 degrees of freedom and a sample size of 440, we will have > .99 power to fit 
and test for a close fit based on RMSEA at a significance level of .05. 
1.4 STUDY TIMELINE 
Table 2  
Study timeline 
Study activities 7/17 8/17-12/17 1/18-2/18 3/18-4/18 5/18-6/18 
IRB submission and approval X 
Solidify procedures with Research 
Registry and Physician Champions X 
Data collection X 
Data cleaning X 
Data analysis X X X 
Abstract and manuscript dissemination X X X 
Dissertation Defense X 
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Figure 4. Full hypothesized structural equation modeling model. Blue circles = latent variables; green rectangles = measured variables. 
Greek letter key: ξ (ksi) = exogenous construct; η (eta) = endogenous construct; β (beta) = estimated regression of one endogenous 
construct on another endogenous construct; γ (gamma) = estimated regression of one exogenous construct onto an endogenous construct; 
λ (lambda) = estimated loading of an indicator on a construct; δ (delta) = residual variance of an indicator for an exogenous construct; and e 
(epsilon) = residual variance of an indicator for an endogenous construct. 
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1.6 POTENTIAL LIMITATIONS AND ALTERNATIVE APPROACHES 
Limitations and pitfalls are anticipated to be encountered during the course of this 
research. It is possible that use of the voluntary research registry through the UPMC Network 
Tumor Registry will not allow us to achieve our sampling goals. If necessary to achieve 
recruitment goals, our next step would be to utilize the honest broker system within the larger 
UPMC Network Cancer Registry, facilitating mailings from physician champions under the 
supervision of the study principal investigator (PI) to introduce the study to prospective 
participants who fall within our inclusion criteria. Methodologically, it is possible that the data will 
not lend itself well to SEM analyses. If models will not hold using full SEM, our alternative 
approach will be to conduct a path analysis or a series of regression models to determine 
associations among variables in the model. Additionally, it is possible that the sample of MPC 
survivors in the UPMC registry will not generalize well to the larger MPC population. Previous 
MPC literature has been largely conducted with non-minority participants with higher 
socioeconomic statuses. To protect against sampling bias, 1) we are offering participants two 
modes of survey completion, allowing for people with limited online access to still participate in 
this research, and 2) we will be oversampling for minority participants. Findings will be 
compared to existing MPC literature and will be discussed in publications. 
1.7 PUBLICATIONS RELEVANT TO THE PROPOSED RESEARCH 
Refereed Articles * = Data Based 
1. * Belcher, S. M., Low, C. A., Posluszny, D. M., Schear, R., Kramer, R. E., & Donovan, H. S.
(2017). Correlates of psychological distress, health behaviors, and benefit finding in
survivors of multiple primary cancers: Results from the 2010 Livestrong survey. Oncology
Nursing Forum, 44 (6), 703-711. doi: 10.1188/17.ONF.703-711
2. * Hagan, T. L., Belcher, S. M., & Donovan, H. S. (2017). Mind the mode:  Differences in
paper vs. web-based survey modes among women with cancer. Journal of Pain and
Symptom Management, 54 (3), 368-375. doi:10.1016/j.jpainsymman.2017.07.005
3. * Belcher, S. M., Hausmann, E. A., Cohen, S. M., Donovan, H. S., & Schlenk, E. A. (2016).
Examining the relationship between multiple primary cancers and psychological distress: A
review of current literature. Psycho-Oncology, 26 (7), 2030-2039. doi:10.1002/pon.4299
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Published Abstracts 
1. Nilsen, M., Belcher, S., Donovan, H., Klem, M. L., Morrison, A., Sereika, S., & Johnson, J.
(2018). Late and long-term treatment effects among survivors of head and neck cancer at
least 5 years post-treatment: A systematic review. International Journal of Radiation
Oncology, Biology, Physics (Red Journal), 100 (5), 1401. doi:10.1016/j.ijrobp.2017.12.242
2. Belcher, S. M., Sereika, S. M., Mattos, M. K., Hagan, T. L., & Donovan, H. S. (2017).
Comparison of symptoms and quality of life in recurrent ovarian cancer by rural/urban
residence: Ancillary analysis of GOG-0259. International Journal of Gynecological Cancer,
27 (Supplement 4), ESGO07-0436, 262.
3. Belcher, S. M., Sereika, S. M., Dodson, Z., Mattos, Meghan K., Hagan, Teresa L., &
Donovan, Heidi S. (2017). Comparison of rural versus urban residence for symptoms and
quality of life in women with advanced ovarian cancer:  Baseline analysis of GOG-0259, an
NRG Oncology/GOG study. Journal of Clinical Oncology, 35 (15_Supplement), e18083. doi:
10.1200/JCO.2017.35.15_suppl.e1803
4. Sherwood, P., Ren, D., Given, C. W., Donovan, H., Weimer, J., Belcher, S., Given, B.
(2016). The impact of caregivers’ depression on their physical health. Psycho-Oncology, 25
(Special Supplement S3), 24. doi: 10.1002/pon.4272
5. Belcher, S., Low, C., Posluszny, D., Donovan, H. (2016). Correlates of psychological
distress, health behaviors, and benefit finding in survivors of multiple primary cancers:
Results from the 2010 LIVESTRONG Survey. 8th Biennial Cancer Survivorship Research:
Innovation in a Rapidly Changing Landscape Abstract Book, A-61, 41-42.
6. Belcher, S. M., Klem, M. L., Cohen, S. M., Hausmann, E., Donovan, H. S., & Schlenk, E. A.
(2016). Examining the relationship between multiple primary cancers and cancer-related
distress:  A systematic literature review. Journal of Clinical Oncology, 34 (Supplement 3S),
214. doi:10.1200/jco.2016.34.3_suppl.214
7. Belcher, S., Arida, J., Campbell, G., Hagan, T., Skrovanek, E., & Donovan, H. S. (2015).
Exploring well-being, social support, and financial vulnerability in women with recurrent
ovarian cancer who report more than one primary cancer diagnosis within the past 3 years.
Nursing Research, 64 (2), E68. doi: 10.1097/NNR.0000000000000089
8. Skrovanek, E., Hagan, T., Campbell, G., Belcher, S., Arida, J., Ackison, G., & Donovan, H.
(2015). Influence of causal attributions on cancer-related distress. Nursing Research, 64 (2),
E126-E127. doi: 10.1097/NNR.0000000000000089
1.8 PROTECTION OF HUMAN SUBJECTS 
1.8.1 Human subjects involvement and characteristics 
We anticipate that approximately 440 MPC survivors will participate in this research. Inclusion 
criteria: cancers diagnoses in adulthood (≥18 years old); history of two or more primary cancers; 
first diagnosis consistent with one of the seven most prevalent first cancers experienced by 
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male/female MPC survivors: female breast, prostate, colorectal, urinary bladder, uterine, 
melanoma, kidney and renal pelvis, lung/bronchus, oral cavity and pharynx, thyroid, or ovary; 
stage I-III cancers (both first and second primary cancers); between 1-10 years following active 
treatment/no evidence of disease; and able to read and complete questionnaires in English. 
Exclusion criteria: non-melanoma skin cancer; in situ cancers; stage IV cancers; and history of 
recurrence. 
Vulnerable participants (i.e., fetuses, pregnant women, children, or institutionalized 
individualized) are not included in this study. Of note, issues relevant to pediatric survivors of 
multiple primary cancers are likely to be fundamentally different from adult survivors. MPC 
survivors who experienced cancer as children warrant additional future study. 
1.8.2 Sources of materials 
Data will be collected in the form of self-reported questionnaires, either via pencil and paper or 
online via Qualtrics, based on individual preference. In addition, disease and treatment data will 
be extracted from participants’ medical records. All data will be identified only by code numbers 
(participant IDs) and will be stored in secure locations, including locked file cabinets and 
password-protected computers and databases. Participant IDs will be linked to participants’ 
names in a password-protected file that is accessible only to the PI and research team.  
1.8.3 Recruitment 
We will utilize the Cancer or Cancer-like Blood Disorder Registry (UPCI protocol #03-038) in 
order to contact individuals with information about the study. Personnel from the UMPC Network 
Cancer Registry (see Appendix C for letter of support) will first match registry participants 
meeting the study's criteria to the UPCI protocol 03-038 patients. For living patients in common 
between these data sets, our research team will be provided with the names and mailing 
addresses for the matching patients in order to conduct the recruitment mailings ourselves. If 
necessary to achieve recruitment goals, our next step would be to utilize the honest broker 
system within the larger UPMC Network Cancer Registry, facilitating mailings from physician 
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champions under the supervision of the study PI to introduce the study to prospective 
participants who fall within our inclusion criteria.  
Based on Dillman’s well established and validated approach, MPC survivors meeting the 
eligibility criteria according to the UPMC Cancer Registry will receive a series of follow-up 
contacts (see study flow chart in Figure 3). On Day 1, letters will be sent from physician 
champions on behalf of the study team to introduce prospective participants to the study and 
invite participation (see sample letter in Appendix B). Each contact will provide potential 
participants with an easy email or phone opt-out option, if they wish to be removed from the 
contact list, and any participant who returns questionnaires will not receive further reminders. 
For individuals who choose not to participate in the study, we request that they complete 
a refusal form, that will include 5 general questions to help us compare our study sample to 
those who declined participation, helping us understand possible sample bias.  
If individuals do want to participate in the study, they can respond accordingly by either 
returning an enclosed postage-paid card, calling the study line, or emailing the PI. They can 
choose to complete the survey in one to two ways: 1) paper/pencil or 2) web-based via 
Qualtrics. Ongoing communication will occur via the mode of participation initiated by and 
contact information provided by the participant. 
For paper/pencil selection, participants will be sent a paper copy of the consent (see 
Appendix B) and survey (see Appendix A). The consent will state that by completing and 
returning the completed questionnaire, individuals have agreed to participate in the study, and 
PI contact information will be provided for questions at any time. If a completed survey is not 
received back, a reminder postcard will be sent followed by replacement questionnaires. A 
thank you card and the $5 Amazon.com gift card code will be mailed to participants upon receipt 
of completed questionnaires.  
For online survey selection, participants will be provided with a link to an electronic copy 
of the consent, which may be viewed within the survey and also downloaded (see Appendix B). 
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Online consent on Qualtrics is a hard stop before participants can move forward with the link to 
complete the survey online. Qualtrics is a system for web-based data collection and is approved 
by the University of Pittsburgh IRB. The consent will state that by completing and submitting the 
online questionnaire, individuals have agreed to participate in the study. The question will be 
repeated in the actual survey platform. PI contact information will be provided for questions at 
any time. If no response or partial response (e.g., participant initiated but did not complete the 
survey), reminder emails will be sent following the initial email. A thank you email and the $5 
Amazon.com gift card code will be sent to participants upon completion of the survey via 
provided emails. 
Surveys are completed at one time point, so retention strategies are not included. Every 
effort has been made to make paper and online surveys as similar as possible. 
1.8.4 Potential risks and adequacy of protection against risks 
One potential risk is a breach of confidentiality. To protect participants’ privacy, only 
members of the research team will be aware of individuals’ participation in this research study. 
Participant names will not be included on the paper or electronic questionnaires they complete 
or the information collected from medical records. All data will be kept in secure, locked file 
cabinets at the School of Nursing. A username and password will be used to access secured 
survey data in Qualtrics. All information will be identified only by a study ID number. The 
information linking ID numbers with identifiable information will be kept separate from the 
research records; paper data and will be stored under lock and key, and identifiable linkage 
code data will be stored in a Box cloud folder separate from the deidentified data. The PI will 
manage access to the identifiable data; access will be provided only to team members who 
require access for study-related work. All researchers involved in this study have been 
thoroughly trained and are up to date on online privacy modules. Individual identities will not be 
revealed in any description or publications of this research, and data will only be presented in 
aggregate. 
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Another possible risk of this research study may include stress from having to complete 
the questionnaires. Participants are advised that, if the questions induce stress or discomfort, 
they can take a break from completing the questionnaires and do not have to complete all 
individual questions. If completing the survey online, they are advised that their data will not be 
lost if they take a break. It is emphasized that survey responses are not sent to their healthcare 
providers and that they should contact or see their healthcare team if they have any questions 
or concerns about physical or emotional symptoms, cancer, or medications or if they experience 
new symptoms or increase in existing symptom severity. It is estimated that survey completion 
will take approximately 30-45 minutes. 
1.8.5 Cost-to-benefit statement 
In light of the relatively minor risks associated with the study (e.g., minor distress or 
physical discomfort, breach of confidentiality), the risk-benefit balance is reasonable. 
Participants will likely no acquire direct benefit from study participation. The primary benefit of 
this study lies in the importance of knowledge to be gained. 
1.8.5.1 Importance of knowledge to be gained. The number of cancer survivors, specifically 
the number of individuals with MPC, is growing dramatically in the United States (American 
Cancer Society, 2014; Bluethmann et al., 2016; DeSantis et al., 2014; Fraumeni et al., 2006; 
National Cancer Institute, n.d.-c, n.d.-b), increasing the need to identify the characteristics of 
those diagnosed with MPC and the potentially modifiable self-management behaviors that 
interrupt negative stress response pathways and have potential to optimize health and well-
being. Data from the proposed study will allow investigators to target particular behavioral 
mechanisms related to prolonged stress in MPC survivors most vulnerable to prolonged stress 
and the cascade of negative outcomes. The goal is that study data will provide findings that can 
be used to improve care for future patients and survivors and to inform future intervention 
studies for this population. 
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2.0 SUMMARY OF STUDY 
2.1 CHANGES TO PROPOSED STUDY 
This section is intended as a bridge between the proposed study, as approved by the 
committee, and the actual study as it was conducted. Reviewed here are the major changes to 
the originally proposed study related to recruitment and resulting data collection procedures.  
2.1.1 Recruitment 
The original plan for our study team to directly recruit the majority of our participants through the 
voluntary Cancer or Cancer-like Blood Disorder Registry (UPCI protocol #03-038) was not 
possible, as we were notified pre-study launch that the protocol had been permanently closed. 
Therefore, we used our previously identified alternative approach to recruit participants by 
partnering with the UPMC Network Cancer Registry’s honest broker system (IRB #HB015) to 
contact prospective participants from the larger cancer registry sampling frame. The UPMC 
Cancer Registry draws from accredited hospitals who actively follow patients, including:  
Altoona, East, Horizon, McKeesport, Magee, Northwest, Passavant, Presbyterian Shadyside, 
and St. Margaret. 
2.1.1.1 Additional participation criteria. In addition to our originally planned inclusion and 
exclusion criteria, additional exclusion criteria were required by the UPMC Registry protocol. 
Based on requests from physician leaders identified prior to study launch, the UPMC Registry 
staff compared the list of potentially eligible participants (n=2233) to the corporate “opt out” 
database maintained by the Medical and Health Sciences Foundation Office and removed 62 
(2.8%) of the potentially eligible patients who were common between lists. Per UPMC Registry 
protocol, each physician champion enlisted as a clinical expert for their respective disease 
site(s) (see 1.4.3) was also provided with a list of potentially eligible patients from his or her 
disease specialty. Opportunities were provided for each physician champion to review the list 
and deem patients not appropriate for contact about this study; 46 (2.1%) potentially eligible 
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participants were removed based on this review. Lastly, 10 prospective participants who were 
mailed study letters of invitation were unable to be contacted regarding study participation, as 
they were either deceased or noted by their families as unable to participate due to dementia; 
these 10 individuals were subtracted from the number of potentially eligible participants (see 
Manuscript 3, section 3.3.4.1 for additional details). 
2.1.1.2 Dillman’s Tailored Design Method. The launch of our initial mailings was delayed due 
to the previously described changes in the source of recruitment and overlap with major 
holidays. Consequentially, the timing of reminder mailings to nonrespondents was also delayed 
until immediately following the start of the new year. See Figure 7 in Manuscript 3 for the 
revised study flow. 
Because we were contacting potential participants using UPMC Registry’s honest broker 
system, we were not provided with an individual’s contact information until he or she first 
contacted us about the study. Thus, our originally planned series of four follow-up contacts with 
potential participants who did not respond to initial mailings was not possible. Balancing 
feasibility of UPMC Registry workload and privacy of potential participants being approached 
through the UPMC Registry, we partnered with the UPMC Registry to send one additional 
reminder postcard to prospective participants who had not responded to the initial study 
mailings (IRB approved). 
For individuals who requested to complete surveys on paper but had not returned their 
completed survey by Day 21, our final contact was accomplished via the mode of 
communication that was used or preferred by each participant. For example, if an individual had 
called the study telephone number to request a paper survey, our final contact consisted of a 
reminder telephone call to answer any questions and encourage participation. 
2.1.1.3 Nonresponse and return to sender. We provided UPMC Registry personnel with 
updated lists of individuals who had contacted us about study participation. The UPMC 
Registry’s honest broker system tracked individuals who did not respond to study mailings. They 
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also identified updated addresses and resent initial letters of invitation for n=114 individuals 
whose first letter had been returned as undeliverable. UPMC Registry personnel tracked 
undeliverable letters of invitation and reminder postcards. 
2.1.1.4 Measures and scoring. Reviews of the planned set of measures were conducted prior 
to study launch. Based on a balance of participant burden and desired measurement, the 
following changes were made pre-survey launch. 
2.1.1.4.1  Psychological responses. We utilized the Mental Health subscale of the PROMIS 
Global Health measure (Hays, Bjorner, Revicki, Spritzer, & Cella, 2009; HealthMeasures, 2017), 
a scale originally planned for exploratory descriptive purposes, as a measure of the 
psychological response latent variable. The version of the scale we administered, v1.0, was 
recently retired. Thus, we followed developer instructions to convert the Global Health data 
observed in our study to v1.2 format for scoring.  
2.1.1.4.2  Physical health outcomes.  The 10-item version of the PROMIS Physical Function 
was administered, rather than the 20-item version, to reduce participant burden. 
2.1.1.4.3  Personality. The IPIP mini was administered (Donnellan, Oswald, Baird, & Lucas, 
2006), rather than the originally planned 20 item version, to decrease participant burden. 
2.1.1.4.4  Exploratory measures. To reduce participant burden and to reduce redundancy 
among measures, the Index of Self-Regulation and Self-Efficacy for Managing Chronic Disease 
exploratory measures were not included in our battery of administered instruments. 
2.1.1.5 Data sources. In addition to self-reported data and data extracted from the medical 
record, we incorporated UPMC Cancer Registry clinical and sociodemographic data in our 
analyses. To maintain consistency with study inclusion criteria based on UPMC Registry 
queries, first cancer diagnoses are based upon diagnoses recorded in the UPMC Cancer 
Registry. 
Due to feasibility and cost, we were not able to collect and bank biological samples for 
future analyses. 
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2.1.2 Data analyses 
2.1.2.1 Missing data. Scales were scored per developer instructions. When no information was 
available regarding number of items required to scale a score, scores were imputed if at least 
80% of scale items were completed. 
Four participants who consented to online study participation did not complete the full 
survey and were dropped from analyses. 
2.1.2.2 Model fit indices. In additional to comparative fit indices (CFI), Tucker-Lewis Index 
(TLI), and root mean square error of approximation (RMSEA), we also used standardized root 
mean square residual (SRMR) to assess model fit. During analyses for determination of good 
model fit, we adopted more stringent cut points than were originally proposed for practical fit 
indices: comparative fit index (CFI)>.95; Tucker-Lewis Index (TLI)>.95; standardized root mean 
residual (SRMR)<.08; root mean square error of approximation (RMSEA)<.08 (Hu & Bentler, 
1999; Kenny, 2015; Little, 2013). 
2.1.2.3 Sample size. We had originally set a sample size goal of n=440 to balance cost, 
feasibility, and analytic power. Ultimately, 215 participants were recruited for this study, and 4 
were dropped due to incomplete data (response rate = 15.2%). After 5 additional participants 
were dropped from analyses due to having multivariate outlier data, a final sample size of 206 
participants was included in multivariate analyses.  
Despite not achieving our originally desired sample size, the SEM for our primary aim 
remained adequately powered. With the retained sample size of 206 and 309 degrees of 
freedom, >.99 power remained for either the test of a close fit (i.e., RMSEA0=.05 vs. 
RMSEAA=.08) or exact fit (i.e., RMSEA0=0.0 vs. RMSEAA=0.05) at a significance level of .05.  
2.1.2.4 Analytic variables for multivariate analyses. Due to sparse cell sizes for race and a 
large amount of missing data for income, we were unable to retain these planned variables as 
covariates in analyses. We did, however, include “difficulty making ends meet” as a variable in 
our multivariate analyses. Clinical variables ultimately examined in Aim 2 included: first cancer 
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site and years since first cancer diagnosis (obtained from Cancer Registry data); second cancer 
site, years since second cancer diagnosis, years since most recent treatment, time between first 
and second cancer diagnoses, presence of three or more cancer diagnoses (yes versus no), 
and most recently documented BMI (obtained from medical record review). 
2.1.2.5 Aim 3 analyses. To explore individual hei-Q item responses by domain for self-
management, responses were collapsed into two categories (disagree and agree) and explored 
by domain. Mean domain scores (without score alterations) and individual item responses are 
reported (see Table 14). 
To evaluate potentially modifiable health behaviors, we analyzed heiQ items, alcohol 
use, tobacco use, and BMI measures in detail (see Tables 14-16). 
2.2 CONCLUSIONS, IMPLICATIONS FOR NURSING, FUTURE STUDIES 
This dissertation is composed of three complementary studies that demonstrate a clear and 
focused progression from an evaluation of the state of the science (Manuscript #1), to a 
secondary analysis to explore associations among select model variables in a national sample 
of MPC survivors (Manuscript #2), the dissertation study in which we carried out a systematic 
model evaluation to elucidate key pathways impacting health in MPC survivors (Manuscript #3), 
and concludes with a characterization of positive and negative self-management behaviors in 
MPC survivors (Aim 3; section 4.0). Here we briefly summarize the implications of the 
preliminary studies prior to focusing on the final dissertation study.  
In Manuscript 1 (Belcher et al., 2016), we reviewed and synthesized the literature to 
determine the relationship between experience of MPC diagnoses and psychological distress in 
adult cancer survivors. This study identified a lack of research focused on and/or including 
adults with MPC diagnoses. Across the five studies that met criteria for inclusion in the review, 
calculated effect sizes supported small but potentially significant increases in psychological 
distress in survivors of MPC compared to single cancer survivors. Findings from this manuscript 
were combined with literature in other populations to select and refine variables and pathways 
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for the conceptual model. Additionally, noted gaps including lack of racial and ethnic diversity in 
MPC samples, self-reported clinical data, inconsistent use of valid and reliable measures, 
inclusion of non-melanoma skin cancer cases, and lack of focus on characterization of MPC 
survivors at risk for increased distress were addressed in the design of the subsequent 
dissertation study.  
In Manuscript 2 (Belcher et al., 2017), we conducted a secondary analysis of a national 
cancer survivorship dataset to compare survivors of single cancer versus MPC diagnoses on 
psychological distress, self-management behaviors, and benefit finding. Having MPC was 
associated with psychological distress and positive healthcare utilization (i.e., attending medical 
appointments, monitoring for second cancer, and being up to date on screenings) but not with 
healthy lifestyle (i.e., regular physical activity, healthier diet, and attempts to take care of health) 
or benefit finding. The study reaffirmed findings of psychological distress for MPC survivors in a 
large, mixed-cancer survivor population and allowed for clearer conceptualization of model 
concepts, including the introduction of self-management as an important consideration in MPC, 
where survivors often view cancer as a chronic disease (Belcher et al., 2017). 
In Manuscript 3, dissertation aims 1 and 2 (see section 3.3), we used structural equation 
modeling to evaluate hypothesized relationships linking stress to poor health in an adapted 
psychobehavioral stress response model. The data fit a modified four-factor measurement 
model, with latent variables including self-management, distress (combined perceived stress 
and psychological distress), financial toxicity, and functional health (combined social health and 
physical health). In the expanded model including possible predictors, overweight BMI, graduate 
education, less neuroticism, and increased social support predicted better self-management; 
poorer self-management, greater neuroticism, and lower social support predicted increased 
distress. The findings provide opportunities for intervention work targeting modifiable pathways 
and for early identification of individuals at increased risk for negative health outcomes. 
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To address dissertation aim 3 (see Chapter 4.0), we explored individual positive self-
management behaviors and indicators of negative health behaviors (i.e., alcohol use, smoking, 
and BMI). Self-management item scores were generally high but variable, and rates of obesity 
were well above population and cancer norms. This exploration of data highlights a need for 
additional study focused on risk factors associated with positive and negative health behaviors 
in MPC survivors.  
Self-management was the upstream latent variable identified in the final modified model, 
predicting the other latent variables either directly (i.e., predicting distress) or indirectly (i.e., 
through distress). In contrast to the common data element instruments recommended by the 
National Institute of Nursing Research (NINR) (Moore et al., 2016), which are limited to 
measures associated with health behaviors (i.e., patient activation, self-regulation, self-efficacy 
for managing chronic conditions, and global health), the internationally-tested heiQ, selected to 
measure self-management in this study, was designed specifically to measure outcomes 
following health education and self-management programs (Elsworth et al., 2015; Osborne et 
al., 2011, 2007) and directly assess the range of self-management domains recommended to 
maintain wellness.  
In this study, the measures used to capture the hypothesized latent variables of 
perceived stress and psychological response loaded onto the same factor, which we called 
distress. Future studies should evaluate the validity of combining these measures. It is possible 
that the high correlations among these sets of variables was a consequence of study design 
and/or measurement issues. The original conceptualization of the perceived stress latent 
variable, the perception that one’s demands overwhelm one’s coping resources (Lazarus & 
Folkman, 1984), was meant to capture current stressors of general life demands, cancer-
specific stress, and cancer worry. Conversely, the psychological response latent variable was 
mean to capture the longer-term (maladaptive) responses to the chronic stress of cancer 
(National Comprehensive Cancer Network, 2018a) and included measures of depressive 
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symptoms, anxiety, and mental health. It is possible that the cross-sectional nature of this study 
precluded distinguishing between these short- and long-term responses in MPC survivors who 
had been living with their diagnoses for, in some cases, multiple years. Similarly, social role 
ability and physical health measures loaded onto a combined factor, which we conceptualized 
as functional health. Ability to participate in social roles and activities does reflect a functional 
ability, but, again, further research is necessary to evaluate the validity of combining these 
different measures into a single latent variable. Finally, the PROMIS Global Mental Health 
measure we attempted to incorporate into this model loaded across many of the latent variables 
in the model, preventing us from using it in multivariate analyses. 
Importantly, these collapsed latent variables demonstrated clear associations among 
each other in the directions that we had hypothesized. Distress, which was predicted by self-
management behaviors, significantly predicted both increased financial toxicity and poorer 
health outcomes. We hypothesize that increased distress may be impairing an individual’s 
productivity, leading to financial toxicity, and that financial toxicity may be impacting an 
individual’s physical health (e.g., through medication adherence). Further, we hypothesize that 
distress may be affecting functional health through biological pathways (e.g., triggered 
glucocorticoid receptor resistance, immune dysregulation, and risk for disease) (Cohen et al., 
2012). It is also possible that mechanisms impacting an individual’s risk for MPC (e.g., genetic 
predisposition, previous cancer treatment, negative health behaviors, etc.) may also influence 
health outcomes in this survivor population. Future studies should identify the individual and 
interacting influence of these different mechanisms.  
Additionally, BMI, education, neuroticism, and social support were significant covariates 
for this variable. Notably, the rate of obesity in this sample (40.7%) is higher than both that of 
the general U.S. population (36.5%) and cancer survivors (31.1%) (Centers for Disease Control 
and Prevention, 2017; National Cancer Institute, 2018b). Also, we recruited a sample of 
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participants with less education than is typical of previous MPC study samples (38.8% with high 
school level or less), making this a sample that is more generalizable to the U.S. population.  
Not all of the originally hypothesized pathways (see Figures 10 and 11, Section 3.3) 
were found to be statistically significant. The direct pathway between self-management 
behaviors and financial toxicity was neither significant nor was it in the direction we had 
hypothesized; for financial toxicity, distress was a more important direct predictor, while distress 
mediated the relationship between self-management and financial toxicity. Also, while the 
coefficient did reflect the hypothesized direction, self-management behaviors also were not a 
significant direct predictor of functional health. The relationship, again, was mediated by 
distress. 
Additional strengths and limitations are acknowledged in this study. Fortunately, we had 
adequate power to conduct the planned structural equation modeling despite a lower than 
expected response rate to study mailings (15.2%). Study participants were similar to 
participants in previously recruited national MPC samples (e.g., similar age, gender, ethnicity, 
marital status), despite being recruited from a regional cancer registry. Additionally, study 
participants did not differ from nonparticipants identified by the Cancer Registry as potentially 
eligible for participation in this study on key variables including age, gender, race, marital status, 
primary payer at first diagnosis, years since first cancer diagnosis, and first cancer site (see 
Table 7 in Section 3.3).   
Some differences did exist between our sample and other published reports. First, as a 
result of our inclusion criteria, this sample of patients was, on average, closer to their first 
cancer diagnosis (M= 5.8 years, SD=2.9) than other published samples (11-17 years), providing 
the opportunity to examine a new cohort of MPC survivors not previously included in this body 
of literature (Belcher, Low, Posluszny, Kramer, & Donovan, 2016; Burris & Andrykowski, 2011; 
Gotay et al., 2007; Thong et al., 2013). This study also included cancer sites not frequently 
represented in MPC literature (i.e., lung and thyroid cancer). Additionally, this sample had 
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higher average BMI and rates of obesity (41%) when compared to other MPC samples (Burris & 
Andrykowski, 2011; Thong et al., 2013). It is not clear whether this reflects the general increase 
in BMI across the U.S. or whether it is an emerging and unique problem among MPC survivors. 
While not successful in recruiting a racially and ethnically diverse sample, we were successful in 
recruiting a sample of participants with a broad range of educational attainment, which is 
representative of the broader U.S. population (Ryan & Bauman, 2016). Importantly, educational 
attainment was identified as an important predictor of self-management in Aim 2 covariate 
analyses. 
The data in this study support healthy self-management behaviors as vitally important to 
positive health outcomes in MPC survivors. Clinicians caring for MPC survivors should assess 
persons with high-risk BMI, low educational levels, low social support, and greater neuroticism 
for poor health behaviors and distress, both of which are modifiable. Assessments should 
include diet, activity, caloric balance, and brief distress screenings. The National 
Comprehensive Cancer Network’s survivorship and distress clinical practice guidelines 
(National Comprehensive Cancer Network, 2018b, 2018a) provide direction on ways to assess 
and intervene in these areas. Clinicians should also increase their awareness of financial 
toxicity and should engage their patients in care value discussions. As evidenced by the 
expertise needed to address these key clinical priorities in MPC patients, collaboration among 
specialists (e.g., nutritionists, behavioral change experts, mental health professionals, financial 
experts, primary care providers, and oncologists) is key. 
As recognized by recent literature documenting increasing rates of MPC in cancer 
survivors (Davidson, 2017; Murphy, Gerber, & Pruitt, 2017), clinical trial eligibility criteria should 
be evaluated to ensure representativeness of the U.S. cancer survivor population. Whenever 
possible, MPC status should not be an explicit exclusion criterion for clinical trial participation. 
Also, organizations should strive to create systems and policies that allow for continuity of care 
among providers for these medically complex patients.  
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Future studies should evaluate this refined model for studying health outcomes in adults 
with MPC, with a particular focus on self-management and financial toxicity, two newly 
highlighted areas of importance. Biological pathways also are an untapped line of inquiry in this 
patient population and could lead to increased understanding of the mechanisms linking distress 
to poor outcomes in this model. It is also important to understand how risks for poor health 
outcomes may differ among different subsets of MPC survivors (e.g., childhood versus 
adulthood diagnoses; MPCs associated with genetic cancer syndromes versus treatment-
related MPCs versus MPCs associated with risky behaviors). Future research should move to 
longitudinal studies to 1) establish temporal relationships among key variables, 2) understand 
how MPC survivorship risk factors change over time, and 3) identify vulnerable phases in the 
MPC survivorship trajectory. 
Future MPC studies should also focus on novel recruitment methods for this hard to 
reach patient population, as survivors do not all attend specialty MPC clinics where focused 
recruitment could occur. Future studies must also focus on conducting studies that are sensitive 
to the challenges and perspectives of more diverse groups of MPC survivors. With increased 
demands being placed on people’s time and attention, survey response rates have been 
declining and costs have been rising (National Science Foundation, n.d.), and this type of data 
collection may be becoming outdated. Attention should also be paid to addressing the reasons 
for nonparticipation identified in this study (i.e., perception by elderly MPC survivors that their 
input is not valuable; lack of knowledge/awareness of their MPC cancer status; and concerns 
about privacy and allowing access to medical records). 
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3.1 DISSERTATION MANUSCRIPT 1: REVIEW OF LITERATURE 
The full text of this manuscript was reproduced with permission from Psycho-Oncology and can 
be found in Appendix E. 
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3.2 DISSERTATION MANUSCRIPT 2:  PILOT TESTING ASSOCIATIONS AMONG KEY 
VARIABLES 
Presented here is the full text version of the manuscript accepted for publication, which was 
subsequently published in Oncology Nursing Forum. The final publication may be accessed at: 
http://store.ons.org/article/find?doi=10.1188/17.ONF.703-711 
Psychological Distress, Health Behaviors, and Benefit Finding in Survivors of Multiple 
Primary Cancers: Results from the 2010 LIVESTRONG Survey 
3.2.1 Abstract 
Purpose: To evaluate whether survivorship of multiple primary cancers (MPC) is associated 
with psychological distress, health behaviors, and benefit finding. 
Design: Secondary analysis of the 2010 LIVESTRONG cross-sectional survey. 
Setting: Online survey. 
Sample: 238 MPC and 3,295 single cancer survivors. 
Methods: Chi-square and t-tests for group comparisons. Multivariate linear regression, adjusted 
for covariates, for associations between variables. 
Main Research Variables: MPC versus single cancer; psychological distress, health behavior 
(healthy lifestyle and positive healthcare utilization), and benefit finding scores. 
Findings: Survivors of MPC, compared to single cancer survivors, were significantly older, less 
likely to have a spouse/partner, further out from original cancer diagnosis, less likely to be 
employed full-time, and differed by cancer diagnoses and survivorship stage. MPC was 
associated with significantly higher psychological distress and healthcare utilization but not 
healthy lifestyle or benefit finding. 
Conclusions: Relative to those with single cancers, MPC survivors are at increased risk for 
psychological distress and are more likely to receive recommended cancer screenings. 
Additional research is needed to understand mechanisms surrounding psychological distress in 
MPC survivors. 
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Implications for Nursing: Targeted distress screening in MPC survivors may allow for early 
identification and interventions to ameliorate distress and reduce negative downstream health 
effects. 
Knowledge Translation: Nurses should assess for previous cancer histories and recognize 
that survivorship experiences may differ between MPC and single cancer survivors. MPC 
survivors have increased psychological distress risk and may have needs related to living with 
cancer as a chronic illness. Further study of psychological distress mechanisms in MPC 
survivors is warranted. 
Keywords: multiple primary cancers, cancer survivorship, psychological distress, health 
behaviors, benefit finding 
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3.2.2 Background 
With improved cancer screenings and treatments, the United States cancer survivor population 
is predicted to reach 20.3 million people by 2026 and 26.1 million by 2040 (American Cancer 
Society, 2016; Bluethmann et al., 2016; Jemal et al., 2017). As survival increases following 
cancer diagnoses and general effects of aging occur, cancer survivors, however, are facing 
additional serious health issues including subsequent malignant neoplasms. One in five cancers 
diagnosed in the United States will occur in someone who has a previous cancer diagnosis, and 
these multiple primary cancers (MPCs) are a major cause of morbidity and mortality in cancer 
survivors (De Gonzalez et al., 2011; Morton et al., 2014).  
  A second, or multiple primary, cancer (MPC) is the occurrence of a new cancer that is 
histologically distinct from the original primary cancer and has been ruled out as metastatic 
disease of the primary tumor (Begg, 1999). An example of someone who is an MPC survivor is 
an individual who experiences breast cancer and later presents with a new diagnosis of ovarian 
cancer. Contrast this with a woman with breast cancer that metastasizes to the bone, which is 
diagnosed as metastatic spread of the original breast cancer; this would not be considered an 
MPC. Risk of developing subsequent MPCs varies by site of first primary cancer, age at first 
cancer diagnosis, environmental and behavioral exposures, genetic susceptibility, and cancer 
treatment effects (American Cancer Society, 2009, 2012; Morton et al., 2014).  
The National Academy of Medicine, professional organizations, cancer survivorship 
advocates, clinicians, and scientists have called for an increased focus on addressing the health 
and psychosocial needs of the growing population of cancer survivors (American Cancer 
Society, 2016; Klein et al., 2014; Knobf et al., 2015; K. D. Miller et al., 2016; Mullan, 1985, 2016; 
National Academy of Sciences, 2006), and the MPC population represents an understudied and 
at risk group in critical need of additional research. While having a single cancer has been 
linked to risks for psychological distress (Holland et al., 2013; Mitchell et al., 2011; National 
Comprehensive Cancer Network, 2015), poor health behaviors (Mowls, Brame, Martinez, & 
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Beebe, 2016; Underwood et al., 2012), and poor physical health outcomes (Ness, Wall, Oakes, 
Robison, & Gurney, 2006; Stein, Syrjala, & Andrykowski, 2008) that can persist throughout 
cancer survivorship, an initial small body of literature is evolving to suggest that the risk for 
these poor outcomes appears to be even greater in MPC survivors (Andrykowski, 2012; 
Belcher, Hausmann, Cohen, Donovan, & Schlenk, 2016; Burris & Andrykowski, 2011; Dowling 
et al., 2013; Gotay, Ransom, & Pagano, 2007; Thong et al., 2013). Most cancer survivorship 
literature, however, has been conducted irrespective to number of cancer diagnoses, limiting 
our ability to understand potentially unique experiences and needs in this survivor subset. 
Additionally, no studies of MPC cancer survivors to date have analyzed a large national dataset, 
such as the LIVESTRONG survey, that focuses entirely on post-treatment cancer survivorship 
issues. 
Many cancer survivors experience persistent late and/or long-term effects of cancer and 
cancer treatment (National Comprehensive Cancer Network, 2017). Uncontrolled psychological 
distress in cancer survivors is known to negatively impact quality of life, adherence to 
surveillance recommendations, and engagement in health promotion activities (National 
Comprehensive Cancer Network, 2016). Previous cancer survivorship literature has 
demonstrated that healthy lifestyle behaviors are associated with decreased chronic illness and 
improved health and quality of life (Blanchard, Courneya, & Stein, 2008; Davies, Batehup, & 
Thomas, 2011; Ford et al., 2009). Benefit finding, the perception of positive changes such as 
renewed appreciation for life following adversity, has been found in single cancer populations 
and may also be related to positive health behavior change and psychological adjustment 
(Harper et al., 2007; Hawkins et al., 2010; Kanera et al., 2016; Low et al., 2014). Previous 
cancer survivorship literature has been conducted without consideration of patients’ history of 
multiple primary cancers, but early literature suggests that this growing population of MCP 
survivors may be at an increased health risk, highlighting a critical need to build the science to 
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identify potentially modifiable risk and protective factors contributing to health outcomes in this 
unique cancer survivor population. 
The purpose of this secondary analysis of 2010 LIVESTRONG national cancer 
survivorship survey data is to evaluate whether MPC survivorship is associated with 
psychological distress, health behaviors, and benefit finding. We report 1) sociodemographic 
and clinical differences between survivors of single cancers versus MPCs and 2) the 
contribution of MPC survivorship to psychological distress, health behaviors, and benefit finding 
after controlling for important covariates. Findings from this study are used to make 
recommendations to support MPC survivors that are applicable to a wide range of nurses. 
3.2.3 Materials and Methods 
3.2.3.1 Data. The 2010 LIVESTRONG Survey for People Affected by Cancer was a cross-
sectional survey fielded online by LIVESTRONG between June 2010 and March 2011. 
Constituents of LIVESTRONG were notified about the survey via email, Twitter, and Facebook, 
and partner organizations, state cancer coalitions, and comprehensive cancer centers shared 
survey information with their respective constituents and/or patients (Beckjord et al., 2014; 
Campbell et al., 2011; Shapiro et al., 2009) .  
The 2010 LIVESTRONG survey was developed in response to the Institute of Medicine 
Report recommendations (National Academy of Sciences, 2006) that nonprofit organizations 
increase their support of cancer survivorship research and associated mechanisms and was 
aimed at examining post-treatment survivorship issues. The LIVESTRONG Foundation 
developed items for the preceding 2006 LIVESTRONG survey through a multi-year formative 
research process, during which experts and cancer survivors were consulted to incorporate 
challenges faced by cancer survivors. Many of the 2006 LIVESTRONG survey items were 
retained in the 2010 survey following a RAND Corporation analysis that examined survey 
response patterns and content (Rechis et al., 2011). Main topic areas in the 2010 survey 
included physical, emotional, and day to day concerns as well as meaning making, information 
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seeking, and advocacy and engagement. Additional details regarding survey development, 
participant recruitment, and survey administration have been previously published (Beckjord et 
al., 2014; Low et al., 2014; Posluszny et al., 2015; Rechis et al., 2011). 
3.2.3.2 Sample. The parent study received Institutional Review Board (IRB) approval (Rechis et 
al., 2011), and this analysis of de-identified 2010 LIVESTRONG survey data was approved by 
the University of Pittsburgh IRB. The initial survey included 4,192 post-treatment adult cancer 
survivors whose data were considered for this study. Sample selection by single and multiple 
cancer groups is described below and is presented as a flow chart in Figure 5.  
Multiple versus single cancer diagnosis. Survey respondents were asked to report “type 
of cancer (primary site)” and could choose from an extensive 88-item checklist of cancer types. 
Respondents were also asked to separately identify any “additional cancer diagnoses or 
recurrences.” As presented in Figure 5, a priori decisions were made to exclude nonmelanoma 
skin cancer cases in both single and MPC groups. Additional exclusion criteria for the MPC 
group included: second cancer identical to first primary cancer (i.e., recurrence); definite or 
probable metastatic disease for common sites of cancer metastases (i.e., bone, liver, lung, and 
brain) (National Cancer Institute, 2013); and/or unclear, missing, “I don’t know,” or non-cancer 
“other” diagnoses that were not actual cancer diagnoses (e.g., “stroke”). 
  54 
 
 
 
 
  
 
861 endorsed  
additional diagnoses or recurrences 
 
 
4,192 original post-treatment 
adult cancer survivor sample 
 
 
3,331 did not endorse  
additional diagnoses or recurrences 
 
 
Excluded 368 cases with identical 
primary cancer and additional cancer 
site responses (i.e.. recurrences) 
 
 
Final sample:  
238 multiple primary cancer cases 
 
 
Final sample:  
3,295 single cancer cases 
 
 
Excluded 36 cases reporting  
nonmelanoma skin cancer  
 
 
Excluded 47 cases with unclear, 
missing, “I don’t know,” or non-
cancer responses reported in the 
additional cancer “other” free text 
category 
 
 
Excluded 102 cases reporting 
nonmelanoma skin cancer  
 
 
Excluded 106 cases reporting additional 
cancer site diagnoses known to be 
common sites of cancer metastases 
(i.e., bone, liver, lung, and brain) 
 
Figure 5. Flow chart of process resulting in (n=3553) post-treatment adult cancer survivor sample 
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3.2.3.3 Variables of Interest. 
Cancer diagnoses. Classification of respondents as either single or MPC survivors is previously 
described under sample. 
The following categories of variables were assessed in the LIVESTRONG survey by 
asking: “Since completing treatment, have any of the following statements been true for you as 
a result of your experience with cancer?” A series of statements followed, to which respondents 
could answer “yes,” “no,” or “I don’t know.” “I don’t know” replies were treated as missing data in 
this study. Individual survey item endorsements were used to compute sum scores for the four 
survey outcome categories of interest. 
Psychological distress, health behaviors, and benefit finding. Psychological distress 
included 8 items pertaining to anxiety; worry, tension, or stress; preoccupation with cancer; 
worry about dying from cancer; worry about cancer recurrence; depression; and mood swings. 
Health behaviors were divided into two categories: 1) healthy lifestyle and 2) positive 
healthcare utilization. Four healthy lifestyle behavior items included leading a healthier lifestyle; 
regular physical activity (2-3 times per week); healthier diet; and attempts to take care of health. 
Positive healthcare utilization included 3 items including attending regular medical 
appointments; monitoring for second cancer; and being up to date on recommended cancer 
screenings. Six benefit finding items included greater appreciation for life; recognition of what’s 
important in life; renewed spirituality; ability to better deal with stress; better coping; and overall 
feeling like a better person.  
Sociodemographic and clinical variables. Sociodemographic variables included age at 
survey; gender; race; partner status (i.e., single, divorced/widowed, and married); children under 
18 living in the home; educational status; total household income; and employment status. 
Cancer-related clinical variables included age at initial cancer diagnosis; years since diagnosis; 
first primary cancer diagnosis (included categories for top 5 most prevalent diagnoses 
represented by respondents [breast, testicular, colorectal, hematologic, prostate]; remaining 
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diagnoses were represented by “other”); years since last treatment; stage of survivorship (i.e., 
currently on treatment, living with cancer as a chronic illness, <1 year post treatment, 1-5 years 
post treatment, >5 years post treatment, prefer not to answer/unsure); and cancer treatment 
received (i.e., no chemo, chemo only, chemo plus surgery and/or radiation). The selection of 
these predictor variables was driven by critical variables identified in the MPC literature 
(Andrykowski, 2012; Belcher et al., 2015; Belcher et al., 2016; Burris & Andrykowski, 2011; 
Dowling et al., 2013; Thong et al., 2013). 
3.2.3.4 Analyses. Descriptive statistics were used to characterize the sample and key variables 
of interest. To compare characteristics between SC and MPC groups, we used independent 
sample t-tests for continuous variables and !2 for categorical variables. Post-hoc contingency 
table analyses using Pearson χ2 testing were conducted for categorical variables reaching 
statistical significance, and Bonferroni adjusted p-values were calculated to correct for Type I 
error. 
Predictor variables of interest were selected a priori based on the literature and were 
included in the empirically driven multivariate analyses. Multivariate linear regression analysis 
with listwise deletion was used to develop models for predicting the overall categories of 
psychological distress, healthy lifestyle behaviors, positive healthcare utilization, and benefit 
finding, adjusted for both statistically (p<.05) and theoretically significant covariates. Variables 
were included as model covariates if they 1) were related to MPC in bivariate analyses at p<.05, 
or 2) were associated with outcomes in previously published work (i.e., were statistically or 
theoretically significant). Standardized	# and p-values are reported for multivariate linear 
regression models.  
The data were analyzed using IBM SPSS Statistics software, version 22. All tests were 
2-tailed, and statistical significance criterion threshold was set at p<.05 unless otherwise noted
for Bonferroni corrections. 
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3.2.4 Results 
Descriptive statistics are displayed in Table 3 for both single (n=3,295) and MPC (n=238) 
groups. MPC participants differed significantly from those with single cancer diagnoses in that 
they were older at the time of survey completion and were further out from their initial diagnosis. 
Additionally, groups differed statistically by partner status, employment status, type of first 
primary cancer diagnosis, and stage of survivorship. Specifically, those with MPC were less 
likely to have had breast cancer and were more likely to have had one of the less common 
cancers represented in the dataset, “other” as a first primary cancer diagnosis. First primary 
cancer diagnoses most frequently represented in the other category for MPC survivors included 
ovarian, uterine, and thyroid cancer. Breast cancer and melanoma were the two most commonly 
reported second primary cancer diagnoses for MPC survivors. MPC survivors were also more 
likely than single cancer survivors to endorse living with cancer as a chronic illness when 
identifying their stage of survivorship. Being divorced or widowed was more common in MPC 
survivors, but this difference was not significant after Bonferroni adjustment. 
Table 3. 
Sample Sociodemographic and Clinical Characteristics by Single Cancer and Multiple Primary Cancer Groups (N=3,533) 
Variables 
Single 
Cancer 
n = 3295 
Multiple 
Primary Cancers 
n = 238 
Statistic (df)a 
95% CI 
or p-value 
p-value
for
Post-hoc 
testingb-d,f Mean (SD) 
Age at Survey, years 48.4 (12.5) 53.3 (11.3) t (3519) = -5.89 -6.54, -3.28*
Age at Initial Diagnosis, years 42.9 (13.8) 41.8 (15.2) t (3488) = 1.15 -0.76, 2.91
Time Since First Diagnosis, years 5.1 (6.5) 11.4 (10.3) t (3372) = -13.53 -7.21, -5.39*
Number (%) 
Gender 
    Female (n=2218) 2060 (62.9) 158 (66.7) χ (1) = 1.37 .24 
Race 
    White (n=3074) 2865 (92.4) 209 (91.7) χ (1) = .16 .69 
Partner Statusb χ (2) = 6.93 .031* 
  Single (n=659) 618 (19.0) 41 (17.4) .535 
  Divorced/Widowed (n=431) 389 (12.0) 42 (17.8) .009 
  Married (n=2397) 2244 (69.0) 153 (64.8) .180 
Children <18 living in the home 
  Yes (n=2303) 2142 (65.1) 161 (67.6) χ (1) = .61 .434 
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Table 3 (continued). 
Educational Status   χ (3) = 1.67 .643  
    No college (n=790) 732 (22.7) 58 (24.8)    
    Some college (n=824) 776 (24.1) 48 (20.5)    
    College graduate (n=1063) 989 (30.7) 74 (31.6)    
    Graduate school (n=778) 724 (22.5) 54 (23.1)    
Total Household Income   χ (5) = 9.12 .105  
    $0-39,999 (n=538) 489 (18.7) 49 (27.1)    
    $40,000-59,999 (n=462) 432 (16.5) 30 (16.6)    
    $60,000-79,999 (n=438) 413 (15.8) 25 (13.8)    
    $80,000-99,999 (n=411) 384 (14.7) 27 (14.9)    
    $100,000-119,999 (n=319) 301 (11.5) 18 (9.9)    
    $120,000 or greater (n=634) 602 (23.0) 32 (17.7)    
Employment Statusc   χ (3) = 18.73 <.001*  
    Full-time, work or student (n=1852) 1775 (64.1) 97 (49.2)   <.001* 
    Part-time (n=350) 317 (11.6) 33 (16.8)   .031 
    Not employed (n=326) 300 (11.0) 26 (13.2)   .332 
    Retired (n=407) 366 (13.4) 41 (20.8)   .004* 
First Primary Cancer Diagnosisd   χ (5) = 28.97 <.001*  
    Breast (n=1003) 950 (28.9) 43 (18.1)   <.001* 
    Testicular (n=306) 296 (9.0) 10 (4.2)   .012 
    Colorectal (n=207) 185 (5.6) 22 (9.3)   .020 
    Hematological (n=386) 358 (10.9) 28 (11.8)   .653 
    Prostate (n=251) 237 (7.2) 14 (5.9)   .453 
    Other (n=1385) 1265 (38.4) 120 (50.4)†   <.001* 
Second Primary Cancer Diagnosise      
    Breast  33 (13.9)    
    Melanoma  32 (13.4)    
    Thyroid  22 (9.2)    
    Uterine  16 (6.7)    
    Prostate  15 (6.3)    
    Cervical  13 (5.5)    
Time Since Last Treatment, years   χ (3) = 1.09 .779  
    <1 (n=1041) 974 (31.3) 67 (30.0)    
    1-4 (n=1313) 1219 (39.1) 94 (42.2)    
    5-9 (n=572) 538 (17.3) 34 (15.2)    
    ≥10 (n=411) 383 (12.3) 28 (12.6)    
Stage of Survivorshipf   χ (5) = 47.41 <.001*  
    Prefer not to answer/unsure (n=47) 44 (1.3) 3 (1.3)   .920 
    Currently on treatment (n=377) 356 (10.8) 21 (8.8)   .337 
    Living with cancer as a chronic illness (n=169) 136 (4.1) 33 (13.9)   <.001* 
    Less than 1 year post-treatment (n=719) 676 (20.5) 43 (18.1)   .358 
    1-5 years post-treatment (n=1206) 1137 (34.6) 69 (29.0)   .080 
    Greater than 5 years post-treatment (n=1010) 941 (28.6) 69 (29.0)   .897 
Cancer Treatment   χ (2) = 1.99 .369  
    No chemotherapy (n=1428) 1340 (40.7) 88 (37.0)    
    Chemotherapy only (n=346) 325 (9.9) 21 (8.8)    
    Chemotherapy plus surgery and/or radiation  
      (n=1759) 
1630 (49.5) 129 (54.2)    
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Table 3 (continued). 
 
Notes. Frequencies and percentages represent all available data for given variables; *Statistical significance, p<.05; aReported statistics 
are Pearson Chi-Square and independent sample t-tests; b-epost-hoc contingency table analyses using Pearson Chi-Square to detect 
within group differences; Bonferroni adjusted p-value thresholds to correct for Type I error are as follows: bpartner status p=.008, 
cemployment status p=.006, dfirst primary cancer diagnosis p=.004, and fstage of survivorship p=.004. 
eOnly second primary cancer diagnoses that represented ≥5% of the MPC sample are reported. 
†Most frequent first primary cancer diagnoses represented in the other category for MPC survivors included: ovarian 14 (5.9%); uterine 
14 (5.9%); and thyroid 10 (4.2%). Remainder of other category diagnoses for MPC survivors not represented here included diagnoses 
with less than 10 respondents per diagnosis. 
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Mean scores for primary outcomes by single and MPC groups are displayed in Table 4. 
Table 4. 
Mean Sum Scores on Outcome Category Scales by Single and Multiple Primary 
Cancer Groups 
Single 
Cancer 
n = 3295 
Multiple 
Primary 
Cancers 
n= 238 
Category (number of respondents) Range Mean Score (SD) 
    Psychological Distresses (n=3028) 0-8 3.6 (2.5) 3.9 (2.5) 
    Health Behaviors: 
 Healthy Lifestyle (n=2723) 0-4 3.3 (1.0) 3.3 (1.0) 
      Positive Healthcare Utilization (n=2739) 0-3 2.4 (0.8) 2.7 (0.6) 
    Benefit Finding (n=3383) 0-6 4.6 (1.6) 4.6 (1.5) 
Multivariate linear regression analysis results are presented in Table 5. The final 
psychological distress model accounted for 8% of the model variance, F(35, 2670) = 7.51, 
p<.001. Significant predictors of psychological distress in the final model included age at survey, 
gender (female), partner status (divorced or widowed and married), first primary cancer 
diagnosis (colorectal), stage of survivorship (living with cancer as a chronic illness), and 
survivorship of MPCs. The final healthy lifestyle behaviors model accounted for 1% of the model 
variance, F(35, 2378) = 1.88, p = .001. Significant predictors of healthy lifestyle in the final 
model included race (nonwhite), total household income ($80,000-$99,999 and $100,000-
$119,999), employment status (not employed), time since last treatment (5-9 years), and stage 
of survivorship (greater than 5 years post-treatment). The final positive healthcare utilization 
behaviors model accounted for 4% of the variance in healthcare utilization, F(35, 2392) = 3.80, 
p<.001. Significant predictors of healthcare utilization in the final model included educational 
status (college graduate), first primary cancer diagnosis (colorectal and prostate), cancer 
treatment (chemotherapy plus surgery and/or radiation), and survivorship of MPCs. Lastly, the 
final benefit finding model accounted for 3% of the model variance, F(35, 2958) = 3.38, p<.001. 
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Significant predictors of benefit finding in the final model included race (nonwhite), partner 
status (divorced or widowed and married), having children under 18 living in the home, total 
household income ($100,000 to $119,999), employment status (not employed), and cancer 
treatment (chemotherapy only and chemotherapy plus surgery and/or radiation). Survivorship of 
MPCs, our primary predictor variable of interest, was significantly associated with psychological 
distress (standardized # = .046, p = .021) and positive healthcare utilization behavior models 
(standardized # = 2.899, p = .004) but not with healthy lifestyle behaviors (standardized # = -
.012, p = .585) or benefit finding (standardized # = .011, p = .562).  
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Table 5. 
Multivariate Linear Regression Models of Psychological Distress, Healthy Lifestyle, Positive Healthcare Utilization, and Benefit Finding “As a Results of Having Cancer” 
Psychological Distress;  
Model Adjusted R2 = .08;  
F(35, 2640) = 7.51, p<.001* 
Healthy Lifestyle;  
Model Adjusted R2 = .01;  
F(35, 2378) = 1.88, p = .001* 
Healthcare Utilization;  
Model Adjusted R2 = .04;  
F(35, 2392) = 3.80, p<.001* 
Benefit Finding;  
Model Adjusted R2 = .03;  
F(35, 2958) = 3.38, p<.001* 
Sociodemographic or Clinical 
  Variables Standardized ! p-value Standardized ! p-value Standardized ! p-value Standardized ! p-value
Age at Survey, yearsa -.195 .012* .005 .963 .064 .512 -.007 .929 
Age at Initial Diagnosis, years -.017 .838 .048 .651 .079 .447 -.066 .394 
Time since First Diagnosis, yearsa -.069 .105 .055 .381 -.008 . 896 .019 .637 
Gender 
  Male 
    Female 
reference 
.171 
- 
<.001* 
reference 
.005 
- 
.865 
reference 
.010 
- 
.722 
-.007 .775 
Race 
  White 
  Other 
reference 
-.004 
- 
.816 
reference 
.057 
- 
.006* 
reference 
-.006 
- 
.749 
reference 
.053 
- 
.003* 
Partner Status 
  Single 
  Divorced/Widowed 
  Married 
reference 
.075 
.054 
- 
.002* 
.045* 
reference 
-.016 
-.004 
- 
.554 
.889 
reference 
-.046 
.006 
- 
.077 
.827 
reference 
-.051 
-.055 
- 
.030* 
.033* 
Children <18 living in the home 
  No 
    Yes 
reference 
.034 
- 
.138 
reference 
-.016 
- 
.551 
reference 
.010 
- 
.669 
reference 
.114 
- 
<.001* 
Educational Status 
  No College 
  Some College 
  College Graduate 
  Graduate School 
reference 
-.014 
.009 
-.023 
- 
.550 
.707 
.328 
reference 
.018 
.029 
.035 
- 
.472 
.274 
.175 
reference 
-.010 
.068 
.042 
- 
.690 
.009* 
.097 
reference 
.013 
-.034 
-.031 
- 
.559 
.142 
.187 
Total Household Income 
 $0-39,999 reference - reference - reference - reference - 
 $40,000-59,999 <.005 .800 .000 .994 -.041 .065 -.019 .333 
 $60,000-79,999 -.008 .693 .020 .371 .031 .169 -.037 .066 
 $80,000-99,999 -.573 .567 .050 .031* -.016 .487 -.034 .093 
 $100,000-119,999 -.025 .226 .060 .009* .036 .113 .043 .035* 
 $120,000 or greater -.022 .330 .041 .102 .011 .647 .012 .574 
Employment Status 
  Full-time 
  Part-time 
  Not employed 
  Retired 
reference 
.006 
.032 
.042 
- 
.848 
.772 
.108 
reference 
.003 
-.053 
.004 
- 
.885 
.013* 
.850 
reference 
.020 
-.038 
.007 
- 
.337 
.067 
.771 
reference 
-.002 
-.061 
-.004 
- 
.909 
.001* 
.859 
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Table 5 (continued). 
First Primary Cancer Diagnosisa 
  Breast 
  Testicular 
  Colorectal 
  Hematological 
  Prostate 
  Other      
reference 
.042 
.042 
.010 
.018 
.034 
- 
.111 
.045* 
.669 
.481 
.194 
reference 
-.045 
.029 
-.006 
.000 
-.010 
- 
.119 
.220 
.823 
.988 
.739 
reference 
.039 
.053 
.011 
-.065 
.017 
- 
.177 
.021* 
.680 
.017* 
.541 
reference 
.002 
.009 
.013 
-.013 
-.011 
- 
.953 
.658 
.572 
.589 
.664 
Time since Last Treatment, years 
  <1 
1-4
5-9
≥10
-.020 
reference 
-1.311
-1.229
.482 
- 
.190 
.219 
-.019 
reference 
-.082 
-.997 
. 
.571 
- 
.011* 
.319 
-.011 
reference 
-.008 
-.055 
.745 
- 
.805 
.138 
-.035 
reference 
-.007 
.003 
.213 
- 
.806 
.935 
Stage of Survivorshipa 
  Prefer not to answer/unsure 
  Currently on treatment 
  Living with cancer as a chronic 
illness 
  Less than 1 year post-treatment 
1-5 years post-treatment
Greater than 5 years post-treatment
-.015
.041
.057
-.031
reference 
-.015 
.434 
.076 
.006* 
.277 
- 
.686 
.005 
1.076 
-.175 
-.279 
reference 
.086 
.826 
.282 
.861 
.781 
- 
.029* 
.026 
-.347 
-1.373
-.017
reference 
-.011 
.193 
.729 
.170 
.606 
- 
.772 
-.021 
.012 
.007 
.040 
reference 
.046 
.256 
.598 
.722 
.159 
- 
.194 
Cancer Treatment 
  No chemotherapy 
  Chemotherapy only 
  Chemotherapy plus surgery and/or 
  radiation 
reference 
-.007 
.037 
- 
.725 
.091 
reference 
.030 
.033 
- 
.204 
.170 
reference 
-.245 
.047 
- 
.807 
.046* 
reference 
.056 
.046 
- 
.007* 
.029* 
Survivorship of Multiple Primary 
Cancers 
.046 .021* -.012 .585 2.899 .004* .011 .562 
Notes. aVariables with statistically significant differences between single cancer and multiple primary cancer groups in t-tests and "2. Theoretically-guided variables from the literature 
were determined a. priori and were also included in the multivariate model. *Statistical significance, p<.05. 
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3.2.5 Discussion 
Most striking in this study was the association between MPC and psychological distress, which 
was consistent with our recent review of literature (Belcher et al., 2016). Consistent with findings 
in a cohort of MPC survivors 10-20 years older than the MPC survivors in our sample (Gotay et 
al., 2007; Thong et al., 2013), survivorship of MPC did not predict benefit finding as a result of 
one’s cancer experience. An unexpected finding unique to this study was that MPC survivors 
were more likely than single cancer survivors to report “living with cancer as a chronic illness” 
when asked to identify their stage of survivorship. This finding may indicate that MPC survivors 
face additional survivorship needs related to chronic illness and warrants additional study. Living 
in a state of chronic illness may be contributing to chronic stress and increasing risk for physical 
and psychological disease in this population (Corbin & Strauss, 1988; Dowrick, Dixon-Woods, 
Holman, & Weinman, 2005; Grady & Gough, 2014; Miller et al., 2002). 
Consistent with other MPC studies, we found that MPC survivors differed from single 
cancer survivors, in that they were older (Andrykowski, 2012; Thong et al., 2013) and had 
experienced more time since their initial cancer diagnosis (Burris & Andrykowski, 2011). 
However, the MPC survivors represented by this LIVESTRONG cancer survivor sample were, 
on average, approximately 11-18 years younger than those currently represented in previous 
MPC literature (Andrykowski, 2012; Burris & Andrykowski, 2011; Gotay et al., 2007; Thong et 
al., 2013). Additionally, MPC and single cancer survivors in this sample also differed by type of 
initial cancer diagnosis, with MPC survivors being less likely to have had breast cancer as their 
first diagnosis and more likely to fit into the “other” category (i.e., ovarian, uterine, and thyroid 
cancer). With differing cancer types come differing treatments and cancer treatment 
experiences. Thus, additional research is needed to determine the complex implications of 
differing diagnoses and treatments on health outcomes in MPC survivors.  
While this study did not find statistical differences for income between groups, MPC 
survivors were less likely to be employed full time and more likely to be retired. Other 
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preliminary work by our team has found that MPC survivors with recurrent ovarian cancer were 
more likely to endorse lower income and difficulty meeting basic needs than survivors with 
recurrent ovarian cancer “only” (Belcher et al., 2015). Another study found that MPC survivors 
experienced greater levels of lost productivity (e.g., employment) as compared to individuals 
without cancer and to survivors of single cancers (Dowling et al., 2013). With respect to partner 
status, we found that being divorced or widowed was more common in MPC survivors, though 
post-hoc testing with Bonferroni adjustments for Type I error did not identify statistical 
differences. Partner status, both divorced or widowed and married, was predictive of 
psychological stress. A study from the Netherlands found that MPC survivors report greater 
cancer impact on life, including body changes and interference with social activities (Thong et 
al., 2013). When viewed in context with findings from previous studies, results from this study 
support further examination of the impact of MPC on work and social role function in future MPC 
studies. 
MPC survivors were more likely to report positive healthcare utilization, including 
engagement in cancer screenings and regular medical appointments. Similarly, Thong and 
colleagues (Thong et al., 2013) found that MPC presence was associated with greater health 
awareness. Conversely, MPC status was not associated with healthy lifestyle behaviors such as 
diet and regular exercise, which was consistent with Burris and Andrykowski’s findings that 
those with MPC were more likely than single cancer survivors to have unhealthy behaviors (i.e., 
physical inactivity, smoking, and alcohol use). This may reflect a maladaptive behavioral coping 
response and warrants additional study in MPC survivors. As day-to-day chronic disease 
management responsibility shifts from providers to individuals (Barlow et al., 2002; Ryan, 2009), 
interventions to support survivors in initiating and maintaining healthy behaviors will be 
increasingly important in limiting exacerbation of existing conditions and preventing new 
conditions.  
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Weaknesses in this study are acknowledged. Given the cross-sectional design, causal 
or temporal relationships between variables cannot be determined. Secondary analysis is 
limited to questions posed in the dataset, and information about psychological distress severity 
was not collected. Although we could account for 8% of variance in psychological distress in this 
large sample of cancer survivors, this suggests that there are other important factors that were 
not able to be included in this secondary data analysis, such as comorbidities, symptoms, 
physical function, perceived stress, social support and coping resources, self-management 
behaviors, financial toxicity, and biological stress responses. Additionally, MPC survivors 
represented 5.7% of our sample, which is slightly less than the 8% MPC representation that is 
typically found in the overall cancer survivor population (Mariotto, Rowland, Ries, Scoppa, & 
Feuer, 2007). By conservatively excluding cases in which survivors reported a common site of 
metastasis as their second cancer, it is possible that we may have excluded true MPC cases 
from our analyses. Also, it has previously been reported that LIVESTRONG respondents are 
younger, less diverse, more educated, and wealthier than would be expected, which may be 
due to the voluntary, online nature of this survey (Low et al., 2014; Rechis et al., 2011) and may 
lead to decreased generalizability to the general cancer survivor population. However, this study 
expands what is currently known about MPC survivors by capturing a sample of survivors at an 
earlier age than has previously been described. Lastly, missing data, mostly in health behavior 
outcomes, may bias findings. Because rates of missingness were similar for variables between 
groups, we included as many cases as possible for both groups and presented all available 
data. 
Strengths of this study include the ability to capture a large sample of post-treatment 
MPC survivors, to provide data on a younger demographic of MPC survivors than has 
previously been reported, the use of both negative (psychological distress) and positive (benefit-
finding and health promotion behaviors) responses as independent outcomes, and models 
adjusted for a wide range of potential confounding variables. 
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3.2.6 Implications for Nursing 
Nurses are uniquely positioned to support unmet needs in MPC survivors. Nurses should be 
aware that survivorship needs may differ in cancer survivors based upon number of previous 
cancer diagnoses, and that the survivorship experience may differ between MPC and single 
cancer survivors. Additionally, MPC survivors are at an increased risk for psychological distress 
and may have additional needs related to living with cancer as a chronic illness (e.g., engaging 
in positive self-management behaviors such as healthy diet and exercise). Targeted and 
ongoing screening for distress in MPC survivors is warranted in specialty and/or primary care 
settings and may promote early identification and treatment to reduce potential negative 
downstream health effects.  
Oncology nurse scientists should contribute to building the science in this area to 
identify, understand, and address the unique needs of MPC survivors. As the number of cancer 
survivors diagnosed with MPC grows, number of primary cancer diagnoses should be 
considered in study designs. While an early body of literature has begun to describe the 
prevalence of health outcomes in MPC survivors, a paucity of research exists surrounding 
mechanisms and risk factors for late and long-term effects of cancer and their potentially unique 
needs. Also unclear is whether the potential for care silos and lack of a clinical home influences 
health outcomes in MPC survivors. Nurses are well suited to study, assess, and address MPC 
care needs.  
3.2.7 Conclusions 
Cancer survivors are increasingly being diagnosed with additional subsequent primary cancers. 
Our findings provide additional evidence that MPC survivors differ from their single cancer 
counterparts and are at increased risk for psychological distress. Our findings support a need to 
specifically identify, understand, and address the ongoing, unique needs of MPC survivors. 
Additional research is needed to identify MPC survivors most at risk for poor outcomes and to 
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understand the care needs and mechanisms that contribute to poor health outcomes in this 
growing cancer survivor population.  
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3.3 DISSERTATION MANUSCRIPT 3:  DISSERTATION AIMS 1 AND 2 
Adapting a Psychobehavioral Stress-Response Model to Characterize Risks in Survivors 
of Multiple Primary Cancers 
3.3.1 Abstract 
Objective:  The purpose of this study was to evaluate hypothesized relationships in an adapted 
psychobehavioral stress-response model among adults with multiple primary cancers (MPC). 
We aimed to 1) test the hypothesized model to examine associations among measured latent 
variables: perceived stress, psychological and behavioral responses, financial toxicity, and 
social role and physical health and 2) explore associations between individual characteristics 
and latent variables in the model.  
Methods: This cross-sectional study of MPC survivors included participants whose first cancers 
(stages I-III) were diagnosed within 1-10 years. Participants were recruited through a regional 
tumor registry. Participants completed a battery of valid questionnaires to measure latent 
variables and covariates; data were extracted from tumor registry and medical record data. 
Structural equation modeling (SEM) was performed to fit and modify the measurement model, 
specify the full SEM, and identify significant predictors. 
Results: 211 participants completed surveys. Data fit a modified four-factor measurement 
model with latent variables including self-management, distress, financial toxicity, and functional 
health. Overweight BMI, graduate level education, less neuroticism, and increased social 
support predicted better self-management. Poorer self-management, greater neuroticism, and 
lower social support predicted increased distress. Greater distress predicted financial toxicity. 
Greater distress and financial toxicity predicted poorer functional health.  
Conclusions: Self-management behaviors and distress are modifiable targets with potential to 
mitigate financial toxicity and improve functional health. MPC survivors with extreme BMIs, less 
education, greater neuroticism, and lower social support should be considered at risk for poorer 
self-management and negative downstream health outcomes. 
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biobehavioral oncology; health behaviors; self-management; distress; financial toxicity; health 
outcomes; conceptual model  
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3.3.2 Introduction 
As the population ages and cancer survival improves, the incidence of subsequent, or multiple, 
primary cancer (MPC) diagnoses is also increasing. Three million, or one in five, U.S. cancer 
survivors are diagnosed with an additional cancer in their lifetime (Morton et al., 2014), which 
increases to one in four for cancer survivors over 65 years old (Murphy et al., 2017). MPCs are 
histologically distinct cancers that have been ruled out as metastatic disease (Begg, 1999) and 
are a leading cause of morbidity and mortality among cancer survivors. Risk for psychological 
distress, risky health behaviors, and poorer physical health is greater in MPC survivors than in 
single- and no-cancer controls (Andrykowski, 2012; Belcher et al., 2017; Belcher et al., 2016; 
Burris & Andrykowski, 2011; Dowling et al., 2013; Gotay et al., 2007; Thong et al., 2013). 
Additionally, there is evidence to suggest that MPC survivors may be at increased risk for 
financial toxicity and impaired social functioning (Belcher et al., 2015; Dowling et al., 2013; 
Thong et al., 2013). 
An adapted psychobehavioral stress model was used to identify pathways linking stress 
to poor health outcomes. Perceived stress is the perception that one’s demands exceed his or 
her coping resources (Lazarus & Folkman, 1984), which, if left uninterrupted, can result in a 
cascade of psychological, behavioral, and biologic responses that negatively impact health 
outcomes. Links between perceived stress, psychological responses (e.g., depression, anxiety) 
and behavioral responses (e.g., positive self-management and risky health behaviors), and 
physical health outcomes (e.g., physical function, symptoms, and comorbidities) have been well 
established (Andersen et al., 1994; Andersen et al., 2008; Bower & Lamkin, 2013; Cohen et al., 
1995; Sherwood et al., 2008).   
 Additional pathways (see Figure 6) impacting financial and social outcomes are also 
important in this adapted model. Financial toxicity is increasingly recognized as a potential 
consequence of cancer and cancer treatment (Zafar & Abernethy, 2013; National Cancer 
Institute, n.d.-a). and has been linked to poor treatment adherence and mortality (Kent et al., 
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2013; National Cancer Institute, 2018c; Park & Look, 2018; Ramsey et al., 2016;). MPC is a 
known risk factor for financial toxicity (Belcher et al., 2015; Dowling et al., 2013; National Cancer 
Institute, 2018c). Cancer is also known to impact social function (i.e., involvement in and 
satisfaction with one’s usual social relationships and activities) (Bode et al., 2010; Costa, 
Mercieca-Bebber, Rutherford, Gabb, & King, 2016; Hahn, Cella, Bode, & Hanrahan, 2010; 
Syrjala & Yi, 2018). Having MPC has been associated with interference in a range of life and 
social role activities (e.g., availability to family, not being understood, impact on daily activities) 
and limitations in ability to do work (Dowling et al., 2013; Thong et al., 2013).   
 
 
 
 
 Despite the rising prevalence of MPC and associated poor health outcomes, there is a 
lack of research examining potential pathways linking MPC to negative outcomes, and research 
in this patient population has lacked conceptual models to guide inquiry. The purpose of this 
study, the first to evaluate hypothesized relationships within an adapted psychobehavioral 
stress-response model in MPC, is to 1) identify important factors associated with negative 
 
Figure 6. Conceptual model. This figure depicts the cascade of 
psychological, behavioral, and biologic responses to perceived 
stress that can negatively impact health outcomes in adults with 
multiple primary cancers. Biologic responses will be investigated 
in future studies. 
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health outcomes and 2) guide early identification of MPC survivors at risk for poor health 
outcomes.  
Specifically, the primary aim was to test the hypothesized model using structural 
equation modeling to examine the linear relations among the measured latent variables of 
perceived stress, psychological response, behavioral response, financial toxicity, social role 
function, and functional health. It was hypothesized that: 
1. Perceived stress has direct effects on a) psychological response, b) behavioral
response, c) financial toxicity, d) social role function, and e) physical health;
2. Behavioral response has direct effects on a) psychological response, b) financial toxicity,
c) social role function, and d) physical health; and
3. Psychological response has direct effects on a) financial toxicity, b) social role function,
and c) physical health.
The secondary aim was to explore individual, sociodemographic, and clinical characteristics that 
may directly impact upstream latent variables in the model. 
3.3.3 Methods 
3.3.3.1 Sample and setting. An honest broker system was used to recruit participants through 
the UPMC Cancer Network Registry, a member of the National Program of Cancer Registries 
who report to the larger Pennsylvania Cancer Registry (“Cancer registry requirements,” n.d.). 
Study eligibility criteria included a history of two primary cancers based on Surveillance, 
Epidemiology, and End Results (SEER) Program coding rules (Johnson et al., 2007), with first 
cancer sites consistent with most prevalent first diagnoses experienced by adults living after 
MPC diagnoses:  female breast, prostate, colorectal, urinary bladder, uterine, melanoma, kidney 
and renal pelvis, lung and bronchus, oral cavity and pharynx, thyroid, or ovary (American 
Cancer Society, 2009). Additional query criteria included first diagnoses 1-10 years ago; stage I-
III cancers at time of diagnosis (both first and second primary cancers); and able to read and 
complete questionnaires in English. Cases of non-melanoma skin cancer; in situ cancer; 
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advanced staging (i.e., stage IV) at diagnosis, and recurrent cancers were excluded from the 
query. Additional study exclusion criteria included being listed in the corporate opt-out database 
and being deemed not appropriate for contact based on physician champion review of cases. 
Sampling was conducted using stratified systematic sampling by disease type with 
oversampling of individuals from traditionally underrepresented races and ethnicities. 
3.3.3.2 Study procedures. Participants were recruited, and cross-sectional data were collected 
using a series of contacts based on a modified version of Dillman’s Tailored Survey Method 
(Dillman et al., 2014). The honest broker system was used to identify prospective participants 
and invite study participation. Letters of invitation were signed by physician champions, and 
follow up reminder postcards were mailed to individuals who did not respond to initial contact. 
Participants could either complete the survey online via Qualtrics, an Institutional Review Board 
(IRB) approved, Web-based survey system (University of Pittsburgh Computing Services and 
Systems Development, n.d.), or request a postage-paid paper survey via mail, email, or 
telephone. Informed consent was obtained based on mode of selected survey delivery. Partially 
completed online surveys prompted reminder emails on Days 5, 10, and 21 following survey 
invitations. For study packets that had not been returned, reminder postcards were sent on Day 
14, and additional follow-up contacts were made via participant-initiated mode of contact on Day 
21. Following survey completion, participants were sent a thank you card or email message and
compensated with a five-dollar Amazon code. Individuals who did not wish to participate were 
asked to complete a voluntary, anonymous refusal form, either online or on paper, that included 
five basic sociodemographic questions. Key clinical variables were obtained from both the 
Cancer Registry database and medical record review. This study was approved by the 
University of Pittsburgh IRB.  
3.3.3.3 Instruments. A battery of valid and reliable measures was administered to 
operationalize model latent variables. Short forms and common measures were administered 
when possible to decrease participant burden and increase generalizability. PROMIS measures 
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were scored using individual participant response pattern scoring through the online 
Assessment Center Scoring Service;SM for resulting T-scores, 50=average, while T-score=60 is 
one standard deviation higher, or better, than average (Cella, Gershon, Bass, & Rothrock, 
2017). When no information was available regarding number of items required to scale a score, 
item scores were imputed if at least 80% of scale items were completed. 
3.3.3.3.1  Sociodemographic, personal, and clinical predictors.  
Sociodemographic. An adapted self-reported instrument (Sereika & Engberg, 2006) was 
administered to assess sociodemographic variables (e.g., age, gender, race, partner status, 
education, and employment).  
Personality. The neuroticism and conscientiousness domains of the International 
Personality Item Pool (IPIP), mini, were administered to assess personality (Donnellan et al., 
2006; Goldberg, 1999). Each 4-item subscale is scored 1 (very accurate) to 5 (very inaccurate), 
with higher sum scores indicating greater neuroticism and conscientiousness.  
Social support. The 12-item Interpersonal Support Evaluation List (ISEL-12) was used to 
measure perceived social support. Items, rated 1 (definitely true) to 4 (definitely false), are 
summed, with higher total scores indicating better perceived social support.  
Clinical variables. First cancer site and time from first cancer diagnosis was obtained 
from the Cancer Registry. Second cancer site, time from second cancer diagnosis and 
treatment, time between cancer diagnoses, more than 2 primary cancer diagnoses, and body 
mass index (BMI) were extracted from the medical record. 
3.3.3.3.2  Latent variables. 
Perceived stress. Three measures were used to capture the latent variable of perceived 
stress. The 10-item Perceived Stress Scale (PSS) captures global perceived stress (Cohen et 
al., 1983; Golden-Kreutz et al., 2004) on a 0 (never) to 4 (very often) scale. The PSS total 
summary score ranges from 0 to 40, where higher scores suggest greater perceived stress. The 
Revised Impact of Event Scale (IES-R) was used to assess cancer-specific stress (Salsman et 
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al., 2015; Weiss, 2007; Weiss & Marmar, 1997). The IES-R, with 22 items rated 0 (not at all) to 
4 (extremely), produces a summary total score ranging from 0 to 88, where higher scores 
indicate greater cancer-specific stress. The 3-item Cancer Worry subscale of the Assessment of 
Survivor Concerns scale was used to measure cancer survivor stress related to future tests, 
new diagnoses, and recurrences (Gotay & Pagano, 2007; Thewes et al., 2012). Worry items are 
rated on a 4-point Likert scale, from 1 (not at all) to 4 (very much), and are summed to yield a 
summary score ranging from 3 to 12. Higher cancer worry subscale scores are indicative of 
greater worry. In the current study, the combined measures of perceived stress demonstrated 
acceptable internal consistency (standardized Cronbach’s ! = .75). 
Psychological responses. Three measures were used to capture the psychological 
response latent variable. Two-item Personal Health Questionnaire (PHQ) depression and 
Generalized Anxiety Disorder (GAD) short form scales were used to measure depression and 
anxiety, respectively (Kroenke et al., 2003, 2007; Löwe, Kroenke, & Gräfe, 2005; Plummer, 
Manea, Trepel, & McMillan, 2016; Whooley, Avins, Miranda, & Browner, 1997). Items from each 
scale, ranked 0 (not at all) to 3 (nearly every day), produce sum scores ranging from 0 to 6; 
scores >3 should prompt further clinical assessment. The 10-item Global Mental Health 
subscale of the PROMIS Global Health measure (Hays et al., 2009; HealthMeasures, 2017), 
version 1.0, was used to assess global mental health. Raw scores were converted to v1.2 
format and submitted to the Assessment Center Scoring Services website for cancer sample 
calibrated scoring as T-scores. Internal consistency of the combined psychological response 
measures in this sample was good (standardized Cronbach’s !	= .85). 
Behavioral responses. Three measures were used to capture the behavioral response 
latent variable. The 40-item Health Education Impact Questionnaire (hei-Q) (Elsworth et al., 
2015; Maunsell et al., 2014; Osborne et al., 2007) assess eight domains of self-management 
behaviors including health-directed activities (HAD); positive and active engagement in life 
(PAE); emotional distress (ED); self-monitoring and insight (SMI); constructive attitudes and 
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approaches (CAA); skill technique and acquisition (STA); social integration and support (SIS); 
and health service navigation (HSN). Items are ranked 1 (strongly disagree) to 4 (strongly 
agree), and are averaged to produce mean subscale scores, with higher scores indicating better 
self-management (except the emotional distress subscale, which is interpreted inversely). The 
PROMIS Alcohol Use short form 7a (Patient-Reported Outcomes Measurement Information 
System, 2014; Pilkonis et al., 2016) was administered to assess alcohol use. Respondents who 
reported alcohol use were administered six additional items, ranked on a 1 to 5 scale, with 
higher raw sum scores, calibrated against a chronic illness sample, indicating greater 
consumption (scale range 5-25; negative screens=0). The Cancer Patient Tobacco Use 
Questionnaire (CTUQ) was used to assess tobacco use (Land et al., 2016; National Cancer 
Institute, 2016), yielding data for calculation of pack-year-history. In the current study these 
combined measures of behavioral response demonstrated questionable internal consistency 
(standardized Cronbach’s	! = .67); when alcohol and tobacco use were later dropped from 
multivariate analyses, acceptable internal consistency was achieved for the set of heiQ 
subscales (standardized Cronbach’s !	= .77), leading to renaming the Behavioral Response 
latent variable as Self-Management Behaviors. 
Financial toxicity. Two measures were used to capture the latent variable of financial 
toxicity. The first was the 11-item Comprehensive Score for financial Toxicity (COST), v1 (De 
Souza et al., 2016; De Souza et al., 2014). Items, ranked on a 5-point scale ranging from 0 (not 
at all) to 4 (very much), were summed to produce a total score, ranging from 0 to 44, where 
higher total scores indicate better financial wellbeing. The second, the Economic Hardship 
Questionnaire (EHQ) (Barrera et al., 2001), includes four subscales: inability to make ends meet 
(MEM), not enough money for necessities (MFN), economic cutbacks and adjustments (EA), 
and anticipation of future financial strain (FS), with higher scores indicating greater hardship. 
The 2-item MEM and FS subscales include items ranked 1 to 5 and yield mean subscale 
scores. The first 4-items from the MFN subscale, ranked 1 (strongly agree) to 5 (strongly 
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disagree), yield a sum score ranging from 4 to 20. The 9-item EA subscale consists of a 
checklist of adjustments made due to financial need, with yes endorsements summed to 
produce a 0-9 subscale score.  Internal consistency of the combined measures in this sample 
was excellent (standardized Cronbach’s ! = .92). 
Social role function. Two measures were used to capture the latent variable of social role 
function. The 8-item PROMIS Ability to Participate in Social Roles and Activities V2.0 and 8-item 
PROMIS Satisfaction with Participation in Social Roles short forms measure perceived ability to 
participate in social roles and activities and satisfaction with participation in usual roles and 
activities, respectively. Items are rated 5 (never) to 1 (always) and 1 (not at all) to 5 (very much) 
on the respective measures. Each measure was calibrated against the default social 
supplement sample yielding a T-score. Internal consistency in this sample was good 
(standardized Cronbach’s ! = .85). 
Physical health. Three measures were used to capture the physical health latent 
variable. The 10-item PROMIS Physical Function 10a short form assesses limitation in physical 
function (Cook et al., 2016; Patient-Reported Outcomes Measurement Information System, 
2015; Rose et al., 2014). Items are ranked 1 to 5 and yield a T-score, calibrated against a 
cancer sample. The 19-item MD Anderson Symptom Inventory (MDASI) (Aktas et al., 2015; 
Cleeland et al., 2000; Cleeland, 2016) was used to assess symptom burden, a mean composite 
of the top five of 13 rated symptoms in the sample (range=0-10, with higher scores indicating 
greater burden), and symptom distress, the overall mean of the 6 interference items (possible 
range=0-10, with higher scores indicating greater interference). The brief 10-item self-report 
comorbidity index was used to assess comorbidities (Charlson et al., 1987; Chaudhry et al., 
2005). Weighted items were summed to create an index score, ranging from 0 to 25, with higher 
scores indicating worse comorbidity. Internal consistency of the combined measures in this 
sample was good (standardized Cronbach’s ! = .86). 
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3.3.3.4 Data analyses. Data for 215 participants were analyzed using IBM® SPSS® software, 
version 25 (IBM Corp., Armonk, NY) at significance level of .05 for two-sided hypothesis testing. 
Chi-square test of independence and independent sample t-tests for two-sided hypothesis 
testing were used to compare characteristics of respondents with nonrespondents. Descriptive 
statistics, frequency distributions, and exploratory analyses were performed to identify any data 
anomalies (i.e., normality, univariate and multivariate outliers, multicollinearity, missing data) 
and characterize the sample. Z-scores and Malahalanobis distance were assessed for 
univariate and multivariate outliers, respectively. Score alterations were applied to variables with 
extreme outliers (see Table 6 footnote). Reverse scoring was applied as necessary to achieve 
consistent direction among sets of measured variables in multivariate analyses. Due to scaling 
differences across measured variables, measured variables were re-scaled, such that variance 
of the measured variable was <10 to enhance model convergence. Confirmatory factor 
analyses were performed for groups of latent variables and the measurement model. Internal 
consistency of the sets of measured variable for each latent variable was evaluated using the 
standardized Cronbach’s alpha (!) coefficient, where Cronbach’s ! >.7 is considered 
acceptable (George & Mallery, 2003). 
SEM was performed in two stages. First, the measurement model was fit and modified. 
All of the measurement models were estimated employing robust maximum likelihood 
estimation to account for normality violations (Li, 2016). Next, the full SEM was then specified 
using Mplus, version 8.1 (Muthén & Muthén, Los Angeles, CA). Post-hoc model modifications 
were made to improve model fit and parsimony based on model test statistics, fit indices, and 
theory. The model chi-square test was evaluated for model fit. Additional practical fit indices 
were evaluated for model fit, and cut points were considered acceptable if: comparative fit index 
(CFI) >.95; Tucker-Lewis Index (TLI) >.95; standardized root mean residual (SRMR) <.08; root 
mean square error of approximation (RMSEA) <.06 (Hu & Bentler, 1999; Kenny, 2015; Little, 
2013). Significance of standardized path coefficients was evaluated to determine paths to retain 
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in the final modified model. For the original SEM with a sample size of 206 with 309 degrees of 
freedom, the analyses had >.99 power for either the test of a close fit (i.e., RMSEA0 = .05 vs 
RMSEAA = .08) or exact fit (i.e., RMSEA0 = 0.0 vs RMSEAA = .05). 
After model adequacy was determined, upstream paths were added to explore possible 
personal, sociodemographic, and clinical covariates for improved model fit and determination of 
significantly associated characteristics that may be used to identifying individuals at risk for poor 
downstream health outcomes. 
3.3.4 Results 
3.3.4.1 Sample statistics. The Cancer Registry identified 2233 people who were potentially 
eligible for study participation. Of these people, 62 (2.8%) were on the corporate “do not 
contact” list, and physicians requested that 46 (2.1%) not be contacted. After sampling, 1443 
letters were mailed to the remaining potentially eligible individuals. Thirty-nine letters (2.7%) had 
undeliverable mailing addresses, 11 (0.8%) were deceased, and 2 (0.1%) had advanced 
Alzheimer’s disease/dementia. This analysis used only complete cases, thus, four were dropped 
due to partial online survey completion (n=211). Of the remaining 1390 cases, 211 (15.2%) 
completed surveys (125 [59.2%] on paper; 86 [40.8%] online). See Figure 7 for recruitment 
flowchart. Five cases were also identified as being multivariate outliers and were also dropped 
from analysis (final sample size for multivariate analysis, n=206). 
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 Sociodemographic and clinical characteristics of 211 participants who completed the 
survey are summarized in Tables 6 and 7 (see also supplementary Tables 9-12). Participants 
were on average 67 years of age. The majority were female, white, married, retired, and 
insured. A broad range of educational levels was represented in the sample, with nearly 40% of 
participants having a high school level education or less. Over 30% of participants reported 
difficulty paying for basic needs. Neuroticism was in the lower quartile of the scale range, 
conscientiousness was in the upper quartile of the possible range (10 and 15, respectively), and 
perceived social support was fairly high (39).  
On average, approximately six years had passed since participants’ first cancer 
diagnoses, and the most common sites of first cancer diagnoses included lung, prostate, breast, 
thyroid, and melanoma. Most commonly identified sites of second cancer diagnoses identified 
via medical record data included breast, lung, thyroid, kidney, and melanoma. Irrespective of 
sequence, breast and prostate cancer were the most commonly diagnosed cancers in this 
sample (n=47 [22.3%] and n=45 [21.3%], respectively), followed by lung cancer (n=42 [19.9%]) 
(see supplementary Table 10 for complete list). Fifty percent of participants experienced their 
Figure 7. Study flow. This flowchart illustrates study recruitment. 
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first and second cancer diagnoses within a six-month time period. An average of approximately 
four years had passed since participants’ cancer treatment completion, and almost 16% of 
participants had more than two documented primary cancer diagnoses. The most common 
combinations of first and second cancer sites diagnosed in this sample were second primaries 
in the same site:  lung/lung (n=29, 9.8%); breast/breast (n=17, 8.3%); thyroid/thyroid (n=12, 
5.9%); melanoma/melanoma (n=11, 5.4%) (full list available in supplementary Tables 11 and 
12). Over 40% of participants were classified as obese (BMI >35), based on most recent 
records. 
Table 6 
 
Self-Reported Sample Characteristics (N=211) 
Characteristics Summary Statistics 
 Mean (SD) Range 
Current Age, years* (n=211) 67.1 (11.4) 29-89 
Personality   
    Neuroticism (n=211) 9.6 (3.7) 4-20 
    Conscientiousness* (n=211) 15.1 (3.2) 6-20 
Social Support 39.1 (7.6) 15-48 
 n % 
Gender (n=211)   
    Female 128 60.7 
Race/Ethnicity (n=211)   
    White or Caucasian 196 93.0 
Partner Status (n=211)   
    Married/Living with Partner 147 69.7 
Educational Attainment (n=209)   
    High School/GED or less 81 38.8 
    Beyond high school through bachelor’s degree 81 38.8 
    Master’s Level or beyond 47 22.5 
Difficulty Paying for Basic Needs (n=209)   
    Not Difficult 142 67.9 
    Somewhat or Extremely Difficult 67 32.1 
Employment Status (n=209)   
    Retired, Not Working 109 52.2 
    Working Full-time (≥35 hours/wk) 39 18.7 
    Retired, Working Part- or Full-time 18 8.6 
    Disabled/Unable to Work 18 8.6 
    Full-time Homemaker 12 5.7 
    Working Part-time (<35 hours/wk) 10 4.8 
    Laid Off/Unemployed/Looking for Work 3 1.4 
Healthcare Insurance (n=210) 208 99.0 
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Table 6 (continued). 
Notes. SD = standard deviation. 
*Values reflect score alterations applied to adjust for extreme values in
multivariate analyses.
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Table 7.  
 
Sample Clinical Characteristics (N=211) 
Characteristics n (%) 
First Cancer Diagnosis Site, (n=211)  
    Lung / Bronchus 33 (15.6) 
    Prostate 30 (14.2) 
    Breast  26 (12.3) 
    Thyroid 22 (10.4) 
    Melanoma 21 (10.0) 
    Uterine Corpus (includes endometrial) 20 (9.5) 
    Kidney / Renal Pelvis 17 (8.1) 
    Colorectal 15 (7.1) 
    Urinary Bladder 12 (5.7) 
    Ovarian (includes fallopian tube) 8 (3.8) 
    Oral Cavity / Pharynx 7 (3.3) 
Years from First Cancer Diagnosis, Mean (SD) (n=211) 5.8 (2.9); range: 0-11 
Most Frequent Second Cancer Diagnosis Sites* (n=205)  
    Breast 38 (18.5) 
    Lung / Bronchus 29 (14.1) 
    Thyroid 19 (9.3) 
    Kidney / Renal Pelvis 18 (8.8) 
    Melanoma 16 (7.8) 
Most Frequently Diagnosed Cancer Site Patterns (First 
Cancer, Second Cancer) * (n=205) 
 
    Lung, Lung 20 (9.8) 
    Breast, Breast 17 (8.3) 
    Thyroid, Thyroid 12 (5.9) 
    Melanoma, Melanoma 11 (5.4) 
    Bladder, Prostate 10 (4.9) 
Years Since Second cancer Diagnosis, Mean (SD) (n=197) 4.0 (2.7); range: 0-10 
Years Since Most Recent Cancer Treatment, Mean (SD) 
(n=204) 
2.7 (2.9); range: 0-10 
First and Second Cancers Diagnosed within 6 Month 
Timeframe (n=206) 
102 (49.5) 
More than Two Cancer Diagnoses documented in medical 
record (n=211) 
33 (15.6) 
Most Recent BMI by Category (n=209)  
    <18.5 (underweight) 5 (2.4) 
    18.5-24.9 (normal) 62 (24.9) 
    25.0-29.9 (overweight) 67 (32.1) 
    >30 (obese) 85 (40.7) 
Note. SD = standard deviation.  
 
*See supplementary online material for complete list of second cancer diagnoses, 
frequencies of cancer sites diagnosed as either first or second cancer, and patterns 
of first and second cancer diagnoses. 
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Ninety-five individuals who did not participate in the study (8.0%) submitted anonymous 
refusal forms. While 18 of these individuals (18.9%) did not provide a refusal reason, top listed 
reasons for not participating included perceived ineligibility (e.g., “I’ve only had one cancer,” 
n=20 [21.1%]), lack of time (n=17 [17.9%]), advanced age (n=12 [12.6%]), concern with 
accessing medical records (n=10 [10.5%]), and health issues (n=9 [9.5%]). Comparison of de-
identified Cancer Registry data using independent sample t-tests and Pearson’s chi-square 
tests of independence indicated that study participants were similar to non-respondents on all 
variables examined, including age, sex, race, marital status, primary payer at first diagnosis, 
years since first cancer diagnosis, and first cancer site (see supplementary online material, 
Table 13). 
3.3.4.2 Description of key variables in the measurement model. Table 8 displays scores for 
all variables considered in the originally hypothesized measurement model. 
Table 8.  
Scores for Variables in the Originally Hypothesized Measurement Model (N=211) 
Measures by Latent Variables Descriptive Statistics 
Mean (SD) Range 
Perceived Stress 
    Perceived Stress, general (n=206) 13.0 (7.0) 0-31
    Cancer-Specific Stress* (n=210) 14.7 (13.0) 0-58
    Cancer worry (n=211) 7.5 (2.9) 3-12
Psychological Response 
    Depression* (n=211) 1.0 (1.4) 0-5
    Anxiety* (n=209) .9 (1.3) 0-5.1
    Global Mental Health (n=210) 48.4 (7.9) 29.0-62.4 
Behavioral Response 
    Self-Management 
 Health Directed Activity (n=208) 2.9 (.7) 1.0-4.0 
 Positive and Active Engagement in Life (n=208) 3.3 (.6) 1.6-4.0 
 Emotional Distress (n=208) 3.1 (.6) 1.3-4.0 
 Self-Monitoring and Insight (n=208) 3.3 (.4) 2.0-4.0 
 Constructive Attitudes and Approaches* (n=208) 3.4 (.5) 1.7-4.0 
 Skill and Technique Acquisition* (n=208) 3.2 (.5) 1.7-4.0 
 Social Integration and Support (n=208) 3.2 (.6) 1.4-4.0 
 Health Service Navigation* (n=208) 3.4 (.5) 2.1-4.0 
    Alcohol Use¥ (n=105) 43.7 (5.0) 38-59.4
    Tobacco Use:  Pack-Year History* (n=205) 15.7 (26.4) 0-150
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Table 8 (continued). 
Financial Toxicity 
    Financial Toxicity (n=205) 28.6 (10.2) 0-44
    Economic Hardship 
 Financial Strain* (n=209) 1.2 (.4) 1-2.3
 Inability to Make Ends Meet (n=208) 2.0 (1.1) 1-5
 Not Enough for Necessities (n=208) 1.9 (1.1) 1-5
 Cutbacks and Adjustments* (n=209) .9 (1.7) 0-6.2
Social Role Function 
    Social Role Function Ability* (n=209) 52.3 (10.3) 25.9-65.4 
    Social Role Function Satisfaction* (n=210) 50.7 (10.9) 26.5-65.5 
Physical Health 
    Physical Functionϯ (n=211) 46.7 (8.3) 29.1-55.2 
    Symptoms 
 Symptom Burden (n=209) 2.2 (2.2) 0-8.6
        Symptom Distress* (n=209) 1.5 (2.3) 0-10
    Comorbidity Index (n=211) 4.8 (3.4) 0-15
Notes. SD=standard deviation. 
*Values reflect score alterations applied to adjust for extreme values in multivariate
analyses.
ϯMean composite of top five most severely rated symptoms in sample (i.e., fatigue, 
drowsy, dry mouth, disturbed sleep, and pain).  
¥Alcohol use scores can only be calculated for individuals who screen positive for
consuming alcohol in the previous 30 days.
3.3.4.3 Measurement model. A confirmatory factor analysis was performed through Mplus. A 
six-factor model for stress, psychobehavioral responses, and health outcomes was originally 
hypothesized and is presented in Figure 8, where the factors or latent variables are represented 
by ovals, and measured variables are represented by rectangles. Absence of a line connecting 
variables implies no hypothesized direct effect. Indicators of factors for the six latent variables 
are described with instrument descriptions (see Section 3.3.3.3). All six factors were 
hypothesized to covary with one another in the measurement model. 
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An examination of bivariate correlations and multicollinearity diagnostics suggested 
possible mild to moderate multicollinearity in the overall model, problematic model correlations, 
and a four-factor solution to the data. The following modifications, with specific rationales, were 
made as a result of the measurement model analyses. Measures of the stress and 
psychological response latent variables were reconceptualized and combined into a new latent 
variable, conceptualized as Distress, due to high correlations among these sets of variables. 
Measures of the social role function-ability and physical function latent variables were combined 
into a new latent variable, conceptualized as Functional Health, due to high correlations among 
these variables. The social role function satisfaction measure was dropped due to lack of 
conceptual congruence with functional health outcomes. The following observed behavioral 
response variables (the risky behaviors) were also dropped from the hypothesized 
measurement model:  pack-year history and alcohol use (did not correlate well with other 
measures), heiQ emotional distress (cross-loaded onto many of the stress and behavioral 
response latent variables).  Because of this, the behavioral response latent variable was 
renamed Self-Management Behaviors. Global mental health (cross-loaded onto the behavioral 
and psychological response latent variables) was also dropped from the measurement model. 
See modified four-factor measurement model in Figure 9.
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3.3.4.3.1  Model fit and parameter estimation. Support was found for the modified four-factor 
measurement model, !2 (203, N = 206) = 455.57, p<.01; TLI = .91, CFI = .92, SRMR = .06, 
RMSEA = .08, 90% confidence interval [CI] for RMSEA = [.07, .09]. 
To improve model fit, a series of post hoc model modifications were performed, allowing 
the following pairs of error terms to correlate:  cancer-related stress and cancer worry; positive 
and active engagement in life and health directed activity; physical function and ability to 
participate in social roles and activities; social integration and support and self-monitoring and 
insight; and symptom distress and physical function. The final revised measurement model, 
illustrated in Figure 10, indicated a better fit !2 (198, N = 206) = 331.32, p = .135; TLI = .95, CFI 
= .96, SRMR = .06, RMSEA = .06, 90% CI for RMSEA=[.05, .07]. 
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Figure 10. M
odified four-factor m
easurem
ent m
odel. This figure includes  
factor loadings, error coefficients, and error term
 correlations. 
error term
 correlations. 
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3.3.4.4 Full structural equation model. 
3.3.4.4.1  The hypothesized model. The hypothesized full structural equation model based on 
the modified four-factor measurement model is presented in Figure 11, where, again, ovals 
represent latent variables, and rectangles represent measured variables. Absence of a line 
connecting variables implies no hypothesized direct effect. Curved lines indicate correlated error 
terms between measured variables. 
 
The hypothesized model examined predictors of financial toxicity and functional health. It 
was hypothesized that distress and self-management behaviors each directly predicted financial 
toxicity and functional health. Specifically, increased distress was hypothesized to directly 
increase financial distress and decrease functional health, and better self-management 
behaviors were hypothesized to directly decrease financial toxicity and increase functional 
Figure 11. Hypothesized full structural equation model based on modified measurement model. 
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health. It was also hypothesized that distress served as an intervening variable between self-
management behaviors and both financial toxicity and functional health. 
Finally, it was hypothesized that, by adding upstream individual, sociodemographic, and 
clinical covariates, model fit would be improved. Specifically, the following variables were 
explored:  personality (neuroticism and conscientiousness), age, social support, gender, 
educational attainment, marital status, difficulty paying for basic needs, years from first cancer 
diagnosis, years from treatment completion, time between first and second cancer diagnoses, 
and BMI.  
3.3.4.4.2  Model fit and parameter estimation.  Even though model fit was good based on 
study data (model 1), !2 (198, N = 206) = 331.32, p<.01; TLI = .95, CFI = .96, SRMR = .06, 
RMSEA = .06, 90% CI for RMSEA=[.05, .07], there were two hypothesized paths that were not 
empirically supported:  the direct path between self-management behaviors and financial toxicity 
(standardized coefficient = 0.02, p=.78) and the direct path between self-management 
behaviors and functional health (standardized coefficient = 0.08, p=.32). 
Using model statistics and alignment with theoretical soundness, post hoc model 
modifications were performed in an attempt to develop a better fitting, more parsimonious 
model. Similar model fit was found by first removing the non-significant direct path between self-
management behaviors and financial toxicity (model 2), !2 (199, N = 206) = 331.46, p<.010; TLI 
= .95, CFI = .96, SRMR = .06, RMSEA = .06, 90% CI for RMSEA=[.05, .07], and then between 
self-management behaviors and functional health (model 3), !2 (199, N = 206) = 331.93, p<.01; 
TLI = .95, CFI = .96, SRMR = .06, RMSEA = .06, 90% CI for RMSEA=[.05, .07]. Lastly, modest 
improvement to model fit but increased parsimony was achieved by removing both direct paths 
between self-management behaviors and financial toxicity and functional health (model 4) !2 
(200, N = 206) = 332.06, p<.01; TLI = .95, CFI = .96, SRMR = .06, RMSEA = .06, 90% CI for 
RMSEA=[.05, .07], see Figure 12. 
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3.3.4.5 Secondary aim. Additional exploratory modification testing was performed on model 4 
to explore the impact of covariates as predictors of health behaviors on model fit. First, the 
model did not converge when all potential covariates were added as predictors of health 
behaviors.	However, a final modified model that included neuroticism, social support, BMI 
(overweight versus normal and high risk [i.e., underweight plus obese]), and educational 
attainment (master’s or higher versus less than high school and high school through bachelor’s) 
predicting health behaviors and additional paths for neuroticism and social support predicting 
distress resulted in good model fit, !2 (282, N = 206) = 511.13, p<.01; TLI = .92, CFI = .93, 
SRMR = .06, RMSEA = .06, 90% CI for RMSEA=[.05, .07]. Figure 13 shows the final 
parsimonious model with modifications for the retained statistically significant covariates. 
Figure 12. Final modified structural equation model based on modified measurement model. This 
figure includes standardized and unstandardized path coefficients and error term correlations. 
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3.3.4.5.1  Direct effects. As hypothesized, increased financial toxicity was predicted by greater 
distress (standardized path coefficient = .60, p<.01) and poorer functional health was predicted 
by greater distress (standardized path coefficient = -.61, p<.01) and by financial toxicity 
(standardized path coefficient = -.23, p<.01). Increased distress was predicted by poorer self-
management behaviors, greater neuroticism, and lower perceived social support (standardized 
path coefficients = -.21, .46, and -.25, respectively, p<.01). BMI (overweight), education 
(master’s or greater), decreased neuroticism, and better perceived social support predicted 
better health behaviors (standardized path coefficients = .10, .14, -.29, .31, respectively, p<.01). 
Better behavioral responses did not significantly predict financial toxicity or functional health 
(unstandardized path coefficients = .12 and .04, respectively, p>.05). 
Figure 13. Final parsimonious structural equation model based on modified measurement model 
with significant covariates retained. This figure includes standardized and unstandardized path 
coefficients and error term correlations. 
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3.3.5 Discussion 
Using an adapted psychobehavioral stress-response model, this study was the first to identify 
pathways and individual risk factors associated with health outcomes in adults with MPC. The 
data in this study fit a modified four-factor measurement model, with latent variables including 
self-management, distress (combined perceived stress and psychological distress), financial 
toxicity, and functional health (combined social health and physical health). Self-management 
was the upstream latent variable identified in the final modified model; self-management 
behavior predicted the other latent variables, either directly (i.e., predicting distress) or indirectly 
(i.e., predicting financial toxicity and functional health through distress). In the expanded model, 
which included possible predictors (i.e., potential risk factors of poor self-management and 
increased distress), overweight BMI, graduate education, less neuroticism, and increased social 
support predicted better self-management; poorer self-management, greater neuroticism, and 
lower social support predicted increased distress.  
Our originally hypothesized six-factor model was not empirically supported by the data in 
this study. As a result, latent variables, associated measurement variables, and pathway 
configurations were modified and reconceptualized based on empirical support and congruence 
with the literature, yielding a four-factor model. The four-factor model, with combined perceived 
stress/psychological response (“distress”) and social role function/physical health (“functional 
health”) variables, highlights important pathways among self-management behaviors, distress, 
financial toxicity, and functional health. Future studies should evaluate the validity of combining 
these measures. It is possible that the high correlations among these sets of variables was a 
consequence of study design and/or measurement issues. The original conceptualization of the 
perceived stress latent variable, the perception that one’s demands overwhelm one’s coping 
resources (Lazarus & Folkman, 1984), was meant to capture current stressors of general life 
demands, cancer-specific stress, and cancer worry. Conversely, the psychological response 
latent variable was mean to capture the longer-term (maladaptive) responses to the chronic 
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stress of cancer (National Comprehensive Cancer Network, 2018a) and included measures of 
depressive symptoms, anxiety, and mental health. It is possible that the cross-sectional nature 
of this study precluded distinguishing between these short- and long-term responses in MPC 
survivors who had been living with their diagnoses for, in some cases, multiple years. Similarly, 
social role ability and physical health measures loaded onto a combined factor, which we 
conceptualized as functional health. Ability to participate in social roles and activities does 
reflect a functional ability, but, again, further research is necessary to evaluate the validity of 
combining these different measures into a single latent variable. Finally, the PROMIS Global 
Mental Health measure we attempted to incorporate into this model loaded across many of the 
latent variables in the model, preventing us from using it in multivariate analyses. 
Importantly, the four key constructs (self-management, distress, financial toxicity, and 
functional health outcomes) and their inter-relationships demonstrated in the final model, 
provide clear direction for future studies. Distress, which was predicted by self-management 
behaviors, significantly predicted both increased financial toxicity and poorer functional health. 
We hypothesize that increased distress may be impairing an individual’s productivity, leading to 
financial toxicity, and that financial toxicity may be impacting an individual’s functional health 
(e.g., through medication adherence). Further, we hypothesize that distress may be affecting 
functional health through biological pathways (e.g., triggered glucocorticoid receptor resistance, 
immune dysregulation, and risk for disease) (Cohen et al., 2012). It is also possible that 
mechanisms impacting an individual’s risk for MPC (e.g., genetic predisposition, previous 
cancer treatment, negative health behaviors, etc.) may also influence health outcomes in this 
survivor population. Future studies should identify the individual and interacting influence of 
these different potential mechanisms.  
Not all of the originally hypothesized pathways were found to be statistically significant. 
The direct pathway between self-management behaviors and financial toxicity was neither 
significant nor was it in the direction we had hypothesized; for financial toxicity, distress was a 
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more important direct predictor, while distress mediated the relationship between self-
management and financial toxicity. Also, while the path coefficient did reflect the hypothesized 
direction, self-management behaviors also were not a significant direct predictor of functional 
health. The relationship, again, was mediated by distress. 
Limitations are acknowledged in this study. Despite adequate power to conduct 
analyses, the response rate to study mailings (15.2%) was lower than expected and could have 
introduced bias into study findings. Several findings mitigate this concern. Study participants 
were similar in age, gender, ethnicity, and marital status to participants in previously recruited 
national MPC samples, despite being recruited from a regional cancer registry. Perhaps more 
importantly, study participants did not differ from nonparticipants identified by the Cancer 
Registry as potentially eligible for participation in this study on key variables including age, sex, 
race, marital status, primary payer at first diagnosis, years since first cancer diagnosis, and first 
cancer site. Also, while path analysis can seem to imply temporal or even causal relationships, 
the cross-sectional design of this study limits interpretation to associations among variables. 
Longitudinal studies could help to identify the temporal nature of relationships, while 
experimental studies will be required to understand whether relationships in the proposed model 
are causal in nature. 
Several unique aspects of this sample and contributions to the science are noteworthy. 
First, as a result of our inclusion criteria, record validated clinical data verified that participants in 
this sample were closer to their first diagnosis (M= 5.8 years, SD=2.9), as compared to 11-17 
years in other studies, providing the opportunity to examine a new cohort of MPC survivors not 
previously described (Belcher et al., 2016; Burris & Andrykowski, 2011; Gotay et al., 2007; 
Thong et al., 2013). This study also included cancer sites not frequently represented in MPC 
literature (i.e., lung and thyroid cancer). Additionally, this sample had higher than average BMI 
and rates of obesity (40.7%) when compared to the general U.S. population (36.5%), cancer 
survivors (31.1%) and other published MPC literature (27.4%) (Burris & Andrykowski, 2011; 
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Centers for Disease Control and Prevention, 2017; National Cancer Institute, 2018b). While not 
successful broadening racial and ethnic diversity of the literature in this study, we did recruit a 
sample of participants with a broad range of educational attainment, which is representative of 
the broader U.S. population (Ryan & Bauman, 2016). Importantly, educational attainment was 
identified as an important predictor of self-management in Aim 2 covariate analyses.  
The data in this study support healthy self-management behaviors as vitally important to 
positive health outcomes in MPC survivors, and MPC survivors should be evaluated for poor 
health behaviors and distress, both of which are modifiable. This is particularly important among 
the subset of MPC patients at increased risk for poor health outcomes (i.e. those with less 
education, less social support, overweight BMI, and greater neuroticism). The National Cancer 
Institute recommends that individuals with MPC diagnoses be considered candidates for cancer 
risk assessment and counseling (i.e., clinical assessment, applicable genetic testing, and 
recommendations of risk management counseling) to guide screening and risk reduction 
interventions (National Cancer Institute, 2018a). Additionally, survivorship clinical practice 
guidelines (National Comprehensive Cancer Network, 2018b, 2018a) recommend clinical 
assessment of and individualized recommendations for healthy lifestyle and provide direction on 
ways to assess for and address key topics such as diet, activity, caloric balance, and brief 
distress screenings. Based on these data, clinicians should also increase their awareness of 
financial toxicity and engage their patients in care value discussions. As evidenced by the 
expertise needed to address the identified key clinical priorities in MPC patients, collaboration 
and communication among specialists (e.g., nutritionists, behavioral change experts, mental 
health professionals, financial experts, primary care providers, oncologists [potentially including 
more than one medical or surgical oncology team for cancer disease site specialists], and 
genetic counselors) is key. 
These findings are also relevant to policy discussions. As recognized by recent literature 
documenting increasing rates of MPC in cancer survivors (Davidson, 2017; Murphy et al., 
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2017), clinical trial eligibility criteria should be evaluated to determine representativeness of the 
U.S. cancer survivor population. Whenever possible, MPC status should not be an explicit 
exclusion criterion for clinical trial participation. Also, organizations should strive to create 
systems and policies that allow for continuity of care among providers in medically complex 
patients.  
Future studies should evaluate and expand upon this refined model for studying health 
outcomes in adults with MPC, with a particular focus on self-management and financial toxicity, 
two newly highlighted areas of importance, and on identification of the individual and interacting 
influences of potential mechanisms impacting health outcomes in MPC survivors. Biological 
pathways also are an untapped line of inquiry in this patient population and could lead to 
increased understanding of the mechanisms linking distress to poor outcomes in this model. It is 
also important to move toward understanding how outcomes may differ among different subsets 
of MPC survivors (e.g., childhood versus adulthood diagnoses; MPCs associated with genetic 
cancer syndromes versus treatment-related MPCs versus MPCs associated with risky 
behaviors), as risk factors and health outcomes may vary among groups. It is possible that 
mechanisms impacting an individual’s risk for MPC (e.g., genetic predisposition, previous 
cancer treatment, negative health behaviors, etc.) may also influence health outcomes in this 
survivor population and warrants future analysis.  
Study design and recruitment are important considerations for the advancement of MPC 
science. Future research should move to longitudinal studies to 1) establish temporal 
relationships among key variables; 2) understand how MPC survivorship risk factors change 
over time; and 3) identify vulnerable phases in the MPC survivorship trajectory. With increased 
demands being placed on people’s time and attention, survey response rates have been 
declining and costs have been rising (National Science Foundation, n.d.), and this type of data 
collection may be becoming outdated when attempting to recruit generalizable samples. Future 
MPC studies should also focus on novel recruitment methods of this hard to reach patient 
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population, as survivors do not all attend specialty MPIC clinics where targeted recruitment 
could occur.  Attention should also be paid to addressing reasons provided for nonparticipation 
in this study (i.e., increased age, perceived ineligibility, privacy/accessing medical records). 
Future research must also focus on conducting studies that are sensitive to the challenges and 
perspectives of more diverse groups of MPC survivors.  
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3.3.9 Supplementary online material 
Table 9 
Frequencies of Second Cancer Diagnosis Sites 
(N=205) 
Site n (%) 
Breast 38 (18.5) 
Lung / Bronchus 29 (14.1) 
Thyroid 19 (9.3) 
Kidney / Renal Pelvis 18 (8.8) 
Melanoma 16 (7.8) 
Prostate 15 (7.3) 
Lymphoma 14 (6.8) 
Uterine Corpus (Endometrial) 13 (6.3) 
Colorectal 9 (4.4) 
Urinary Bladder 9 (4.4) 
Oral Cavity, Pharynx, Larynx 7 (3.4) 
Ovarian 5 (2.4) 
Leukemia 2 (1.0) 
Multiple Myeloma 2 (1.0) 
Neuroendocrine Tumor 2 (1.0) 
Cervical 1 (0.5) 
Liver 1 (0.5) 
Merkel Cell 1 (0.5) 
Pancreatic 1 (0.5) 
Sarcoma 1 (0.5) 
Vulvar 1 (0.5) 
Unknown Origin 1 (0.5) 
Note. Data were not able to be obtained from 
medical records for 6 cases. 
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Table 10 
 
Frequencies of Sample First or Second Cancer 
Diagnoses Sites (N=211) 
Site n (%) 
Breast 47 (22.3) 
Prostate 45 (21.3) 
Lung / Bronchus 42 (19.9) 
Uterine Corpus (Endometrial) 31 (14.7) 
Thyroid 29 (13.7) 
Kidney / Renal Pelvis 28 (13.3) 
Melanoma 26 (12.3) 
Colorectal 23 (10.9) 
Urinary Bladder 20 (9.5) 
Lymphoma 14 (6.6) 
Ovarian 13 (6.2) 
Oral Cavity, Pharynx, Larynx 11 (5.2) 
Leukemia 2 (0.9) 
Multiple Myeloma 2 (0.9) 
Neuroendocrine Tumor 2 (0.9) 
Note. Data were not able to be obtained from 
medical records for 6 second cancer cases. 
Additional single cases included cervical, liver, 
merkel cell, pancreatic, sarcoma, vulvar, and 
unknown primary sites. 
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Table 11 
 
Sample Patterns of First and Second Cancer Diagnoses Sites 
(N=205) 
First Cancer Site Second Cancer Site n (%) 
Lung Lung 20 (9.8) 
Breast Breast 17 (8.3) 
Thyroid Thyroid 12 (5.9) 
Melanoma Melanoma 11 (5.4) 
Bladder Prostate 10 (4.9) 
Renal Renal 7 (3.4) 
Prostate Bladder 6 (2.9) 
Prostate Lymphoma 6 (2.9) 
Uterine Breast 6 (2.9) 
Thyroid Breast 4 (2.0) 
Prostate Colorectal 4 (2.0) 
Prostate Renal 4 (2.0) 
Colorectal Breast 4 (2.0) 
Breast Uterine 3 (1.5) 
Ovarian Uterine 3 (1.5) 
Prostate Lung 3 (1.5) 
Uterine Ovarian 3 (1.5) 
Renal Prostate 3 (1.5) 
Oral Cavity/Pharynx Oral Cavity/Pharynx 3 (1.5) 
Breast Renal 2 (1.0) 
Thyroid Uterine 2 (1.0) 
Ovarian Breast 2 (1.0) 
Prostate Melanoma 2 (1.0) 
Prostate Oral Cavity/Pharynx 2 (1.0) 
Colorectal Uterine 2 (1.0) 
Colorectal Lung 2 (1.0) 
Uterine Uterine 2 (1.0) 
Uterine Lymphoma 2 (1.0) 
Melanoma Breast 2 (1.0) 
Melanoma Thyroid 2 (1.0) 
Renal Lymphoma 2 (1.0) 
Lung Breast 2 (1.0) 
Lung Renal 2 (1.0) 
Breast Thyroid 1 (0.5) 
Breast Ovarian 1 (0.5) 
Breast Leukemia 1 (0.5) 
Thyroid Prostate 1 (0.5) 
Thyroid Colorectal 1 (0.5) 
Thyroid Melanoma 1 (0.5) 
Thyroid Lung 1 (0.5) 
Thyroid Leukemia 1 (0.5) 
Ovarian Lymphoma 1 (0.5) 
Ovarian Pancreatic 1 (0.5) 
Prostate Multiple Myeloma 1 (0.5) 
Prostate Neuroendocrine Tumor 1 (0.5) 
Colorectal Colorectal 1 (0.5) 
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Table 11 (continued). 
Colorectal Bladder 1 (0.5) 
Colorectal Renal 1 (0.5) 
Colorectal Laryngeal 1 (0.5) 
Colorectal Lymphoma 1 (0.5) 
Colorectal Liver 1 (0.5) 
Bladder Bladder 1 (0.5) 
Bladder Renal 1 (0.5) 
Uterine Colorectal 1 (0.5) 
Uterine Melanoma 1 (0.5) 
Uterine Renal 1 (0.5) 
Uterine Thyroid 1 (0.5) 
Uterine Cervical 1 (0.5) 
Uterine Neuroendocrine Tumor 1 (0.5) 
Uterine Vulvar 1 (0.5) 
Melanoma Prostate 1 (0.5) 
Melanoma Bladder 1 (0.5) 
Melanoma Lung 1 (0.5) 
Melanoma Lymphoma 1 (0.5) 
Melanoma Merkel Cell 1 (0.5) 
Renal Breast 1 (0.5) 
Renal Lung 1 (0.5) 
Renal Thyroid 1 (0.5) 
Renal Ovarian 1 (0.5) 
Oral Cavity/Pharynx Colorectal 1 (0.5) 
Oral Cavity/Pharynx Lung 1 (0.5) 
Oral Cavity/Pharynx Thyroid 1 (0.5) 
Oral Cavity/Pharynx Multiple Myeloma 1 (0.5) 
Lung Colorectal 1 (0.5) 
Lung Uterine 1 (0.5) 
Lung Melanoma 1 (0.5) 
Lung Oral Cavity/Pharynx 1 (0.5) 
Lung Thyroid 1 (0.5) 
Lung Lymphoma 1 (0.5) 
Lung Sarcoma 1 (0.5) 
Lung Unknown Origin 1 (0.5) 
Note. Second cancer data were not able to be obtained from 
medical records for 6 cases. 
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Table 12 
Most Common Second Cancer Sites within Each First Primary 
Cancer Site Group (N=205) 
First Cancer Site Second Cancer Site n (%) 
Lung/Bronchus* (n=32) Lung/Bronchus 20 (62.5) 
Prostate* (n=29) Bladder 6 (20.7) 
Lymphoma 6 (20.7) 
Breast* (n=25) Breast 17 (69.0) 
Thyroid (n=22) Thyroid 12 (54.5) 
Melanoma* (n=20) Melanoma 11 (55.0) 
Uterine Corpus (n=20) Breast 6 (30.0) 
Kidney/Renal Pelvis* (n=16) Kidney/Renal Pelvis 7 (43.8) 
Colorectal* (n=14) Breast 4 (28.6) 
Urinary Bladder (n=12) Prostate 10 (83.3) 
Ovarian (n=8) Uterine 3 (37.5) 
Oral Cavity/Pharynx (n=7) Oral Cavity/Pharynx 3 (42.9) 
Note. Data were not able to be obtained from medical records 
for 6 cases (*one case per each disease site indicated). 
Percentages were calculated based on number of total cases 
per first cancer site. 
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Table 13 
Sociodemographic and Clinical Comparisons of Cancer Registry Sociodemographic and Clinical Data: 
Participants versus Nonparticipants 
Participants Nonparticipants Test Statistic* 
(df) p-valuen = 215 n = 1176 
Age Mean (SD) 67.2 11.5 67.7 12.1 t (1389) = 0.502 .248 
Years Since First Cancer 
Diagnosis Mean (SD) 5.8 2.8 5.6 2.9 t (1384) = -0.916 .176 
n % n % 
Sex 
  Male 85 39.5 512 43.5 χ2(1) = 1.189 .276 
  Female 130 60.5 664 56.5 
Race χ2 (1) = 2.323 .136 
  White 200 93.0 1049 89.7 
  Other 15 7.0 121 10.3 
Marital Status χ2 (1) = 2.358 .125 
  Married/Living with a Partner 147 72.1 739 66.6 
  Other 57 27.9 371 33.4 
Primary Payer at First Cancer 
Diagnosis χ
2 (2) = 4.812 .090 
  Private Insurance 129 66.5 637 58.5 
  Medicare, Tricare, or VA 53 27.3 384 35.3 
  Medicaid  12 6.2 67 6.2 
First Cancer Site χ2 (2) = 13.319 .206 
  Breast 26 12.6 180 15.3 
  Prostate 32 14.9 117 9.9 
  Colorectal 15 7.0 121 10.3 
  Bladder 12 5.6 86 7.3 
  Uterine 20 9.3 109 9.3 
  Melanoma 21 9.8 97 8.2 
  Kidney/Renal Pelvis 17 7.9 116 9.9 
  Oral Cavity/Pharynx 7 3.3 65 5.5 
  Lung/Bronchus 33 15.3 139 11.8 
  Thyroid 23 10.7 107 9.1 
  Ovarian 8 3.7 39 3.3 
Notes. SD = standard deviation 
*Reported statistics are Pearson chi-square test of independence and independent samples t-tests.
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4.0 DESCRIPTION OF SELF-MANAGEMENT BEHAVIORS (DISSERTATION AIM 3) 
4.1 THE IMPORTANCE OF SELF-MANAGEMENT BEHAVIORS 
Previous literature has demonstrated poorer health in MPC survivors versus their single cancer 
counterparts. Cancer diagnosis and the post-treatment survivorship phase can result in both 
negative and positive influence on health behaviors (Carmack, Basen-Engquist, & Gritz, 2011; 
Park, Edmondson, Fenster, & Blank, 2008). However, unhealthier behaviors have been 
documented in MPC survivors (Burris & Andrykowski, 2011), including greater likelihood of 
physical inactivity, greater alcohol consumption when drinking (though less likely to use alcohol 
overall), and greater likelihood of cigarette and smokeless tobacco use. Given known health 
deficits in this population of cancer survivors, positive self-management behaviors represent 
targets (Risendal et al., 2015), providing opportunities to interrupt negative downstream health 
outcomes and maintain and/or restore optimal wellness.  
Corbin and Strauss first identified the process of self-management by describing the 
work (e.g., medical management, behavioral management, and emotional management) of 
living with a chronic illness (Corbin & Strauss, 1988). As this day-to-day work of managing one’s 
health is shifting from providers to survivors (Barlow et al., 2002) and their family members, 
studies in patients with chronic illness (Grady & Gough, 2014; Grey et al., 2015; Lorig & 
Holman, 2003) and general cancer (Chen et al., 2015; Hammer et al., 2015; McCorkle et al., 
2011; Miller et al., 2009; Risendal et al., 2015) have established that self-management is both a 
public health and clinical priority. The National Institutes of Health and others (Grady, Daley, & 
Gough, 2014; Grady & Gough, 2014; Knobf et al., 2015; National Cancer Survivorship Resource 
Center, n.d.; National Institute of Health, 2017; Rudy & Grady, 2005) have called for 
biobehavioral research to identify mechanisms underlying self-management behaviors.  
No prior work has examined how MPC survivors self-manage their health. It is vital to 
identify the individual characteristics (i.e., personal, clinical, sociodemographic) that are 
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associated with self-management in MPC survivors and to understand mechanisms linking self-
management to health outcomes to 1) better characterize at risk MPC survivors and 2) better 
understand mechanisms linking self-management to health outcomes. Targeted and tailored 
self-management interventions, which have been shown to provide positive benefit in varying 
ethnic, geographic, and age groups in other patient populations (Grady & Gough, 2014), could 
reduce long-term health problems experienced by MPC survivors.  
In Aim 3 of this dissertation study, we describe potentially modifiable health behaviors by 
analyzing the heiQ items, alcohol use, tobacco use, and BMI measures in detail. 
4.2 RESULTS 
4.2.1 Self-management domain scores 
Table 14 displays scores for self-management domains, as measured by the heiQ (no score 
alterations applied). In general, most mean heiQ subscale scores were above 3.0, though 
ranges demonstrate good variability in the scale scores. Health Directed Behavior, which 
includes items that reflect incorporation of healthy behaviors (e.g., physical and healthy activity) 
into one’s lifestyle, had the lowest subscale score (Mean=2.9, SD=0.7) and lowest observed 
minimum scores (1.0).  
Table 14 
Raw Scores for Self-Management Domains, as Measured by Health Education 
Impact Questionnaire Measure Subscales (N=208) 
Domains 
Result 
Mean (SD) Range 
Health Directed Activity 2.9 (0.7) 1.0-4.0 
Positive and Active Engagement in Life 3.3 (0.6) 1.6-4.0 
Emotional Distress* 3.1 (0.6) 1.3-4.0 
Self-Monitoring and Insight 3.3 (0.4) 2.0-4.0 
Constructive Attitudes and Approaches 3.4 (0.5) 1.4-4.0 
Skill and Technique Acquisition 3.2 (0.5) 1.5-4.0 
Social Integration and Support 3.2 (0.6) 1.4-4.0 
Health Service Navigation 3.4 (0.5) 1.8-4.0 
Notes. SD=standard deviation. 
*Emotional distress is interpreted inversely, with higher scores indicating
increased negative impact of health on emotions.
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4.2.2 Self-management behavior item scores 
Frequencies and percentages of self-management behaviors by individual items are presented 
in Table 15. Across items, only about 54-78% of individuals agreed that they were engaging in 
regular health directed activities, with the lowest percentage observed being for the walking for 
exercise item (53.8%). Approximately 82-95% of individuals agreed that they participated in 
activities to positively and actively engage in life.  Approximately 13-48% of individuals agreed 
with items in the emotional distress domain, with nearly 50% of participants agreeing that they 
often worried about their health. Approximately 80-98% agreed with doing things reflective of 
self-monitoring and insight; the lowest frequency in this domain was knowing what triggers and 
makes health problems worse (79.8%). Frequency of agreement with items in the constructive 
attitudes and approaches and skill technique acquisition ranged from high 80’s-90’s. Social 
integration and support varied by item (78.4-92.8%); 78.4% of participants felt that family and 
caregivers understood what they were going through when feeling ill. Lastly, frequencies for 
health service navigation were approximately 90% or above. 
Table 15 
Frequencies of participants who agree with performing self-management behaviors, by domain 
and item (N=208) 
Individual Items by Domain 
Item Results 
n % 
Health Directed Activity 
    Activity at least 1 day per week to improve health 161 77.4 
    At least 1 type of physical activity daily for 30 minutes 154 78.0 
    Set aside time for healthy activities on most days of week 149 71.6 
    Walk for exercise at least 15 minutes per day most days of week 112 53.8 
Positive and Active Engagement in Life 
    Do some of things I really enjoy on most days 172 82.7 
    Try to make most of life 198 95.2 
    Doing interesting things in my life 171 82.2 
    Have plans to do enjoyable things for self during next few days 185 88.9 
    Feel like actively involved in life 182 87.5 
Emotional Distress* 
    Often worry about health 98 47.1 
    Health problems make me dissatisfied with life 45 21.6 
    Often feel angry when think about health 39 18.8 
 Feel hopeless because of health problems 26 12.5 
    I get upset when think about my health 41 19.7 
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Table 15 (continued). 
    I get depressed if I think about my health 41 19.7 
Self-Monitoring and Insight 
    As well as seeing doctor, regularly monitor changes in my health 193 92.8 
    I know what triggers and makes health problems worse 166 79.8 
    Have very good understanding of when/why I should take my meds 203 97.6 
    Have clear understanding of what to do to control health problems 193 92.8 
    Carefully watch health and do what is necessary to keep healthy 176 84.6 
    Have realistic expectations of what can and cannot do with health 
in mind 
193 92.8 
Constructive Attitudes and Approaches 
    Try not to let health problems stop from enjoying life 196 94.2 
    My health problems do not ruin my life 192 92.3 
    Feel well looked after by friends/family 199 95.7 
    Do not let health problems control life 196 94.2 
    If others can cope with problems like mine, I can too 204 98.1 
Skill and Technique Acquisition 
    Have effective ways to prevent symptoms from limiting what can do 184 88.5 
    Have very good idea of how to manage health problems 198 95.2 
    Have skills to help cope when have symptoms 190 91.3 
    Have clear understanding of equipment that could make life easier 183 88.0 
Social Integration and Support 
    Have plenty of people can rely on if need help 181 87.0 
    Have enough friends who help me cope with health problems 181 87.0 
    Family and carers really understand when I feel ill 163 78.4 
    Feel well looked after by friends or family 193 92.8 
    Get enough chances to talk about health problems with people who 
understand me 
176 84.6 
Health Service Navigation 
    Have very positive relationships with my healthcare professionals 205 98.6 
    Communicate very confidently with my doctor about my healthcare 
needs 
202 97.1 
    Confidently give healthcare professionals the information they need 
to help me 
205 98.6 
    Get needs met from available healthcare resources 201 96.6 
    I work in a team with doctors and other healthcare professionals 186 89.4 
Notes. SD=standard deviation. Scales were scored based on developer guidelines, which 
required over 50% item completion per subscale for valid response scale scoring.   
4.2.3 Indicators of negative health behaviors 
Table 16 displays data describing indicators of potentially modifiable negative health behaviors. 
Approximately 50% of the sample reported drinking alcoholic beverages within the past 
30 days. The sample mean raw score for alcohol use, with negative alcohol screens set equal to 
zero, was 3.6. For individuals who screened positive for alcohol use, the mean sample T-score 
was 43.7 (SD=5.0, range 38-59.4). Because T-scores are a standardized score with a mean of 
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50 and a standard deviation of 10 (Patient-Reported Outcomes Measurement Information 
System, 2014), participants with negative alcohol consumption screens were not assigned a T-
score. 
Approximately 53% of participants reported that they had smoked 100 cigarettes in their 
lifetime. Of those 109 individuals, the mean age at first cigarette was 15.6 years (range 6-30 
years). The average pack year history, with nonsmokers equal to zero, was around 16 pack-
years (range 0-150). Around 9% of respondents were current or recent (within the past 12 
months) smokers, however, 44% (n=91) were past smokers. 
The average BMI in this sample was 29.4kg/m2 (range 16.6-52.9). Because BMI has 
been shown to be associated with a J-shaped dose response curve for mortality (Aune et al., 
2016), categorical data are also presented. Less than 3% of the sample was underweight. 
Around 25% were normal weight. Over 32% were overweight, and over 40% were obese.  
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Table 16 
Sample Characterization of Modifiable Health Behaviors (N=211) 
Concept 
Result 
Mean (SD) or n  % or range 
Alcohol Use 
Alcohol Use Raw Score (n=211) 3.6 (4.0) 0-16
Drank Alcoholic Beverages within Past 30 Days 
(n=211) 
    No 106 50.2 
    Yes 105 49.8 
Alcohol Use T-Score for Positive Screens (n=105) 43.7 (5.0) 38-59.4
Tobacco Use 
Smoked 100 Cigarettes in Lifetime (n=208) 
    No 95 45.7 
    Yes 110 52.9 
        If Yes, Age at First Cigarette (n=109) 15.6 (3.5) 6-30
Pack Year History (n=205) 15.7 (26.4) 0-150
Current Smoking Status (n=207) 
    Non-Smoker 95 45.9 
    Past Smoker 91 44.0 
    Current or Recent Smoker 18 8.7 
Anthropometric Data 
Most Recently Documented BMI (kg/m2) (n=209) 29.4 (7.0) 16.6-52.9 
Most Recent BMI by Category (n=209) 
    <18.5 (Underweight) 5 2.4 
    18.5-24.9 (Normal) 62 24.9 
    25.0-29.9 (Overweight) 67 32.1 
>30 (Obese) 85 40.7 
Note. SD=standard deviation. 
4.3 DISCUSSION 
This study describes positive self-management behaviors and indicators of negative health 
behaviors in a sample of MPC survivors. While self-management behaviors were generally high 
there was variability among scores. Tobacco use findings were comparable to population 
norms, but rates of obesity were higher than both cancer and general populations. 
Our analyses of self-management results were consistent with previous literature 
identifying MPC patients as more likely to be physically inactive than single cancer patients 
(Burris & Andrykowski, 2011). Across items, about half to three quarters of the sample agreed 
that they were engaging in health directed activities, with walking for exercise only agreed upon 
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by about half of the sample. Our finding that most of the sample agreed with activities reflective 
of self-monitoring and insight was also consistent with previous studies noting greater health 
awareness and positive healthcare utilization (i.e., attending regular appointments, monitoring 
for cancer, and current with cancer screenings) in MPC patients versus single cancer patients 
(Belcher et al., 2016; Thong et al., 2013). Less than 80% of participants felt that family and 
caregivers understood what they were going through when feeling ill, which is in line with 
previous literature finding greater interference with social activities in MPC patients than in 
single cancer patients (Thong et al., 2013), as measured by the Impact of Cancer scale (Costa 
et al., 2016). As identified in Section 3.0, BMI (overweight vs normal weight and obesity), 
graduate education, lower neuroticism, and increased social support were identified as 
characteristics associated with improved self-management and should be used to identify MPC 
patients at risk for poor self-management. 
The National Institute for Nursing Research (NINR) describes the science of self-
management as examining strategies to aid understanding and management of one’s illness 
and improve health behaviors (National Institute of Nursing Research, n.d.). The topic of self-
management has generated a great deal of interest in oncology over the past five years, with 
influence from a long history of research in chronic illness. Noted issues within self-
management science have included need for greater conceptual clarity, identification of valid 
measures, and identification of mechanisms (Grady et al., 2014).  There is a great deal of 
debate as to how to best include self-management in oncology research and translate findings 
into practice. Current recommendations for common data elements (CDE) to use in studies of 
self-management include measures of activation (Patient Activation MeasureÒ), self-regulation 
(Index of Self-Regulation), self-efficacy for managing chronic conditions (Self-efficacy for 
Managing Chronic Illnesses Scale), global health (Patient-Reported Outcomes Measurement 
Information System [PROMIS] Global Heath short form), and biomarkers based on NINR 
symptom priorities of fatigue, depression, cognition, pain, and sleep disturbance (cytokines, 
115 
HPA axis marker, neuropeptide, and DNA polymorphisms) (Moore et al., 2016; Page et al., 
2018).  
In contrast to the CDE recommended by NINR, which are limited to measures 
associated with health behaviors, the internationally-tested heiQ, selected to measure self-
management behaviors in this study, was designed specifically to measure outcomes following 
health education and self-management programs (Elsworth et al., 2015; Osborne et al., 2011, 
2007) and directly addresses the range of self-management domains recommended to maintain 
wellness, including: health directed activity; positive and active engagement in life; emotional 
distress; self-monitoring and insight; constructive attitudes and approaches; skill technique and 
acquisition; social integration and support; and health service navigation. Future self-
management studies and nursing scientists should continue to study the best measures of self-
management, with consideration for whether the study intent is to measure the actual self-
management behaviors or the variables that are associated with self-management behaviors. 
Our findings that approximately half of the sample reported drinking alcoholic beverages 
within the past 30 days is lower than the national rate (56.0%) (National Institute on Alcohol 
Abuse and Alcoholism, 2017). Other literature using Behavioral Risk Factor Surveillance 
System data (Burris & Andrykowski, 2011) has described higher alcohol consumption among 
MPC survivors who consume alcohol, based on analysis of typical number of drinks consumed 
in the past month when drinking. However, the effect sizes for these comparisons were small, 
and, as authors acknowledge, are not likely to be clinically meaningful. 
Smoking is the number one preventable cause of death in the U.S. and increases risk for 
heart disease, stroke, and cancer (Center for Disease Control and Prevention, 2018). Tobacco 
smoking is a known carcinogen in the general population and has been implicated as a 
causative factor associated with increased risk for additional cancer development in cancer 
survivors (Fraumeni Jr et al., 2006); length and duration of exposure are known to impact 
carcinogenesis (National Cancer Institute, 2015). Only around 9% of our study participants were 
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current or recent smokers; however, 44% were past smokers. Of these individuals, the mean 
age at first cigarette was 15.6 (range: 6-30 years), and pack year history ranged from 0-150 
(Mean=16). When compared to national and regional data, the rates of current smoking in this 
sample was lower than the national average, similar to rates in adults 65 years of age and older, 
and lower than rates in Pennsylvania (9% versus 15.5% and 18.6-21.7%, respectively) (The 
Centers for Disease Control and Prevention, 2018; Underwood et al., 2012). Both the early age 
at which some of our participants first smoked (i.e., 6 years old) and the high pack year history 
(i.e., 150) are notable. Future studies should evaluate triggers for smoking cessation in patients 
with MPC. 
 Obesity is a risk factor for many diseases and conditions [e.g., heart disease, 
osteoarthritis, sleep apnea, depression, anxiety, pain, physical function impairment), including 
being a risk factor for cancer (i.e., breast [post-menopausal women], endometrial, colon, kidney, 
gallbladder, and liver) (Centers for Disease Control and Prevention, 2015). Additionally, diet, 
physical inactivity, and obesity are implicated as potential risk factors for subsequent cancer 
development among survivors of breast (female), reproductive organs, and upper and lower 
digestive tract cancers (Fraumeni et al., 2006). The high rates of obesity in this sample (over 
40%) is concerning, given the associated known health risks. The American Society of Clinical 
Oncology and other organizations have published position statements on obesity and cancer 
offer strategies for healthcare providers to address obesity with their patients (Ligibel et al., 
2014).  
Previous studies have suggested greater health awareness in MPC versus single cancer 
patients (Belcher et al., 2017; Thong et al., 2013). However, awareness does not directly 
translate to behavioral change. A cancer diagnosis or experience has been described as a 
teachable moment, but studies have pointed out that desire to change varies by individuals and 
is impacted by many complex factors (Corbett et al., 2018; Demark-Wahnefried, Aziz, Rowland, 
& Pinto, 2005). Others have suggested that the teachable moment afforded during one’s cancer 
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experience may be halted by subsequent cancer diagnoses (Burris & Andrykowski, 2011). 
Future research should evaluate how having more than one cancer impacts health behavior 
changes. 
In addition to the poorer health observed in patients with MPC (Andrykowski, 2012; 
Belcher et al., 2017; Burris & Andrykowski, 2011; Dowling et al., 2013; Gotay et al., 2007; 
Thong et al., 2013), some MPC patients (16% in this study) will go on to develop more than two 
primary cancers. In addition to non-modifiable familial cancer syndromes and potential 
carcinogenetic effects of previous cancer treatments, risk for development of more than one 
primary cancer diagnosis increases with modifiable causative exposures (e.g., smoking and 
alcohol); diet, obesity, physical inactivity, and reproductive risk factors have also been 
implicated in the development of subsequent cancers in patients with breast (female), 
reproductive, and upper and lower digestive tract cancers (Fraumeni et al., 2006; Schottenfeld & 
Beebe-Dimmer, 2006). Health optimization and risk reduction remain critical in this subset of 
cancer survivors; future MPC research should include self-management as a modifiable target 
through which this may be achieved. 
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APPENDIX A 
STUDY RECRUITMENT MATERIALS AND REFUSAL FORM 
  
October 11, 2016 
 
Sarah M. Belcher, RN, BSN, OCN 
Predoctoral Scholar 
Robert Wood Johnson Foundation Future of Nursing Scholars 
Health & Community Systems, University of Pittsburgh School of Nursing 
3500 Victoria Street  
Room 434 Victoria Building 
Pittsburgh, PA 15261 
 
Dear Sarah, 
 
This letter is to formally confirm the number of patients in the UPMC Network Cancer Registry who fit the criteria for 
the human subjects portion of the American Cancer Society Doctoral Degree Scholarship in Cancer Nursing 
application that you are submitting entitled "Characterizing Psychobehavioral Risks in Multiple Primary Cancer 
Survivors.”  
 
As you are aware, the UPMC Network Cancer Registry maintains a standardized data system designed for the 
collection, management, and analysis of patient demographic, grading, staging, treatment and progression data on 
patients having a diagnosis of cancer who are treated at UPMC hospitals and hospital based clinics of UPMC 
CancerCenters.  Given the criteria you provided (e.g. Include:  adults [18 or older]; all cancer diagnosed during 
adulthood; history of 2 or more primary cancers; only Stage I-III cancers; all UPMC sites; and all years of registry 
inclusiveness. Exclude:  cases of non-melanoma skin cancer; in situ cancers; Stage IV/M1 cases at presentation; and 
disease recurrent cases [same as original cancer diagnosis]), there is expected to be an sufficient pool of potential 
participants (5,757 survivors) to assure that you will be able to attain your target sample size.  
 
Should you have any questions about the data provided by the UPMC Network Cancer Registry and our Registry 
Information Services, or should you need additional data, please feel free to contact me. 
 
Sincerely,  
 
Sharon Winters, MS, CTR 
Director, Registry Information Services, UPMC CancerCenter 
Manager, HSTB/RIS/DBMI Collaborative Honest Broker System (IRB#HB015) 
Adjunct Instructor, University of Pittsburgh 
Shadyside Place 
First Floor, Suite 110 
580 South Aiken Avenue 
Pittsburgh, PA 15232Pittsburgh, PA 15232-1304 
(412) 647-6390 
winterssb@upmc.edu 
 
 
 
 
[Address Block]          [Date] 
 
 
Dear [Title] [Patient Name], 
 
I’m writing to tell you about an exciting new research study called Shining a light on Life 
After Multiple Primary cancers: The LAMP study. This research study is led by Sarah 
Belcher, a nurse and graduate student at the University of Pittsburgh School of Nursing. 
 
We want to learn more about patients who have had more than one cancer. You have 
been identified through UPMC’s tumor registry as someone who may be eligible for this 
research study. 
 
If you choose to participate, you will be asked to provide consent to participate in the 
research study. You will then fill out a one-time survey (30-40 minutes) online or through 
the mail. This survey asks about your stress, health behaviors, emotions, and overall 
health. With your permission, we will then combine your responses with health and 
cancer treatment information from your medical record. We will use this information to 
better understand and better support cancer survivors like you. You will receive a $5 
Amazon gift card for completing the survey. 
 
You can complete the survey in a couple of different ways: 
1. You can easily complete the consent and survey online by typing the following 
website URL into your browser:  http://tinyurl.com/LAMP-PittNursing 
2. If you would rather have a paper copy, please complete and return the enclosed 
Paper Survey Request Form in the pre-paid envelope included with this letter. 
 
If you do not wish to be in the study, you can complete a voluntary refusal form either 
online at http://tinyurl.com/LAMP-PittNursing or via the enclosed paper Refusal Form.  
 
Please call or email the study lead, Sarah Belcher, with any questions at:  
• 412-624-8938 or  
• LAMPstudy@pitt.edu  
 
This research study is funded by the American Cancer Society, the Robert Wood 
Johnson Foundation Future of Nursing Scholars program, the Nightingale Awards of 
Pennsylvania, and the School of Nursing.  
 
I fully support this study and believe it will help us to better meet the needs of cancer 
survivors like you. I hope you will take the time to participate in this important research 
study. 
 
 
Sincerely, 
 
 
 
 
[Cancer Center Physician Name] 
 
 
University of Pittsburgh  
School of Nursing 
Department of Health and Community Systems 
 
Paper Survey Request Form 
 
Thank you for your interest in the LAMP study! 
 
Please fill out the information below, and return this form in the included postage-paid 
envelope. We will mail you a paper copy of the survey. 
 
I am interested in completing questionnaires on paper. 
 
My name is: ______________________________________________________ 
 
My mailing address is:_______________________________________________ 
 
   _______________________________________________ 
 
   _______________________________________________ 
 
   _______________________________________________ 
 
 
My email address is: _______________________________________________ 
 
 
Thank you for your time!  If you have any questions, please contact Sarah Belcher at 
412-624-8938 or LAMPstudy@pitt.edu.  
ID: _____________ 
(for study use only) 
 
 
University of Pittsburgh  
School of Nursing 
Department of Health and Community Systems 
Refusal Form 
 
We understand that not everyone is able or interested in completing the survey.  We are trying to 
understand more about the people who do not complete the survey.  If you are willing, it would 
help us if you would answer and return the following 5 general questions about yourself in the 
included prepaid envelope. These answers are confidential and voluntary.  
 
If you prefer, this information may also be completed online at: 
 
http://tinyurl.com/LAMP-PittNursing 
 
Instructions: Please circle the answers that best describe you. 
 
1. What is your sex? 
a. Male 
b. Female 
 
2. How long has it been since your most recent cancer treatment? 
a. 0-1 year  
b. 1-5 years 
c. 5-10 years 
d. Over 10 years 
e. I am currently receiving treatment for cancer. 
 
3. What best describes your race? Select all that apply. 
a. White or Caucasian 
b. African American 
c. American Indian 
d. Alaska Native 
e. Native Hawaiian or other Pacific Islander 
f. Asian 
g. Unknown 
h. Other __________________ 
 
4. What is the highest grade or degree you have completed? 
a. Less than High School 
b. High school diploma or GED 
c. 2 year/ Associate’s Degree 
d. 4 year/Bachelor’s Degree 
e. Graduate/Professional Degree (Masters, PhD, MD, JD, etc.) 
 
5. What age group best describes you:  
a. 18-29 
b. 30-49 
c. 50-69 
d. 70 and above 
 
Please turn form over for remainder of questions. 
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Can you briefly share why you don’t want to participate in this study? ________________________ 
 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________ 
 
 
Is there anything else you would like us to know? __________________________________________ 
 
_____________________________________________________________________________________ 
 
_____________________________________________________________________________________ 
 
 
 
 
Thank you for your time! 
 
Please return this form in the postage-paid envelope included with this mailing. 
 
If you have any questions, please contact Sarah Belcher at  
412-624-8938 or LAMPstudy@pitt.edu. 
ID: _____________ 
(for study use only) 
University of Pittsburgh School of Nursing 
You may have recently received a letter inviting you to participate in 
The LAMP study, a research study led by a nurse and graduate student 
at the University of Pittsburgh School of Nursing.  
Thank you if you already responded! If you have not yet responded 
and would like more information about this one-time study, please 
contact us via the phone or email information listed below. You can 
also log on to the following website to complete the one-time survey 
or a refusal form online: http://tinyurl.com/LAMP-PittNursing Please call or email the study lead, Sarah Belcher,  with any questions or to request a paper survey copy. 412-624-8938 | LAMPstudy@pitt.edu 
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The LAMP Study 
University of Pittsburgh School of Nursing 
415 Victoria Building 
3500 Victoria Street 
Pittsburgh, PA  15261 
[Recipient Name] 
[Street Address] 
[Address 2] 
[City, ST  ZIP Code] 
The LAMP Study 
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If you have not yet completed the survey, this is a friendly reminder 
to complete and return it in the included postage-paid envelope. If you 
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APPENDIX B 
STUDY COVER LETTER AND INSTRUMENTS 
 
 
School of Nursing    
Department of Health & Community Systems  
 
 
Thank you so much for your interest in volunteering to participating in the LAMP research study. As 
you may know, I am an oncology nurse and graduate student at the University of Pittsburgh School of 
Nursing. I am conducting this study as part of my dissertation work to better understand and support 
cancer survivors like you who have had two separate types of cancer. We call these types of 
cancers, "multiple primary cancers."  
 
First, please review and complete one copy of the Consent Form included with this mailing. The 
signed consent form must be returned along with your survey responses in order for us to include you 
in the study. A second copy is provided for you to keep for yourself. 
The study consists of two parts: 
   
1. We ask you to complete and return the included paper survey questionnaire packet and return 
it along with the Consent Form in the included prepaid envelope. 
 
The questions will ask about your stress, health behaviors, emotions, and overall health. This 
survey will take you about 30 - 40 minutes to complete. We realize that we are asking you for a 
significant amount of time to complete the questions. If you need a break, you can pause and 
come back to the survey later. We truly believe that the experiences of people like you who 
have had multiple primary cancers have not be adequately been addressed in research and 
clinical practice. It is our hope that your participation in this study will help us address this 
critical lack of understanding and help people like you in the future. 
 
2. Next, our research team will review your medical records to find out more about your cancer 
and health history. 
 
You will receive a $5 Amazon.com gift card code for completing the survey. 
 
Please note that your responses to this survey will not be sent to your healthcare providers. It is 
important that you contact or see your professional healthcare team if you have any questions or 
concerns about physical or emotional symptoms, cancer, or medications. If you experience a new 
symptom or increase in severity of an existing symptom, please report this to your healthcare team or 
emergency medical services immediately. 
 
Each questionnaire has a unique set of instructions and possible response options. Questions will ask 
you to think back about different periods of time. Some questions may seem similar, because we are 
testing different ways of asking about similar ideas. There are no right or wrong answers. 
 
If you have questions at any point, you can contact me, Sarah Belcher, at LAMPstudy@pitt.edu or 
412-624-8938. 
 
Sincerely, 
 
 
Sarah M. Belcher, PhD(c), RN, OCN® 
  
Shining a light on 
Life After Multiple Primary cancers 
 
 
 
LAMP Study Questionnaires 
 
Thank you for being a part of this study! 
 
 
Please return this completed packet and a copy of the signed consent and to Sarah Belcher in the 
enclosed postage-paid envelope. 
  
ID: _____________ 
(for study use only) 
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Socio-Demographic Questionnaire – Part 1 
 
Please begin by entering the following basic information about yourself. 
 
 
SD_1.  First Name: __________________________________________________ 
 
 
SD_2.  Middle Initial: ___________ 
 
 
SD_3.  Last Name: ___________________________________________________ 
 
 
SD_4.  Date of birth: ______ / ____ / ________  
(month /  day / year) 
. 
 
SD_5.  Current Age in years: _____________ years old 
 
 
SD_6.  What is your sex? •  Male •  Female 
 
 
SD_7.  Do you consider yourself to be Hispanic or Latino? That is, of Mexican, Puerto Rican, 
Cuban, Caribbean, or of Latin American descent. 
 
•  Yes   •  No       •  Do not know 
 
SD_8.  Please select the racial and ethnic category or categories with which you most closely 
identify. Check all that apply. 
 
•  White or Caucasian 
 
•  Black or African American 
 
•  American Indian (SD8a.  specify tribe __________________________ ) 
 
•  Alaska Native 
 
•  Native Hawaiian or other Pacific Islander 
 
•  Asian 
 
•  Unknown 
 
•  Other (SD8b.  specify _________________________ ) 
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(socio-demographics, continued) 
 
 
SD_9.  Email Address: ________________________________________________ 
 
 
SD_10.  Phone Number:  (___________)______________-______________________ 
 
 
SD_11.  Does your current household income meet your basic needs?      •  Yes •  No 
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Multiple Primary Cancer (MPC) Items – Part 1 
 
In order to provide the best care and support, we need to understand how a second cancer 
diagnosis may be different than a first cancer diagnosis. Thank you for taking the time to share 
your experiences with us. 
 
 
MPC_1.  How old were you when you were first diagnosed with cancer? ____________ years old 
 
 
MPC_2.  What type of cancer were you first diagnosed with? _____________________________ 
 
 
MPC_3. How old were you when you were diagnosed with a second type of cancer?  
 
____________ years old 
 
 
MPC_4.  What type of cancer was your second cancer diagnosis? __________________________ 
 
 
MPC_5. Were you diagnosed with any additional cancers? For example, a third or more different  
type of cancer. 
 
•   No → Skip to MPC_6 on page 4. 
 
•   Yes 
 
MPC_5a. If YES, please explain: ________________________________________ 
 
__________________________________________________________________ 
 
__________________________________________________________________ 
 
__________________________________________________________________ 
 
__________________________________________________________________ 
 
__________________________________________________________________ 
 
__________________________________________________________________ 
 
__________________________________________________________________ 
 
__________________________________________________________________ 
 
__________________________________________________________________ 
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(MPC items, continued) 
 
 
MPC_6. What is your current stage of cancer survivorship? Please indicate with a check all that 
apply. 
 
•   I finished treatment less than 1 year ago. 
 
•   I finished treatment between 1 and 5 years ago. 
 
•   I finished treatment between 5 and 10 years ago. 
 
•   I finished treatment 10 or more years ago. 
 
•   I am currently receiving treatment for cancer. 
 
•   I am living with cancer as a chronic illness. 
 
•   I am currently receiving palliative care. 
 
•   I am currently receiving hospice care. 
 
•   I prefer not to answer, or I am not sure. 
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(MPC items, continued) 
 
MPC_7.  For each of the following common challenges or stressors, please select whether your  
second cancer diagnosis was more difficult, the same, or less difficult than your first 
cancer diagnosis. Select N/A if this was not a problem with either cancer diagnosis. 
 
 
This was more 
difficult with my 
second cancer. 
This was the 
same for 
both cancers. 
This was less 
difficult with my 
second cancer. 
N/A – This was 
not a problem for 
me with either 
cancer diagnosis. 
MPC_7a.  Managing stress 
             
MPC_7b.  Feeling down or blue 
             
MPC_7c. Feeling nervous or  
anxious 
 
            
MPC_7d.  Managing my overall  
health 
 
            
MPC_7e.  Finding good ways to  
cope 
 
            
MPC_7f.  Completing life activities  
(e.g., bathing/dressing, 
light housework, walking 
more than a mile) 
 
            
MPC_7g.  Treatment- and/or  
cancer-related symptoms 
 
            
MPC_7h.  Financial hardship 
             
MPC_7i.  Managing my  
relationships 
 
            
MPC_7j.  Getting the support that I  
need 
 
            
MPC_7k.  Communicating with my  
healthcare team 
 
            
MPC_7l.  Other challenge or 
stressor? – please specify: 
 
MPC_7m. ___________________ 
 
__________________________ 
 
   
 
   
 
   
 
   
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(MPC items, continued) 
 
MPC_8n.  Would you like to further explain any of the answers you provided in the previous table? 
 
•   No → Skip to PSS_1 on page 7. 
 
•   Yes → MPC_8o. If YES, please explain in the space below:  
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
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General Stress 
 
The questions in this scale ask you about your feelings and thoughts during the last month. In 
each case, please indicate with a check how often you felt or thought a certain way. 
 
 
 Never Almost 
never 
Some- 
times 
Fairly 
often 
Very 
often 
PSS_1.  In the last month, how often have you  
 been upset because of something that    
 happened unexpectedly? 
               
PSS_2.  In the last month, how often have you felt  
  that you were unable to control the   
  important things in your life? 
               
PSS_3.  In the last month, how often have you felt  
  nervous and “stressed”?                
PSS_4.  In the last month, how often have you felt  
  confident about your ability to handle  
  your personal problems? 
               
PSS_5.  In the last month, how often have you felt  
  that things were going your way?                
PSS_6.  In the last month, how often have you  
  found that you could not cope with all  
  the things that you had to do? 
               
PSS_7.  In the last month, how often have you  
  been able to control irritations in your  
  life? 
               
PSS_8.  In the last month, how often have you felt  
  that you were on top of things?                
PSS_9.  In the last month, how often have you  
  been angered because of things that were    
  outside of your control? 
               
PSS_10.  In the last month, how often have you  
felt difficulties were piling up so high 
that you could not overcome them? 
               
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Cancer-Related Stress 
 
Instructions – Below is a list of difficulties people sometimes have after a diagnosis of cancer. 
Please reach each item, and then indicate how distressing (or how common) each difficulty has 
been for you during the past seven days.  
 
(check one box on each line) 
 
 Not at 
all 
0 
A little 
bit 
1 
Moder-
ately 
2 
Quite a 
bit 
3 
Extreme
-ly 
4 
IES_1.  Any reminder of cancer brought back feelings  
 about it.                
IES_2.  I had trouble staying asleep.                
IES_3.  Other things kept making me think about  
 cancer.                
IES_4.  I felt irritable and angry.                
IES_5.  I avoided letting myself get upset when I  
 thought about cancer or was reminded of it.                
IES_6.  I thought about cancer when I didn’t mean to.                
IES_7.  I felt as if it hadn’t happened or wasn’t real.                
IES_8.  I stayed away from reminders about cancer.                
IES_9.  Pictures about being ill with cancer popped  
 into my mind.                
IES_10.  I was jumpy and easily startled.                
IES_11.  I tried not to think about cancer.                
IES_12.  I was aware that I still had a lot of feelings  
 about cancer, but I didn’t deal with them.                
IES_13.  My feelings about cancer were kind of  
 numb.                
IES_14.  I found myself feeling as though I was back  
 at that time of my bad news.                
IES_15.  I had trouble falling asleep.                
IES_16.  I had waves of strong feelings about cancer.                
IES_17.  I tried to remove cancer from my memory.                
IES_18.  I had trouble concentrating.                
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(cancer-related stress, continued) 
 
 Not at 
all 
0 
A little 
bit 
1 
Moderate
-ly 
2 
Quite a 
bit 
3 
Extreme-
ly 
4 
IES_19.  Reminders of cancer caused me to have  
physical reactions, such as sweating, 
trouble breathing, nausea, or a pounding 
heart. 
               
IES_20.  I had dreams about cancer.                
IES_21.  I felt watchful or on-guard.                
IES_22.  I tried not to talk about cancer.                
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Cancer Survivor Concerns 
 
Below is a list of worries people sometimes have after a diagnosis of cancer. Please indicate how 
much worry you experience with each of the following topics. 
 
I worry about… Not at all 
1 
A little bit 
2 
Somewhat 
3 
Very much 
4 
ASC_1.  Future diagnostic tests 
             
ASC_2.  Another type of cancer 
             
ASC_3.  My cancer coming  
back 
 
            
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Emotions, part 1 
 
Over the last 2 weeks, how often have you been bothered by any of the following problems?  
 
(check one box on each line) 
 
How often during the past 2  
weeks were you bothered by… 
Not 
at all 
0 
Several 
days 
1 
More 
than 
half 
the days 
2 
Nearly 
every 
day 
3 
     
PHQ_1.  Little interest or pleasure in doing  
things……………………………….             
 
PHQ_2.  Feeling down, depressed, or  
hopeless…………………………….             
 
If you answered “Not at All” for BOTH PHQ_1 and PHQ_2 above, skip ahead now to page 
12 (GAD_1). Otherwise, continue to PHQ_3 below. 
 
 
PHQ_3.  Trouble falling or staying asleep, or 
sleeping too much………………...             
 
PHQ_4.  Feeling tired or having little  
energy………………………………             
     
 
PHQ_5.  Poor appetite or  
overeating…………………….…….             
 
PHQ_6.  Feeling bad about yourself, or that  
you are a failure, or have let yourself 
or your family down………………             
     
 
PHQ_7.  Trouble concentrating on things,  
such as reading the newspaper or 
watching television…………………             
 
PHQ_8.  Moving or speaking so slowly that  
other people could have noticed. Or 
the opposite – being so fidgety or 
restless that you have been moving 
around a lot more than usual……….             
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Emotions, part 2 
 
Over the last 2 weeks, how often have you 
been bothered by the following problems? 
(check one box on each line) 
Not 
at all 
sure 
0 
Several 
days 
1 
Over 
half 
the days 
2 
Nearly 
every day 
3 
     
GAD_1.  Feeling nervous, anxious, or on edge 
 
            
GAD_2.  Not being able to stop or control  
worrying 
 
            
 
If you answered “Not at All” for BOTH GAD_1 and GAD_2 above, skip ahead now to 
heiQ_1 on page 13. Otherwise, continue to GAD_3 below. 
 
GAD_3.  Worrying too much about different  
things 
 
            
GAD_4.  Trouble relaxing 
 
            
GAD_5.  Being so restless that it’s hard to sit  
still 
 
            
GAD_6.  Becoming easily annoyed or irritable 
 
            
GAD_7.  Feeling afraid as if something awful  
might happen 
 
            
 
 
GAD_8.  If you checked off any of the problems, how difficult have these made it for you to do  
your work, take care of things at home, or get along with other people? 
 
Not difficult at all__________ 
 
Somewhat difficult_________ 
 
Very difficult_____________ 
 
Extremely difficult_________ 
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Self-Management of Your Health 
Instructions 
There are no right or wrong answers but please make sure that you answer every question the 
best you can. 
Please indicate how strongly you disagree or agree with the following statements by checking 
the response which best describes you now. 
Please answer the following questions: 
Check a box by crossing it:  Right now 
heiQ_1.  On most days of the week, I do at least one activity to improve my 
health (e.g., walking, relaxation, exercise). 
heiQ_2.  Most days I am doing some of the things I really enjoy. 
heiQ_3.  As well as seeing my doctor, I regularly monitor changes in my 
health. 
heiQ_4.  I often worry about my health. 
heiQ_5.  I try to make the most of my life. 
heiQ_6.  I know what things can trigger my health problems and make them 
worse. 
heiQ_7.  My health problems make me very dissatisfied with my life. 
heiQ_8.  I am doing interesting things in my life. 
heiQ_9.  I do at least one type of physical activity every day for at least 30 
minutes (e.g., walking, gardening, housework, golf, bowls, dancing, 
Tai Chi, swimming) 
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(self-management, continued) 
Check a box by crossing it:  Right now 
heiQ_10.  I have plans to do enjoyable things for myself during the next few 
days. 
heiQ_11.  I have a very good understanding of when and why I am supposed 
to take my medication. 
heiQ_12.  I often feel angry when I think about my health. 
heiQ_13.  On most days of the week, I set aside time for healthy activities 
(e.g., walking, relaxation, exercise). 
heiQ_14.  I feel hopeless because of my health problems. 
heiQ_15.  I feel like I am actively involved in life. 
heiQ_16.  When I have health problems, I have a clear understanding of 
what I need to do to control them. 
heiQ_17.  I carefully watch my health and do what is necessary to keep as 
healthy as possible. 
heiQ_18.  I get upset when I think about my health. 
heiQ_19.  I walk for exercise, for at least 15 minutes per day, most days of 
the week. 
heiQ_20.  With my health in mind, I have realistic expectations of what I can 
and cannot do. 
heiQ_21.  If I think about my health, I get depressed. 
heiQ_22.  If I need help, I have plenty of people I can rely on. 
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(self-management, continued) 
 
Check a box by crossing it:        Right now 
 
 
 
 
 
heiQ_23.  I have effective ways to prevent my symptoms (e.g., discomfort,  
pain, and stress) from limiting what I can do in my life. 
 
heiQ_24.  I have very positive relationships with my healthcare  
professionals. 
 
heiQ_25.  I have a very good idea of how to manage my health problems. 
 
heiQ_26.  When I have symptoms, I have skills that help me cope. 
 
heiQ_27.  I try not to let my health problems stop me from enjoying life. 
 
heiQ_28.  I have enough friends who help me cope with my health  
problems.  
heiQ_29.  I communicate very confidently with my doctor about my  
healthcare needs. 
 
heiQ_30.  I have a good understanding of equipment that could make my life  
easier. 
 
 
heiQ_31.  When I feel ill, my family and carers really understand what I am  
going through. 
 
heiQ_32.  I confidently give healthcare professionals the information they  
need to help. 
 
 
heiQ_33.  I get my needs met from available healthcare resources (e.g.,  
doctors, hospitals, and community services). 
 
heiQ_34.  My health problems do not ruin my life. 
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(self-management, continued) 
 
Check a box by crossing it:        Right now 
 
 
 
 
 
heiQ_35.  Overall, I feel well looked after by friends or family. 
 
heiQ_36.  I feel I have a very good life even when I have health problems. 
 
heiQ_37.  I get enough chances to talk about my health problems with  
people who understand me. 
 
 
heiQ_38.  I work in a team with my doctors and other healthcare  
professionals. 
 
heiQ_39.  I do not let my health problems control my life. 
 
heiQ_40.  If others can cope with problems like mine, I can too. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 Deakin University. Authors: RH Osborne, K Whitfield, GR Elsworth 
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Alcohol Use
The following questions ask about your alcohol use and behaviors. Please recall that all answers 
will be kept confidential. 
Yes No 
ETOH_1 In the past 30 days, did you drink any 
type of alcoholic beverages? 
    
If yes, proceed to items below (ETOH_2). 
If no, skip the remaining items on this page 
and go to ETOH_7 on page 18. 
In the past 30 days.. 
1-2
drinks 
3-4
drinks 
5-6
drinks 
7-10
drinks 
More 
than 
10 
drinks 
ETOH_2 On a typical day when I drank 
alcohol, I had…………………...           
ETOH_3 The largest number of drinks 
that I had in a single day was…..           
Never 
1-2
times 3-5 times
6-10
times
More 
than 
10 
times 
ETOH_4 I became drunk or intoxicated….           
Never 1 time 2 times 
3 
times 
4 or 
more 
times 
ETOH_5 I spent a whole weekend 
drinking………………………...           
1-7
drinks 
8-14
drinks 
15-21
drinks
22-28
drinks
More 
than 
28 
drinks 
ETOH_6 In a typical week I drank……….           
© 2008-2012 PROMIS Health Organization and PROMIS Cooperative Group 
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Alcohol Use in Relation to Cancer Diagnosis and Treatment 
In the following section, you will be asked about when you were first told you had a second 
cancer. Please answer these questions about your second cancer diagnosis. 
Yes No 
ETOH_7 I quit drinking alcohol more than 1 
year before I was told I had a second 
cancer. 
Also check “yes” if you never drank 
alcohol. 
    
If yes, skip the remaining items on this page 
and go to CTUQ_1 on page 19. 
If no, proceed to items below (ETOH_8). 
ETOH_8. During each of the following time frames, please indicate whether you drank 
              alcohol every day, some days, or not at all. 
Drank 
every day 
Drank 
some days 
Didn’t 
drink at 
all 
Don’t 
know/ Not 
sure 
ETOH_8a.  The year before you were told 
you had a second cancer         
ETOH_8b.  After your second cancer 
diagnosis, and before treatment for the 
second cancer started 
        
ETOH_8c.  During the course of 
treatment for your second cancer         
ETOH_8d.  After treatment ended for 
your second cancer         
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Tobacco Use 
 
Section 1. Basic Tobacco Use Information 
 
 
CTUQ_1.  Have you smoked at least 100 cigarettes (5 packs = 100 cigarettes) in your entire  
life? 
 
  Yes 
  No → Go to PGLOB_1 (page 22). 
  Don’t know / Not sure → Go to PGLOB_1 (page 22). 
 
 
CTUQ_2.  How old were you when you first smoked a cigarette (even one or two puffs)? 
 
_______ years old 
 
 
CTUQ_3.  Have you ever smoked cigarettes regularly? 
 
  No. I have never smoked cigarettes regularly. 
  Yes 
 
CTUQ_3a.  If YES, how old were you when you first began smoking cigarettes  
regularly? 
 
_______ years old 
 
 
CTUQ_4.  How many total years have you smoked (or did you smoke) cigarettes? Do not  
count any time you may have stayed off cigarettes. 
 
_______ Years    If you smoked less than one year, write “1.” 
 
 
CTUQ_5.  On average when you have smoked, about how many cigarettes do you (or did  
you) smoke a day? 
 
A pack usually has 20 cigarettes in it. 
 
_______ Number of cigarettes per day 
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(tobacco use, continued) 
CTUQ_6.  How long has it been since you last smoked a cigarette (even one or two puffs)? 
First check which one of the following choices applies to you. Then, if applicable, write 
a number on the line for how many days, weeks, months, or years it has been since your 
last cigarette. 
  I smoked a cigarette today (at least one puff). 
  1-7 days.  →  CTUQ_6a.  Number of days since last cigarette: _______
  Less than 1 month.  →  CTUQ_6b.  Number of weeks since last cigarette: _______ 
  Less than 1 year.  →  CTUQ_6c.  Number of months since last cigarette: _______ 
  More than 1 year.  → CTUQ_6d.  Number of years since last cigarette: _______ 
  Don’t know / Don’t remember 
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(tobacco use, continued) 
 
INSTRUCTIONS 
 
In the following section, you will be asked about when you were first told you had a second 
cancer. Please answer these questions about your second cancer diagnosis. 
 
Section 2. Tobacco Use in Relation to Cancer Diagnosis and Treatment 
 
 
 
 Yes No 
CTUQ_7 I quit smoking more than 1 year before 
I was told I had a second cancer.  
Also check “yes” if you never smoked 
or smoked less than 100 cigarettes in 
your entire life. 
      
  If yes, skip the remaining items on this page 
and go to PGLOB_1 on page 22. 
 
If no, proceed to items below (CTUQ_8). 
 
 
CTUQ_8. During each of the following time frames, please indicate whether you smoked 
cigarettes every day, some days, or not at all. 
 
 
Smoked 
every day 
Smoked 
some days 
Didn’t 
smoke at 
all 
Don’t 
know/ Not 
sure 
 
CTUQ_8a.  The year before you were 
told you had a second cancer 
 
            
 
CTUQ_8b.  After your second cancer 
diagnosis, and before treatment for 
the second cancer started 
 
            
 
CTUQ_8c.  During the course of 
treatment for your second cancer 
 
            
 
CTUQ_8d.  After treatment ended for 
your second cancer 
 
            
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Overall Health 
 
 
Please respond to each item by marking one box per row. 
 
  
Excellent 
5 
Very 
Good 
4 
Good 
3 
Fair 
2 
Poor 
1 
PGLOB_1 In general, would you say 
your health is: ……………                
       
PGLOB_2 In general, would you say 
your quality of life is: …… 
 
   
 
   
 
   
 
   
 
   
       
PGLOB_3 In general, how would you 
rate your physical health? …                
       
PGLOB_4 In general, how would you 
rate your mental health, 
including your mood and 
your ability to think? ……… 
               
       
PGLOB_5 In general, how would you 
rate your satisfaction with 
your social activities and 
relationships? …………… 
               
       
PGLOB_6 In general, please rate how 
well you carry out your usual 
social activities and roles. 
(This includes activities at 
home, at work and in your 
community, and 
responsibilities as a parent, 
child, spouse, employee, 
friend, etc.)…………………. 
               
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(overall health, continued) 
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Completely 
5 
Mostly 
4 
Moderately 
3 
A 
little 
2 
Not 
at all 
1 
PGLOB_7 To what extent are you able 
to carry out your everyday 
physical activities such as 
walking, climbing stairs, 
carrying groceries, or 
moving a chair?.................... 
               
 
In the past 7 days… 
Never 
1 
Rarely 
2 
Sometimes 
3 
Often 
4 
Always 
5 
PGLOB_8 How often have you been 
bothered by emotional 
problems such as feeling 
anxious, depressed or 
irritable?................................. 
               
 
 
None 
1 
Mild 
2 
Moderate 
3 
Severe 
4 
Very 
Severe 
5 
PGLOB_9 How would you rate your 
fatigue on average?...............                
PGLOB_10 How would you rate your pain 
on average?.................................. 
 
Please circle a number. 
0 
No 
pain 
1 2 3 4 5 6 7 8 9 10 
Worst 
imaginable 
pain 
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Physical Function 
 
Please respond to each item by marking one box per row. 
 
 
  
 Not at all 
5 
Very 
little 
4 
Somewhat 
3 
Quite 
a lot 
2 
Cannot 
do 
1 
PFX_1 
 
 
 
 
Does your health now limit you in 
doing vigorous activities, such as 
running, lifting heavy objects, 
participating in strenuous sports?...... 
               
       
PFX_2 Does your health now limit you in 
walking more than a mile?................                
       
PFX_3 Does your health now limit you in 
climbing one flight of stairs?.............                
       
PFX_4 Does your health now limit you in 
lifting or carrying groceries?.............                
       
PFX_5 Does your health now limit you in 
bending, kneeling, or stooping?........                
 
 
  
 
Without 
any 
difficulty 
5 
With a 
little 
difficulty 
4 
With 
some 
difficulty 
3 
With 
much 
difficulty 
2 
Unable 
to do 
1 
PFX_6 Are you able to do chores such as 
vacuuming or yard work?................                
       
PFX_7 Are you able to dress yourself, 
including tying shoelaces and 
doing buttons?................................. 
               
       
PFX_8 Are you able to shampoo your 
hair?.................................................                
       
PFX_9 Are you able to wash and dry your 
body?...............................................                
       
PFX_10 Are you able to get on and off the 
toilet?...............................................                
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Symptoms 
 
Part I. How severe are your symptoms? 
 
People with cancer frequently have symptoms that are caused by their disease or by their 
treatment. We ask you to rate how severe the following symptoms have been in the last 24 
hours. Please select a number from 0 (symptom has not been present) to 10 (the symptom was as 
bad as you can imagine it could be) for each item. 
 
 
Please circle one number per row. 
 
Not 
Present 
       As Bad As 
You 
Can Imagine 
MDASI_1.  Your pain at its WORST? 
 0 1 2 3 4 5 6 7 8 9 10 
 
MDASI_2.  Your fatigue (tiredness) at its  
WORST? 
 
0 1 2 3 4 5 6 7 8 9 10 
 
MDASI_3.  Your nausea at its WORST? 
 0 1 2 3 4 5 6 7 8 9 10 
 
MDASI_4.  Your disturbed sleep at its  
WORST? 
 
0 1 2 3 4 5 6 7 8 9 10 
 
MDASI_5.  Your feelings of being distressed  
(upset) at its WORST? 
 
0 1 2 3 4 5 6 7 8 9 10 
 
MDASI_6.  Your shortness of breath at its  
WORST? 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
MDASI_7.  Your problem with remembering  
things at its WORST? 
 
0 1 2 3 4 5 6 7 8 9 10 
 
MDASI_8.  Your problem with lack of  
appetite at its WORST? 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
MDASI_9.  Your feeling drowsy (sleepy) at  
its WORST? 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
MDASI_10.  Your having a dry mouth at its  
WORST? 
 
0 1 2 3 4 5 6 7 8 9 10 
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(symptoms, continued) 
Part II. How have your symptoms interfered with your life? 
Symptoms frequently interfere with how we feel and function. How much have your symptoms 
interfered with the following items in the last 24 hours? Please select a number from 0 
(symptoms have not interfered) to 10 (symptoms interfered completely) for each item. 
Please circle one number per row. Did Not 
Interfere 
Interfered 
Completely 
MDASI_14.  General activity? 0 1 2 3 4 5 6 7 8 9 10 
MDASI_15.  Mood? 0 1 2 3 4 5 6 7 8 9 10 
MDASI_16.  Work (including 
work around the 
house)? 0 1 2 3 4 5 6 7 8 9 10 
MDASI_17.  Relations with other 
people? 0 1 2 3 4 5 6 7 8 9 10 
MDASI_18.  Walking? 0 1 2 3 4 5 6 7 8 9 10 
MDASI_19.  Enjoyment of life? 0 1 2 3 4 5 6 7 8 9 10 
© 2000 The University of Texas MD Anderson Cancer Center 
All rights reserved 
Please circle one number per row. 
Not 
Present 
As Bad As 
You 
Can Imagine 
MDASI_11.  Your feeling sad at its 
WORST? 0 1 2 3 4 5 6 7 8 9 10 
MDASI_12.  Your vomiting at its WORST? 
 0 1 2 3 4 5 6 7 8 9 
10 
MDASI_13.  Your numbness or tingling at 
its WORST? 0 1 2 3 4 5 6 7 8 9 10 
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Health History 
Please use this form to indicate with a check whether you have any of the following health 
conditions you may have experienced or be dealing with presently. 
Please check yes or no for each row. Yes No 
CCI_1.  Asthma, emphysema, or chronic bronchitis     
CCI_2.  Arthritis or rheumatism     
CCI_3.  Cancer diagnosed in the past 3 years     
CCI_4.  Diabetes     
CCI_5.  Digestive problems (such as ulcer, colitis, or gallbladder disease)     
CCI_6.  Heart trouble (such as angina, congestive heart failure, or coronary artery 
disease) 
    
CCI_7.  HIV illness or AIDS     
CCI_8.  Kidney disease     
CCI_9.  Liver problems (such as cirrhosis)     
CCI_10. Stroke     
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Financial Impact of Cancer
People who have experienced cancer may be impacted financially. We are trying to learn the 
financial impacts of having multiple cancers. 
The next set of questions will ask you about financial problems you may have experienced. As 
with the rest of the study, all responses will be kept confidential. 
Below is a list of statements that other people with cancer have said are important. Please check 
one box per line to indicate your response as it applies to the past 7 days. 
Not 
at all 
0 
A 
little 
bit 
1 
Some-
what 
2 
Quite 
a bit 
3 
Very 
much 
4 
COST_1 
I know that I have enough money in savings, 
retirement, or assets to cover the costs of my 
treatment………………………….…………………           
COST_2 My out-of-pocket medical expenses are more than I 
thought they would be…………………………..…..           
COST_3 I worry about the financial problems I will have in 
the future as a result of my illness or treatment…….           
COST_4 I feel I have no choice about the amount of money I 
spend on care………………………...……………...           
COST_5 I am frustrated that I cannot work or contribute as 
much as I usually do………………………………...           
COST_6 I am satisfied with my current financial situation…..           
COST_7 I am able to meet my monthly expenses……………           
COST_8 I feel financially stressed……………………………           
COST_9 I am concerned about keeping my job and income, 
including work at home……………………………..           
COST_10 My cancer or treatment has reduced my satisfaction 
with my present financial situation…………………           
COST_11 I feel in control of my financial situation…………...           
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Financial Hardships
Please check one answer per row that best applies to you. 
Financial Strain 
Almost 
never 
1 
Once in a 
while 
2 
Sometimes 
3 
A lot of the 
time 
(frequently) 
4 
Almost 
always 
5 
EH_1.  In the next three months, how 
often do you think that you and 
your family will experience bad 
times such as poor housing or 
not having enough food? 
          
EH_2.  In the next three months, how 
often do you expect that you will 
have to do without the basic 
things that your family needs? 
          
Inability to Make Ends Meet A great 
deal of 
difficulty 
1 
Quite a bit 
of 
difficulty 
2 
Some 
difficulty 
3 
A little 
difficulty 
4 
No 
difficulty 
at all 
5 
EH_3.  Think back over the past 3 
months and tell us how much 
difficulty you had paying your 
bills. Would you say you had... 
          
More than 
enough 
money left 
1 
Some 
money left 
2 
Just 
enough 
money left 
3 
Somewhat 
short of 
money 
4 
Very 
short of 
money 
5 
EH_4.  Think again over the past 3 
months. Generally, at the end of 
each month, did you end up 
with... 
          
LAMP Study Questions 
30 
(financial hardships, continued) 
Please check one answer per row that best applies to you. 
Not Enough Money for Necessities 
Please think about how you felt about 
your family’s economic situation over 
the past 3 months. Indicate how much 
you would agree or disagree with each 
statement. 
Strongly 
agree 
1 
Agree 
2 
Neutral/ 
Mixed 
3 
Disagree 
4 
Strongly 
disagree 
5 
EH_5.  My family had enough money to 
afford the kind of home we 
should have. 
          
EH_6.  We had enough money to afford 
the kind of clothing we should 
have. 
          
EH_7.  We had enough money to afford 
the kind of furniture or 
household appliances we should 
have. 
          
EH_8.  We had enough money to afford 
the kind of car we need. 
          
EH_9.  We had enough money to afford 
the kind of food we should have. 
          
EH_10.  We had enough money to afford 
the kind of medical care we 
should have. 
          
EH_11.  My family had enough money 
to afford leisure and recreational 
activities. 
          
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(financial hardships, continued) 
Please check one answer per row that best applies to you. 
Economic Adjustments/Cutbacks 
In the past 3 months, has your family made any of the following 
adjustments because of financial need? Yes 
1 
No 
2 
EH_12.  Changed food shopping or eating habits a lot to save money     
EH_13.  Shut down the heat or air conditioning to save money even 
though it made the house uncomfortable 
    
EH_14.  Didn’t go to see the doctor or dentist when you needed to 
because you had to save money 
    
EH_15.  Fell far behind in paying bills     
EH_16.  Asked relatives or friends for money or food to help you get by     
EH_17.  Added another job to help make ends meet     
EH_18.  Received government assistance     
EH_19.  Sold some possessions because you needed the money (even 
though you really wanted to keep them) 
    
EH_20.  Moved to another house or apartment to save money     
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Ability to Participate in Social Roles and Activities 
Please respond to each item by marking one box per row. 
Never 
5 
Rarely 
4 
Some-
times 
3 
Usually 
2 
Always 
1 
PABIL_1 
I have trouble doing all of my 
regular leisure activities with 
others........................................... 
          
PABIL_2 
I have trouble doing all of the 
family activities that I want to 
do……………………………….           
PABIL_3 
I have trouble doing all of my 
usual work (include work at 
home)…………………………... 
          
PABIL_4 
I have trouble doing all of the 
activities with friends that I want 
to do……………………………. 
          
PABIL_5 I have to limit the things I do for 
fun with others………………….           
PABIL_6 
I have to limit my regular 
activities with friends…………..           
PABIL_7 
I have to limit my regular family 
activities………………………...           
PABIL_8 
I have trouble doing all of the 
work that is really important to 
me (including work at home)….. 
          
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Satisfaction with Participation in Social Roles 
 
Please respond to each question or statement by marking one box per row. 
 
 
  
In the past 7 days… 
 
 
Not at 
all 
5 
A little 
bit 
4 
Some-
what 
3 
Quite a 
bit 
2 
Very 
much 
1 
PSAT_1 
 
I am satisfied with how much 
work I can do (include work at 
home)…………………………... 
               
       
PSAT_2 
I am satisfied with my ability to 
work (include work at home)….. 
 
   
 
   
 
   
 
   
 
   
       
PSAT_3 
I am satisfied with my ability to 
do regular personal and 
household responsibilities……... 
               
       
PSAT_4 I am satisfied with my ability to 
perform my daily routines……...                
       
PSAT_5 
I am satisfied with my ability to 
meet the needs of those who 
depend on me…………………... 
               
       
PSAT_6 
I am satisfied with my ability to 
do household chores/tasks……...                
       
PSAT_7 I am satisfied with my ability to 
do things for my family………...                
       
PSAT_8 
I am satisfied with the amount of 
time I spend performing my 
daily routines…………………... 
               
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General Outlook 
 
Please use the rating scale below to indicate how accurately each statement describes you.  
 
How much do you agree with each statement about you as you generally are now, not as you 
wish to be in the future? 
 
In general, I… 
Strongly 
Disagree 
1 
Somewhat 
Agree 
2 
Neither 
Agree nor 
Disagree 
3 
Somewhat 
Agree 
4 
Strongly 
Agree 
5 
IPIP_1.  Get chores done right away.                
IPIP_2.  Have frequent mood swings.                
IPIP_3.  Often forget to put things back in  
            their proper place. 
               
IPIP_4.  Am relaxed most of the time.                
IPIP_5.  Like order.                
IPIP_6.  Get upset easily.                
IPIP_7.  Make a mess of things.                
IPIP_8.  Seldom feel blue.                
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Social Support 
Instructions:  This scale is made up of a list of statements each of which may or may not be true 
about you. For each statement circle “definitely true” if you are sure it is true about you and 
“probably true” if you think it is true but are not absolutely certain. Similarly, you should circle 
“definitely false” if you are sure the statement is false and “probably false” if you think it is false 
but are not absolutely certain. 
ISEL_1.  If I wanted to go on a trip for a day (for example, to the country or mountains), I 
would have a hard time finding someone to go with me. 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL_2.  I feel that there is no one I can share my most private worries and fears with. 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL_3.  If I were sick, I could easily find someone to help me with my daily chores. 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL_4.  There is someone I can turn to for advice about handling problems with my family. 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL_5.  If I decide one afternoon that I would like to go to a movie that evening, I could 
easily find someone to go with me. 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL_6.  When I need suggestions on how to deal with a personal problem, I know someone I 
can turn to. 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL_7.  I don’t often get invited to do things with others. 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL_8.  If I had to go out of town for a few weeks, it would be difficult to find someone who 
would look after my house or apartment (the plants, pets, garden, etc.). 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL_9.  If I wanted to have lunch with someone, I could easily find someone to join me. 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL_10.  If I was stranded 10 miles from home, there is someone I could call who could 
come and get me. 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL11.  If a family crisis arose, it would be difficult to find someone who could give me good 
advice about how to handle it. 
1. definitely false 2. probably false 3. probably true 4. definitely true
ISEL_12.  If I needed some help in moving to a new house or apartment, I would have a hard 
time finding someone to help me. 
1. definitely false 2. probably false 3. probably true 4. definitely true
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Socio-demographic Questionnaire – Part 2 
SD_13.  Which of the following best describes your current marital status? 
• Never married
• Currently married
• Living with partner / significant other
• Widowed
• Separated
• Divorced
• Other (SD_13a.  specify ___________________________ )
SD_14.  How many years have you been at your current marital status? 
Answer “1” if less than one year. __________ years 
SD_15.  Is English your primary language (the one you speak most often)? •  Yes •  No 
SD_16.  What is the zip code where you live most of the time?   _______________ (5-digit) 
SD_17.  In what type of area did you live most of your childhood? 
• Urban, large city
• Urban, small city
• Suburb of large city
• Suburb of small city
• Rural, farm
• Rural, non-farm
• Other (SD_17a.  specify _________________________ )
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(socio-demographics, continued) 
SD_18.  How many total years of formal education do you have? __________ 
SD_19.  What is the highest grade or degree you have completed? 
• Grade school (grades 1-8)
• High school diploma (grades 9-12)
• GED (Graduate Equivalent Degree)
• Vocational/Technical school certificate
• 2-year college (Associate’s level)
• 4-year college (Bachelor’s level)
 Graduate school (Master’s level) 
• Professional school (i.e., MD, DVM, JD)
• Graduate school (Doctoral level, i.e., PhD, EdD)
• Unknown
SD_20.  What is your current employment status? 
• Full time (working at least 35 hours a week)
• Part time (working less than 35 hours a week)
• Laid off or unemployed, looking for work
• Laid off or unemployed, not looking for work
• Retired, not working at all
• Retired, but working part or full time
• Disabled/unable to work
• Full time homemaker
• Student
• Other (SD_20a.  specify _________________________ )
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(socio-demographics, continued) 
SD_21.  Are you currently employed?  •  Yes •  No 
If you are NOT currently employed: 
SD_21a.  What was your primary occupation? ___________________________________ 
SD_21b.  When was the last year you were employed? _________________ 
If you ARE currently employed: 
SD_21c.  What is your primary occupation? ___________________________________ 
SD_22.  Did you make changes at work since your second cancer diagnosis? 
• Yes •  No (If no, skip to SD_23 on page 39.)
SD_22a.  If YES, why? 
• I changed because of the physical demands of my job.
• I changed because of the mental demands of my job.
• I changed for other reasons.
• No, my change in occupation was not because of my cancer.
SD_22b.  If YES, what change(s) did you make at work since your second cancer 
diagnosis? 
Please specify: _____________________________________________________ 
__________________________________________________________________ 
__________________________________________________________________ 
SD_22c.  Did that change affect your insurance coverage?  •  Yes •  No 
SD_22d.  If YES, please specify how: ____________________________________ 
__________________________________________________________________ 
SD_22e.  Did that change affect your retirement benefits? •  Yes •  No 
SD_22f.  If YES, please specify how: ____________________________________ 
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(socio-demographics, continued) 
 
SD_23.  Has your cancer or treatment caused you to take paid time off work?  •  Yes •  No 
 
SD_23a.  If YES, how many days in the past month? Please specify: __________________ 
 
 
SD_24.  Has your cancer or treatment caused to take unpaid time off work?  •  Yes •  No 
 
SD_24a.  If YES, how many days in the past month? Please specify: __________________ 
 
 
 
 
 
SD_25.  Do you have any children?  •  Yes •  No  (If no, skip to SD_26.) 
 
SD_25a.  If YES, specify number of children: ____________________ 
 
SD_25b.  If YES, specify current age(s) of children:  
  For example, you might write, “2, 7, 21” on  
the line below, if these are the ages of your 
children. 
______________________________ 
 
 
SD_26.  How many people presently live in your household, including yourself? 
 
SD_26a.  Adults: _______________ 
 
SD_26b.  Children (under 18 years old): ___________ 
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(socio-demographics, continued) 
SD_27.  How important is religion or spirituality in your life? 
• Not at all important
• Somewhat important
• Extremely important
SD_28.  Do you have a religious background or preference?  •  Yes •  No (If no, skip to SD_29 
on page 41.) 
SD_28a.  If YES, please specify: 
• Christianity
• Judaism
• Islam
• Hinduism
• Buddhism
• Other (SD_28b.  specify: _________________________ )
SD_28c.  To what extent do you follow the customs and practices of your religion? 
• Never
• Sometimes
• Frequently
• Always
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(socio-demographics, continued) 
 
SD_29.  Do you have health care insurance?  •  Yes •  No (If no, skip to SD_30, page 42.) 
 
SD_29a.  If YES, please specify type: 
 
•  Medicare 
 
•  Medicaid/Medical Assistance 
 
•  SSI 
 
•  Veterans Administration 
 
•  Workers Compensation 
 
•  Private health insurance (SD_29b.  specify _________________________ ) 
 
•  Other (SD_29c.  specify _________________________ ) 
 
SD_29d.  Does your insurance cover the cost of your medications? 
 
•  Yes, all the cost 
 
•  Yes, some of the cost (SD_29e.  specify ________________________________ ) 
 
•  No 
 
•  Unknown 
 
SD_29f.  Does your insurance cover the cost of your health care? 
 
•  Yes, all the cost 
 
•  Yes, some of the cost - for example, it does not cover the cost of co-pays or 
other expenses 
(SD_29g.  specify _________________________________________________ ) 
 
•  No 
 
•  Unknown 
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(socio-demographics, continued) 
SD_30.  What are the sources of your own total gross annual income (all sources of income 
before taxes)? Select all that apply: 
• Wages, salaries, commissions, bonus, tips from all jobs
• Self employment income from farm or non-farm business
• Interest, dividend, net rental income, royalties, or from estates or trusts
• Social security or railroad retirement
• Supplemental security income or other public assistance income
• Retirement, survivor, or disability pensions
• Other (SD_30a.  please specify ____________________________________ )
SD_31.  What is the total gross annual income for your household (all sources of income before 
taxes and donations)? 
• Under $10,000
• $10,000 - $14,999
• $15,000 - $19,999
• $20,000 - $29,999
• $30,000 - $39,999
• $40,000 - $49,999
• $50,000 - $59,999
• $60,000 - $69,999
• $70,000 - $79,999
• $80,000 - $99,999
• $100,000 - $150,000
• Over $150,000
• Unknown
• Refuse/Prefer not to answer
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SD32.  How difficult is it to pay for your basic needs? 
• Not at all difficult
• Somewhat difficult
• Extremely difficult
Health Care Use 
HCU_1.  In the past 6 months, how many times did you visit a physician? 
Do NOT include visits while in the hospital or the hospital emergency 
room. ...................................................................................................... ______ visits 
HCU_2.  In the past 6 months, how many times did you go to a hospital 
emergency room? ………………………………………………….... ______ times 
HCU_3.  How many different times did you stay in a hospital overnight or 
longer in the past 6 months? ………………………………………. ______ times 
HCU_4.  How many total NIGHTS did you spend in the hospital in the past 6 
months? …………………………………………….......................... ______ nights 
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Multiple Primary Cancer (MPC) Items – Part 2 
MPC_9.  What do you wish every healthcare provider knew about what it’s like to be diagnosed 
with cancer more than once? Please feel free to attach additional sheets if more space is needed. 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
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You have completed all questionnaires. 
A sincere thank you for being a part of this study! 
Please return 1) this packet of questionnaires and 2) one signed copy of the 
consent form to Sarah Belcher in the enclosed postage-paid envelope. 
The second consent form copy is for your records. 
You will be receiving instructions from our research team for accessing your 
compensation. 
If you have any questions or concerns, 
please contact the study’s principal investigator, 
Sarah Belcher, at 412-624-8938 
or LAMPstudy@pitt.edu. 
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LAMP Study 
MEDICAL RECORD REVIEW 
Medical Record Data Extraction Form 
Participant Study ID: Medical Record Number: 
Data Collector Name: 
Data Collection Date (mm/dd/yyyy): 
Participant Socio-Demographics 
Insurance:  Record types from up to 1 year prior to 1st cancer diagnosis to present. 
Insurance Type(s): Date(s) Recorded in Medical Record 
(mm/dd/yyyy) 
Anthropometric Data 
Time Point Height (centimeters) Weight (kilograms) BMI (kg/m2) 
At first diagnosis 
Date: _____________ _____________ cm ______________ kg _________ (kg/m2) 
At second diagnosis 
Date: _____________ _____________ cm _____________ kg _________ (kg/m2) 
Most recently recorded 
Date: _____________ _____________ cm _____________ kg _________ (kg/m2) 
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Family Cancer History 
Family history of cancer in 1st degree relative (parent, brother, sister, or child)? 
☐ Yes      ☐  No    If yes, list:
Relationship: Type of Cancer: 
Genetic Testing 
Did participant receive any type of genetic testing? 
☐ Yes      ☐  No    If yes, describe:
Date: Type/Findings: 
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Most Current Medication List (prescription and OTC): 
Date Recorded in Medical Record (mm/dd/yyyy): _________________________ 
☐ aspirin ☐ Other (specify on lines below):
☐ atorvastatin (Lipitor)
☐ diphenhydramine hydrochloride (Benadryl)
☐ famotidine (Pepcid)
☐ furosemide (Lasix)
☐ hydrochlorothiazide (Microzide)
☐ hydrocodone/acetaminophen (Vicodin, Norco,
Xodol)
☐ levothyroxine (Synthroid, Levoxyl, Unithyroid)
☐ lisinopril (Prinivil, Zestril)
☐ meclizine hydrochloride (Bonine, Verticalm)
☐ metformin hydrochloride (Glucophage)
☐ metoprolol (Lopressor, Toprol XL)
☐ omeprazole (Prilosec)
☐ ondansetron (Zofran)
☐ prednisone (Delasone, Sterapred)
☐ ranitidine (Zantac)
☐ sertraline hydrochloride (Zoloft)
☐ simvastin (Zocor, FloLipid)
☐ zolpidem tartrate (Ambien)
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Non-Cancer Past Medical/Surgical History (Comorbidities): 
Include non-invasive skin cancer (e.g. basal cell carcinoma) here if applicable. 
Cancer History: 
Number of primary cancer diagnoses, excluding non-invasive skin cancers (e.g. basal cell). 
Do not count metastases or recurrences!   
_______ primary cancer diagnoses 
Were primary cancer diagnoses: 
☐ Synchronous (at same time)?     ☐  Metachronous (at different times)?
Relevant notes:  ______________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
☐ Arthritis ☐ Other (specify below):
☐ Cardiac Disease (If yes, describe below:)
☐ Depression
☐ Diabetes
☐ Dyslipidemia
☐ Hypertension
☐ Hypothyroidism
☐ Menopause
☐ Obesity
☐ Osteoporosis &/or Osteopenia
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First Primary Cancer Type: 
  Note:  Exclude cases of non-invasive skin cancer (list in past medical/surgical history). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date of Diagnosis: ___________________________________________________________ 
 
 
Histology: __________________________________________________________________ 
 
 
Cancer Stage at first cancer diagnosis: ____________________________________________________ 
 
 
Did the first cancer recur? 
 ☐  Yes      ☐  No     
 
If yes:  List number of total recurrences: __________________ (describe in table below) 
 
Recurrence(s) Date: 
(mm/dd/yyyy) 
Site(s) of Recurrent/Metastatic Disease: 
1st Recurrence  
 
 
2nd Recurrence  
 
 
3nd Recurrence   
 
 
4th Recurrence  
 
 
 
 
 
 
☐  Breast Cancer 
 
☐  Kidney / Renal Pelvis Cancer 
☐  Prostate Cancer 
 
☐  Oral Cavity / Pharynx Cancer 
☐  Colorectal Cancer 
 
☐  Lung / Bronchus Cancer 
☐  Urinary Bladder Cancer 
 
☐  Thyroid Cancer 
☐  Uterine Corpus Cancer 
 
☐  Ovarian Cancer 
☐  Melanoma 
 
☐  Other (specify below): 
 
       _________________________________ 
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Cancer Treatment Type(s) Received for First Cancer: 
☐ Surgery, If yes, describe below
_______________________________
☐ Targeted Therapy
  ____________________________ 
☐ Radiation Therapy ☐ Hormone Therapy
☐ Chemotherapy ☐ Stem Cell Transplant
☐ Immunotherapy ☐ Other:
__________________________
Date of Treatment Initiation for First Primary Cancer: 
___________________________________________________________________ 
Date of Treatment Completion for First Primary Cancer:      (check here if treatment ongoing: • ) 
___________________________________________________________________ 
Note Frontline Therapy Received for First Primary Cancer Below: 
(e.g. FOLFOX 32mg/m2, every 6 weeks x 6 cycles; 6 cycles received; last dose held due to grade 4 neuropathy; 
Radiation therapy doses of 75.6-79 Gy in conventional 36-41 Gy fractions to the prostate with 3D-CRT/IMRT with 
daily image-guided radiotherapy (IGRT) or brachytherapy) 
Regimen 
Name(s) 
Individual Drug 
Name(s) and 
Prescribed Dosages 
Time 
Interval/ 
Frequency 
Dosage 
Received 
Dose 
Delay? 
(Y or N) 
Dose 
Reduction? 
(Y or N) 
Additional Notes 
(include regimen 
alteration rationale) 
Note Subsequent Lines of Therapy (e.g. palliative, salvage intent) Received for First Primary Cancer Below: 
Regimen Name(s) 
Individual Drug Name(s) 
and Prescribed Dosages 
Time Interval/ 
Frequency 
# Cycles 
Received 
Additional Notes 
(include regimen 
alteration rationale) 
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Second Primary Cancer Type: 
  Note:  Exclude cases of non-invasive skin cancer (list in past medical/surgical history). 
Date of Diagnosis: ___________________________________________________________ 
Histology: __________________________________________________________________ 
Cancer Stage at second cancer diagnosis: ____________________________________________________ 
Did the second cancer recur? 
☐ Yes      ☐  No
If yes:  List number of total recurrences: __________________ (describe in table below) 
Recurrence(s) Date: 
(mm/dd/yyyy) 
Site(s) of Recurrent/Metastatic Disease: 
1st Recurrence 
2nd Recurrence 
3nd Recurrence 
4th Recurrence 
☐ Breast Cancer ☐ Kidney / Renal Pelvis Cancer
☐ Prostate Cancer ☐ Oral Cavity / Pharynx Cancer
☐ Colorectal Cancer ☐ Lung / Bronchus Cancer
☐ Urinary Bladder Cancer ☐ Thyroid Cancer
☐ Uterine Corpus Cancer ☐ Ovarian Cancer
☐ Melanoma ☐ Other (specify below):
_________________________________
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Cancer Treatment Type(s) Received for Second Cancer: 
☐ Surgery, If yes, describe below
_______________________________
☐ Targeted Therapy
  ____________________________ 
☐ Radiation Therapy ☐ Hormone Therapy
☐ Chemotherapy ☐ Stem Cell Transplant
☐ Immunotherapy ☐ Other:
__________________________
Date of Treatment Initiation for Second Primary Cancer: 
___________________________________________________________________ 
Date of Treatment Completion for Second Primary Cancer:      (check here if treatment ongoing: • ) 
___________________________________________________________________ 
Note Frontline Therapy Received for Second Primary Cancer Below:  
(e.g. FOLFOX 32mg/m2, every 6 weeks x 6 cycles; 6 cycles received; last dose held due to grade 4 neuropathy; 
Radiation therapy doses of 75.6-79 Gy in conventional 36-41 Gy fractions to the prostate with 3D-CRT/IMRT with 
daily image-guided radiotherapy (IGRT) or brachytherapy) 
Regimen 
Name(s) 
Individual Drug 
Name(s) and 
Prescribed Dosages 
Time 
Interval/ 
Frequency 
Dosage 
Received 
Dose 
Delay? 
(Y or N) 
Dose 
Reduction? 
(Y or N) 
Additional Notes 
(include regimen 
alteration rationale) 
Note Subsequent Lines of Therapy (e.g. palliative, salvage intent) Received for Second Primary Cancer Below: 
Regimen Name(s) 
Individual Drug Name(s) 
and Prescribed Dosages 
Time Interval/ 
Frequency 
# Cycles 
Received 
Additional Notes 
(include regimen 
alteration rationale) 
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Third Primary Cancer Type: 
  Note:  Exclude cases of non-invasive skin cancer (list in past medical/surgical history). 
Date of Diagnosis: ___________________________________________________________ 
Histology: __________________________________________________________________ 
Cancer Stage at third cancer diagnosis: ____________________________________________________ 
Did the third cancer recur? 
☐ Yes      ☐  No
If yes:  List number of total recurrences: __________________ (describe in table below) 
Recurrence(s) Date: 
(mm/dd/yyyy) 
Site(s) of Recurrent/Metastatic Disease: 
1st Recurrence 
2nd Recurrence 
3nd Recurrence 
4th Recurrence 
☐ Breast Cancer ☐ Kidney / Renal Pelvis Cancer
☐ Prostate Cancer ☐ Oral Cavity / Pharynx Cancer
☐ Colorectal Cancer ☐ Lung / Bronchus Cancer
☐ Urinary Bladder Cancer ☐ Thyroid Cancer
☐ Uterine Corpus Cancer ☐ Ovarian Cancer
☐ Melanoma ☐ Other (specify below):
_________________________________
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Cancer Treatment Type(s) Received for Third Cancer: 
☐ Surgery, If yes, describe below
_______________________________
☐ Targeted Therapy
  ____________________________ 
☐ Radiation Therapy ☐ Hormone Therapy
☐ Chemotherapy ☐ Stem Cell Transplant
☐ Immunotherapy ☐ Other:
__________________________
Date of Treatment Initiation for Third Primary Cancer: 
___________________________________________________________________ 
Date of Treatment Completion for Third Primary Cancer:      (check here if treatment ongoing: • ) 
___________________________________________________________________ 
Note Frontline Therapy Received for Third Primary Cancer Below: 
(e.g. FOLFOX 32mg/m2, every 6 weeks x 6 cycles; 6 cycles received; last dose held due to grade 4 neuropathy; 
Radiation therapy doses of 75.6-79 Gy in conventional 36-41 Gy fractions to the prostate with 3D-CRT/IMRT with 
daily image-guided radiotherapy (IGRT) or brachytherapy) 
Regimen 
Name(s) 
Individual Drug 
Name(s) and 
Prescribed Dosages 
Time 
Interval/ 
Frequency 
Dosage 
Received 
Dose 
Delay? 
(Y or N) 
Dose 
Reduction? 
(Y or N) 
Additional Notes 
(include regimen 
alteration rationale) 
Note Subsequent Lines of Therapy (e.g. palliative, salvage intent) Received for Third Primary Cancer Below: 
Regimen Name(s) 
Individual Drug Name(s) 
and Prescribed Dosages 
Time Interval/ 
Frequency 
# Cycles 
Received 
Additional Notes 
(include regimen 
alteration rationale) 
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Fourth Primary Cancer Type: 
  Note:  Exclude cases of non-invasive skin cancer (list in past medical/surgical history). 
Date of Diagnosis: ___________________________________________________________ 
Histology: __________________________________________________________________ 
Cancer Stage at fourth cancer diagnosis: ____________________________________________________ 
Did the fourth cancer recur? 
☐ Yes      ☐  No
If yes:  List number of total recurrences: __________________ (describe in table below) 
Recurrence(s) Date: 
(mm/dd/yyyy) 
Site(s) of Recurrent/Metastatic Disease: 
1st Recurrence 
2nd Recurrence 
3nd Recurrence 
4th Recurrence 
☐ Breast Cancer ☐ Kidney / Renal Pelvis Cancer
☐ Prostate Cancer ☐ Oral Cavity / Pharynx Cancer
☐ Colorectal Cancer ☐ Lung / Bronchus Cancer
☐ Urinary Bladder Cancer ☐ Thyroid Cancer
☐ Uterine Corpus Cancer ☐ Ovarian Cancer
☐ Melanoma ☐ Other (specify below):
_________________________________
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Cancer Treatment Type(s) Received for Fourth Cancer: 
☐ Surgery, If yes, describe below
_______________________________
☐ Targeted Therapy
  ____________________________ 
☐ Radiation Therapy ☐ Hormone Therapy
☐ Chemotherapy ☐ Stem Cell Transplant
☐ Immunotherapy ☐ Other:
__________________________
Date of Treatment Initiation for Fourth Primary Cancer: 
___________________________________________________________________ 
Date of Treatment Completion for Fourth Primary Cancer:      (check here if treatment ongoing: • ) 
___________________________________________________________________ 
Note Frontline Therapy Received for Fourth Primary Cancer Below:  
(e.g. FOLFOX 32mg/m2, every 6 weeks x 6 cycles; 6 cycles received; last dose held due to grade 4 neuropathy; 
Radiation therapy doses of 75.6-79 Gy in conventional 36-41 Gy fractions to the prostate with 3D-CRT/IMRT with 
daily image-guided radiotherapy (IGRT) or brachytherapy) 
Regimen 
Name(s) 
Individual Drug 
Name(s) and 
Prescribed Dosages 
Time 
Interval/ 
Frequency 
Dosage 
Received 
Dose 
Delay? 
(Y or N) 
Dose 
Reduction? 
(Y or N) 
Additional Notes 
(include regimen 
alteration rationale) 
Note Subsequent Lines of Therapy (e.g. palliative, salvage intent) Received for Fourth Primary Cancer Below: 
Regimen Name(s) 
Individual Drug Name(s) 
and Prescribed Dosages 
Time Interval/ 
Frequency 
# Cycles 
Received 
Additional Notes 
(include regimen 
alteration rationale) 
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UPMC Cancer Registry Data 
Hospital ID: 
Managing Physician 
of Record (Last, First): 
Surgeon of Record 
(Last, First): 
Date of Last Contact 
(mm/dd/yyyy): 
Cancer Registry -  Cancer Data: 
First Primary Cancer: 
Diagnosis 1 
Date of Diagnosis 1 (mm/dd/yyyy) 
Laterality 
Histology 
Stage at Diagnosis 
Second Primary Cancer: 
Diagnosis 2 
Date of Diagnosis 2 (mm/dd/yyyy) 
Laterality 
Histology 
Stage at Diagnosis 
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Third Primary Cancer: 
Diagnosis 3 
Date of Diagnosis 3 (mm/dd/yyyy) 
Laterality 
Histology 
Stage at Diagnosis 
Fourth Primary Cancer: 
Diagnosis 4 
Date of Diagnosis 4 (mm/dd/yyyy) 
Laterality 
Histology 
Stage at Diagnosis 
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HUMAN SUBJECTS APPROVALS AND CONSENTS (PRO16050542) 
Pitt Seal University of Pittsburgh
Institutional Review Board
3500 Fifth Avenue
Pittsburgh, PA 15213
(412) 383-1480
(412) 383-1508 (fax)
http://www.irb.pitt.edu
Memorandum
To: Sarah Belcher 
From: IRB Office
Date: 10/3/2017 
IRB#: PRO16050542
Subject: Characterizing Psychobehavioral Risks in Survivors of Multiple Primary Cancers
The University of Pittsburgh Institutional Review Board reviewed and approved the above referenced
study by the expedited review procedure authorized under 45 CFR 46.110 and 21 CFR 56.110.  Your
research study was approved under:
45 CFR 46.110.(5)
45 CFR 46.110.(7)
The risk level designation is Minimal Risk.
Approval Date: 10/3/2017
Expiration Date: 10/2/2018
For studies being conducted in UPMC facilities, no clinical activities can be undertaken by investigators
until they have received approval from the UPMC Fiscal Review Office.
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated problems
involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)]. Refer to the IRB
Policy and Procedure Manual regarding the reporting requirements for unanticipated problems which
include, but are not limited to, adverse events.  If you have any questions about this process, please
contact the Adverse Events Coordinator at 412-383-1480.
The protocol and consent forms, along with a brief progress report must be resubmitted at least one
month prior to the renewal date noted above as required by FWA00006790 (University of Pittsburgh),
FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 (Children’s Hospital of
Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), FWA00003338 (University of
https://www.osiris.pitt.edu/osiris/Doc/0/UVHFP06MRJ84VCS5J...
1 of 2 6/7/18, 9:32 PM
Pittsburgh Medical Center Cancer Institute).
Please be advised that your research study may be audited periodically by the University of
Pittsburgh Research Conduct and Compliance Office.
https://www.osiris.pitt.edu/osiris/Doc/0/UVHFP06MRJ84VCS5J...
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Pitt Seal University of Pittsburgh
Institutional Review Board
3500 Fifth Avenue
Ground Level
Pittsburgh, PA 15213
(412) 383-1480
(412) 383-1508 (fax)
http://www.irb.pitt.edu
Memorandum
To: Sarah Belcher 
From: IRB Office
Date: 10/17/2017
IRB#: MOD16050542-01 / PRO16050542
Subject: Characterizing Psychobehavioral Risks in Survivors of Multiple Primary Cancers
The University of Pittsburgh Institutional Review Board reviewed and approved the requested
modifications by expedited review procedure authorized under 45 CFR 46.110 and 21 CFR 56.110.
Modification Approval Date:   10/17/2017
Expiration Date:                   10/2/2018
For studies being conducted in UPMC facilities, no clinical activities that are impacted by the
modifications can be undertaken by investigators until they have received approval from the UPMC
Fiscal Review Office.
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated problems
involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)]. Refer to the IRB
Policy and Procedure Manual regarding the reporting requirements for unanticipated problems which
include, but are not limited to, adverse events. If you have any questions about this process, please
contact the Adverse Events Coordinator at 412-383-1480.
The protocol and consent forms, along with a brief progress report must be resubmitted at least one
month prior to the renewal date noted above as required by FWA00006790 (University of Pittsburgh),
FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 (Children’s Hospital of
Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), FWA00003338 (University of
Pittsburgh Medical Center Cancer Institute).
Please be advised that your research study may be audited periodically by the University of
Pittsburgh Research Conduct and Compliance Office.
https://www.osiris.pitt.edu/osiris/Doc/0/E943INLG1DVKFA8EO...
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Pitt Seal University of Pittsburgh
Institutional Review Board
3500 Fifth Avenue
Ground Level
Pittsburgh, PA 15213
(412) 383-1480
(412) 383-1508 (fax)
http://www.irb.pitt.edu
Memorandum
To: Sarah Belcher 
From: IRB Office
Date: 12/7/2017
IRB#: MOD16050542-02 / PRO16050542
Subject: Characterizing Psychobehavioral Risks in Survivors of Multiple Primary Cancers
The University of Pittsburgh Institutional Review Board reviewed and approved the requested
modifications by expedited review procedure authorized under 45 CFR 46.110 and 21 CFR 56.110.
Modification Approval Date:   12/7/2017
Expiration Date:                   10/2/2018
For studies being conducted in UPMC facilities, no clinical activities that are impacted by the
modifications can be undertaken by investigators until they have received approval from the UPMC
Fiscal Review Office.
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated problems
involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)]. Refer to the IRB
Policy and Procedure Manual regarding the reporting requirements for unanticipated problems which
include, but are not limited to, adverse events. If you have any questions about this process, please
contact the Adverse Events Coordinator at 412-383-1480.
The protocol and consent forms, along with a brief progress report must be resubmitted at least one
month prior to the renewal date noted above as required by FWA00006790 (University of Pittsburgh),
FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 (Children’s Hospital of
Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), FWA00003338 (University of
Pittsburgh Medical Center Cancer Institute).
Please be advised that your research study may be audited periodically by the University of
Pittsburgh Research Conduct and Compliance Office.
https://www.osiris.pitt.edu/osiris/Doc/0/RRQUTPL6DL84VCKL...
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Pitt Seal University of Pittsburgh
Institutional Review Board
3500 Fifth Avenue
Ground Level
Pittsburgh, PA 15213
(412) 383-1480
(412) 383-1508 (fax)
http://www.irb.pitt.edu
Memorandum
 
To: Sarah Belcher 
From: IRB Office
Date: 12/20/2017
IRB#: MOD16050542-03 / PRO16050542
Subject: Characterizing Psychobehavioral Risks in Survivors of Multiple Primary Cancers  
The University of Pittsburgh Institutional Review Board reviewed and approved the requested
modifications by expedited review procedure authorized under 45 CFR 46.110 and 21 CFR 56.110.
Modification Approval Date:   12/20/2017
Expiration Date:                   10/2/2018
For studies being conducted in UPMC facilities, no clinical activities that are impacted by the
modifications can be undertaken by investigators until they have received approval from the UPMC
Fiscal Review Office.
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated problems
involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)]. Refer to the IRB
Policy and Procedure Manual regarding the reporting requirements for unanticipated problems which
include, but are not limited to, adverse events. If you have any questions about this process, please
contact the Adverse Events Coordinator at 412-383-1480.
The protocol and consent forms, along with a brief progress report must be resubmitted at least one
month prior to the renewal date noted above as required by FWA00006790 (University of Pittsburgh),
FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 (Children’s Hospital of
Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), FWA00003338 (University of
Pittsburgh Medical Center Cancer Institute).
Please be advised that your research study may be audited periodically by the University of
Pittsburgh Research Conduct and Compliance Office.
https://www.osiris.pitt.edu/osiris/Doc/0/MDMGP1G5PTI4JD9S8...
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University of Pittsburgh
Institutional Review Board
3500 Fifth Avenue
Ground Level
Pittsburgh, PA 15213
(412) 383-1480
(412) 383-1508 (fax)
http://www.irb.pitt.edu
Memorandum
To: Sarah Belcher
From: IRB Office
Date: 2/8/2018
IRB#: MOD16050542-04  / PRO16050542
Subject: Characterizing Psychobehavioral Risks in Survivors of Multiple Primary Cancers
The University of Pittsburgh Institutional Review Board reviewed and approved the requested
modifications by the expedited review procedure authorized under 45 CFR 46.110 and 21 CFR 56.110.
Modification Approval Date: 2/8/2018
Expiration Date: 10/2/2018
[see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)].  Refer to the IRB Policy and Procedure Manual
regarding the reporting requirements for unanticipated problems which include, but are not limited to,
adverse events.  If you have any questions about this process, please contact the Adverse Events
Coordinator at 412-383-1480.
The protocol and consent forms, along with a brief progress report must be resubmitted at least one
month prior to the renewal date noted above as required by FWA00006790 (University of Pittsburgh),
FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 (Children’s Hospital of
Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), FWA00003338 (University of
Pittsburgh Medical Center Cancer Institute).
Please be advised that your research study may be audited periodically by the University of
Pittsburgh Research Conduct and Compliance Office.
https://www.osiris.pitt.edu/osiris/Doc/0/E0H1TSM565CKTB97...
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University of Pittsburgh
Institutional Review Board
3500 Fifth Avenue
Ground Level
Pittsburgh, PA 15213
(412) 383-1480
(412) 383-1508 (fax)
http://www.irb.pitt.edu
Memorandum
To: Sarah Belcher 
From: IRB Office
Date: 3/13/2018
IRB#: MOD16050542-06 / PRO16050542
Subject: Characterizing Psychobehavioral Risks in Survivors of Multiple Primary Cancers
The University of Pittsburgh Institutional Review Board reviewed and approved the requested
modifications by expedited review procedure authorized under 45 CFR 46.110 and 21 CFR 56.110.
Modification Approval Date:   3/13/2018
Expiration Date:                   10/2/2018
For studies being conducted in UPMC facilities, no clinical activities that are impacted by the
modifications can be undertaken by investigators until they have received approval from the UPMC
Fiscal Review Office.
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated problems
involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)]. Refer to the IRB
Policy and Procedure Manual regarding the reporting requirements for unanticipated problems which
include, but are not limited to, adverse events. If you have any questions about this process, please
contact the Adverse Events Coordinator at 412-383-1480.
The protocol and consent forms, along with a brief progress report must be resubmitted at least one
month prior to the renewal date noted above as required by FWA00006790 (University of Pittsburgh),
FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 (Children’s Hospital of
Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), FWA00003338 (University of
Pittsburgh Medical Center Cancer Institute).
Please be advised that your research study may be audited periodically by the University of
Pittsburgh Research Conduct and Compliance Office.
https://www.osiris.pitt.edu/osiris/Doc/0/BE68FB23CQU4B74O...
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University of Pittsburgh
Institutional Review Board
3500 Fifth Avenue
Ground Level
Pittsburgh, PA 15213
(412) 383-1480
(412) 383-1508 (fax)
http://www.irb.pitt.edu
Memorandum
To: Sarah Belcher 
From: IRB Office
Date: 3/16/2018
IRB#: MOD16050542-07 / PRO16050542
Subject: Characterizing Psychobehavioral Risks in Survivors of Multiple Primary Cancers
The University of Pittsburgh Institutional Review Board reviewed and approved the requested
modifications by expedited review procedure authorized under 45 CFR 46.110 and 21 CFR 56.110.
Modification Approval Date:   3/16/2018
Expiration Date:                   10/2/2018
For studies being conducted in UPMC facilities, no clinical activities that are impacted by the
modifications can be undertaken by investigators until they have received approval from the UPMC
Fiscal Review Office.
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated problems
involving risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)]. Refer to the IRB
Policy and Procedure Manual regarding the reporting requirements for unanticipated problems which
include, but are not limited to, adverse events. If you have any questions about this process, please
contact the Adverse Events Coordinator at 412-383-1480.
The protocol and consent forms, along with a brief progress report must be resubmitted at least one
month prior to the renewal date noted above as required by FWA00006790 (University of Pittsburgh),
FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 (Children’s Hospital of
Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), FWA00003338 (University of
Pittsburgh Medical Center Cancer Institute).
Please be advised that your research study may be audited periodically by the University of
Pittsburgh Research Conduct and Compliance Office.
https://www.osiris.pitt.edu/osiris/Doc/0/6HG1HCK1M0G43BO...
1 of 1 6/7/18, 9:29 PM
   University Of Pittsburgh 
     Institutional Review Board  
Approval Date: «Approval Date» 
Renewal Date:  «Renewal Date» 
IRB #:   «IRBNo» 
University of Pittsburgh
School of Nursing 
Department of Health and Community Systems
1 
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
TITLE OF RESEARCH PROJECT:   
Characterizing Psychobehavioral Risks in Survivors of Multiple Primary Cancers: The LAMP Study 
PRINCIPAL INVESTIGATOR: Sarah M. Belcher, PhD(c), RN, OCN® 
Doctoral Candidate 
University of Pittsburgh School of Nursing 
415 Victoria Building 
3500 Victoria Street 
Pittsburgh, PA  15261 
412-624-8938
CO-INVESTIGATORS: 
Leonard Appleman, MD, PhD 
Physican, Division of Hematology-Oncology 
UPMC 
412-648-6507
Dana Bovbjerg, PhD 
Director, Biobehavioral Oncology Program 
University of Pittsburgh Cancer Institute 
412-623-5965
Adam Brufsky, MD, PhD 
Associate Chief, Division of Hematology-Oncology 
Co-Director, Comprehensive Breast Center 
UPMC 
412-641-6500
Grace Campbell, PhD, MSW, RN, CRRN 
Assistant Professor 
School of Nursing 
412-417-8804
Edward Chu, MD 
Chief, Division of Hematology-Oncology 
UPMC 
412-648-6589
Heidi Donovan, PhD, RN 
Professor and Vice Chair for Research 
School of Nursing 
412-624-2699
Robert Edwards, MD 
Chair, Gynecology & Reproductive Sciences 
Magee-Womens Hospital of UPMC 
412-641-4212
Jonas Johnson, MD 
Chairman, Otolaryngology 
UPMC 
412-647-2100
John Kirkwood, MD 
Director, Melanoma and Skin Cancer Program 
UPMC 
412-623-7707
Susan Sereika, PhD 
Director, Center for Research and Evaluation 
School of Nursing 
412-624-0799
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   University Of Pittsburgh 
     Institutional Review Board  
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You are being asked to take part in a research study being conducted by the University of Pittsburgh’s 
School of Nursing. We will ask you to complete a one-time set of questionnaires that will take 
approximately 30-40 minutes to complete. 
WHY IS THIS RESEARCH BEING DONE? 
We are doing this study to help us understand the experiences of adult cancer survivors like you who 
have had two separate types of cancer. We call two or more separate types of cancers “multiple primary 
cancers.” We want to learn more about how having multiple primary cancers impacts stress, health 
behaviors, and emotional and overall health. 
WHO IS BEING ASKED TO TAKE PART IN THIS RESEARCH STUDY? 
You are being invited to take part in this research study because you have a history of two separate types 
of cancer, or multiple primary cancers.  We will enroll 450 multiple primary cancer survivors like you in this 
study. 
WHAT PROCEDURES WILL BE PERFORMED FOR RESEARCH PURPOSES? 
The study procedures consist of a one-time completion of a set of questionnaires and a medical record 
review. We will send you either a personalized internet link to complete the questionnaire online or a 
pencil-paper copy of the questionnaires with a pre-stamped, pre-addressed return envelope. 
1. The questionnaire can be completed online, or we can mail you the questionnaire to do on paper.
You will complete a set of questionnaires that include demographic and health information and questions
about stress, health behaviors, your experience with cancer, and emotional and overall health.
If done on paper, you will then return the signed consent form (required) along with the completed 
questionnaires in the return envelope provided to you.  
Online responses are automatically recorded. 
We estimate that the questionnaire will take 30-40 minutes to complete. 
SOURCES OF SUPPORT: American Cancer Society Doctoral Degree Scholarship in Cancer Nursing 
Robert Wood Johnson Foundation Future of Nursing Scholars 
Nightingale Awards of Pennsylvania  
University of Pittsburgh School of Nursing 
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If we do not receive your questionnaires after we sent you the initial packet in the mail, we will send you a 
reminder postcard two weeks after the initial letter and a reminder letter and replacement questionnaire 
three weeks after the initial letter. 
 
2. We will review your medical record to find out about your health. 
We will record information about types of cancer, dates diagnosed, cancer treatments, and any other 
illnesses you may have had. 
 
3. A refusal form is requested if you do not want to participate in the study. 
If you choose not to participate in the study, you will be asked to complete five questions to help us 
understand why people are not participating in this study. Answering these additional five questions is 
voluntary. 
 
 
WHAT ARE THE POSSIBLE RISKS, SIDE EFFECTS, AND DISCOMFORTS OF THIS RESEARCH 
STUDY? 
 
This is a very low risk study, but you should be aware of risks. 
 
1. One potential risk is a breach of confidentiality, but we will do everything possible to protect your 
privacy. To protect your privacy, only Ms. Belcher (the principle investigator) and members of the 
research team will be aware of your participation in this research study. Your name will not be included on 
the questionnaires we ask you to complete or the information we collect from your medical record. Mailed 
questionnaires and information collected about you from your medical record will be kept in secure, 
locked file cabinets at the School of Nursing. All information will be identified only by a study ID number. 
The information linking these ID numbers with your identify will be kept separate from the research 
records and will be stored under lock and key. If you complete the questionnaires online, the website 
where you complete the questionnaire is secure, and your data will be safely stored and can only be 
accessed by study team members. All researchers involved in this study have been thoroughly trained to 
maintain your privacy. All information you provide will be kept by the Principle Investigator in a locked file 
cabinet within a locked office at the School of Nursing. Your identity will not be revealed in any description 
or publications of this research, and data will only be presented about groups and not individual 
participants. 
 
2. Another possible risk of this research study may include stress from having to complete the 
questionnaires. If the questions cause you stress or discomfort, you can take a break from completing the 
questionnaires. If any individual questions makes you feel distressed (anxious, sad, or nervous), you do 
not have to answer them. 
 
 
WHAT ARE POSSIBLE BENEFITS FROM TAKING PART IN THIS STUDY? 
 
You will likely receive no direct benefit from taking part in this research study. The results from this study 
may benefit survivors like you who experience multiple primary cancer diagnoses in the future but will 
have no direct benefit to you. 
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WILL I BE PAID IF I TAKE PART IN THIS RESEARCH STUDY? 
Each participant will be provided with a $5 Amazon.com gift card code in recognition of his or her time 
and expertise after completing and returning the survey to Ms. Belcher. 
WHO WILL KNOW ABOUT MY PARTICIPATION IN THIS RESEARCH STUDY? 
Any information about you obtained from this research will be kept strictly confidential (private), and any 
data that includes your identity will be stored in locked files in Research Project Office or in a password 
protected computer system.  All records related to your involvement in this research study will be stored in 
a locked file cabinet in a locked room at the School of Nursing. Your identity on these records, and in the 
corresponding data entered into the computerized system, will be indicated by an ID number rather than 
by your name. The information linking these ID numbers with your identity will be kept separate from the 
research records. You will not be identified by name in any publication of the research. All records will be 
retained by us for a minimum of seven years. 
It is possible that we may use the information obtained from this study to answer more research questions 
in other research studies.  This information may also be shared with other researchers here, and at other 
research centers, but those researchers will never be provided with any personal identifiers that would 
allow them to learn who you are.   
Why is my authorization being requested? 
We are also requesting your authorization, or permission, to review your medical records to 
confirm information about your cancer and medical history and treatments. The authorization to access 
your medical records will be valid for a minimum of 7 years. We will obtain the following information: 
your diagnoses and treatments, age, past medical history, and results of any tissue biopsies or blood 
tests done as part of your standard evaluation at the Cancer Center. This identifiable medical record 
information will be made available to members of the research team for an indefinite period of 
time. Your medical information, as well as information obtained during this research study, may be 
shared with other groups, possibly including authorized officials from the University of Pittsburgh 
Research Conduct and Compliance Office, for the purpose of monitoring the study. Authorized 
representatives of UPMC or affiliated health care providers may also have access to this information to 
provide services and address billing and operational issues. 
We will make every attempt to protect your privacy and the confidentiality of your records, as described in 
this document, but cannot guarantee the confidentiality of your research records, including 
information obtained from your medical records once your personal information is disclosed to others 
outside UPMC or the University. You can always withdraw your authorization to allow the research 
team to review your medical records by contacting the investigator listed on the first page and making 
the request in writing. If you do so, you will no longer be permitted to participate in this study. Any 
information obtained from you up to that point will continue to be used by the research team.  
IS MY PARTICIPATION IN THIS STUDY VOLUNTARY? 
Your participation in this study is completely voluntary.  You may refuse to take part in it, or you may stop 
participating at any time, even after signing this form.  Your decision will not affect your relationship or 
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current or future care at a UPMC hospital or affiliated health care provider or your current or future 
relationship with a health care insurance provider. 
 
If you are eligible to participate, you will not be removed from this study without your consent. 
 
 
HOW CAN I GET MORE INFORMATION ABOUT THIS STUDY? 
 
If you have any further questions about this research study, you may contact Ms. Belcher (412-624-8938 
or LAMPstudy@pitt.edu) or the investigators listed at the beginning of this consent form. If you have any 
questions about your rights as a research subject, please contact the Human Subjects Protection 
Advocate at the University of Pittsburgh IRB Office at 866-212-2668. 
 
 
************************************************************************************************************************ 
 
Agreement to Participate 
 
 
By clicking “Yes, I agree,” in the online survey, you are providing your consent to participate in this 
research study and your agreement with the following information: 
 
• I have read the consent form for this study and any questions I had, including explanation of all 
terminology, have been answered to my satisfaction. A copy of this consent form has been made 
available to me. 
 
• I understand that I am encouraged to ask questions about any aspect of this research study and that 
those questions will be answered by the researchers listed on the first page of this form. 
 
• I understand that my participation in this study is voluntary and that I am free to refuse to participate or 
to withdraw my consent and discontinue my participation in this study at any time without affecting my 
future relationship with this institution. 
 
• I consent to participate in this research study and provide my authorization to share my medical 
records with the research team for the purposes described above. 
 
Completion of the following questions in the online survey will serve as verification of electronic consent 
to participate in this research study and HIPAA authorization for use of medical records for the purposes 
described above: 
 
• Subject’s full name 
• Subject’s birthdate 
• Subject’s answer to one of the following verifiable questions: 
1. What is your mother’s maiden name? 
2. In what city were you born? 
3. What high school did you attend? 
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     Institutional Review Board  
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University of Pittsburgh
School of Nursing 
Department of Health and Community Systems
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CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
TITLE OF RESEARCH PROJECT:   
Characterizing Psychobehavioral Risks in Survivors of Multiple Primary Cancers: The LAMP Study 
PRINCIPAL INVESTIGATOR: Sarah M. Belcher, PhD(c), RN, OCN® 
Doctoral Candidate 
University of Pittsburgh School of Nursing 
415 Victoria Building 
3500 Victoria Street 
Pittsburgh, PA  15261 
412-624-8938
CO-INVESTIGATORS: 
Leonard Appleman, MD, PhD 
Physican, Division of Hematology-Oncology 
UPMC 
412-648-6507
Dana Bovbjerg, PhD 
Director, Biobehavioral Oncology Program 
University of Pittsburgh Cancer Institute 
412-623-5965
Adam Brufsky, MD, PhD 
Associate Chief, Division of Hematology-Oncology 
Co-Director, Comprehensive Breast Center 
UPMC 
412-641-6500
Grace Campbell, PhD, MSW, RN, CRRN 
Assistant Professor 
School of Nursing 
412-417-8804
Edward Chu, MD 
Chief, Division of Hematology-Oncology 
UPMC 
412-648-6589
Heidi Donovan, PhD, RN 
Professor and Vice Chair for Research 
School of Nursing 
412-624-2699
Robert Edwards, MD 
Chair, Gynecology & Reproductive Sciences 
Magee-Womens Hospital of UPMC 
412-641-4212
Jonas Johnson, MD 
Chairman, Otolaryngology 
UPMC 
412-647-2100
John Kirkwood, MD 
Director, Melanoma and Skin Cancer Program 
UPMC 
412-623-7707
Susan Sereika, PhD 
Director, Center for Research and Evaluation 
School of Nursing 
412-624-0799
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You are being asked to take part in a research study being conducted by the University of Pittsburgh’s 
School of Nursing. We will ask you to complete a one-time set of questionnaires that will take 
approximately 30-40 minutes to complete. 
 
WHY IS THIS RESEARCH BEING DONE? 
 
We are doing this study to help us understand the experiences of adult cancer survivors like you who 
have had two separate types of cancer. We call two or more separate types of cancers “multiple primary 
cancers.” We want to learn more about how having multiple primary cancers impacts stress, health 
behaviors, and emotional and overall health. 
 
 
WHO IS BEING ASKED TO TAKE PART IN THIS RESEARCH STUDY? 
 
You are being invited to take part in this research study because you have a history of two separate types 
of cancer, or multiple primary cancers.  We will enroll 450 multiple primary cancer survivors like you in this 
study. 
 
 
WHAT PROCEDURES WILL BE PERFORMED FOR RESEARCH PURPOSES? 
 
The study procedures consist of a one-time completion of a set of questionnaires and a medical record 
review. We will send you either a personalized internet link to complete the questionnaire online or a 
pencil-paper copy of the questionnaires with a pre-stamped, pre-addressed return envelope. 
 
1. The questionnaire can be completed online, or we can mail you the questionnaire to do on paper. 
You will complete a set of questionnaires that include demographic and health information and questions 
about stress, health behaviors, your experience with cancer, and emotional and overall health.  
 
If done on paper, you will then return the signed consent form (required) along with the completed 
questionnaires in the return envelope provided to you.  
 
Online responses are automatically recorded. 
 
We estimate that the questionnaire will take 30-40 minutes to complete. 
 
SOURCES OF SUPPORT: American Cancer Society Doctoral Degree Scholarship in Cancer Nursing 
Robert Wood Johnson Foundation Future of Nursing Scholars 
Nightingale Awards of Pennsylvania      
University of Pittsburgh School of Nursing 
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If we do not receive your questionnaires after we sent you the initial packet in the mail, we will send you a 
reminder postcard two weeks after the initial letter and a reminder letter and replacement questionnaire 
three weeks after the initial letter. 
 
2. We will review your medical record to find out about your health. 
We will record information about types of cancer, dates diagnosed, cancer treatments, and any other 
illnesses you may have had. 
 
3. A refusal form is requested if you do not want to participate in the study. 
If you choose not to participate in the study, you will be asked to complete and return five questions to 
help us understand why people are not participating in this study. Answering these additional five 
questions is voluntary. 
 
 
WHAT ARE THE POSSIBLE RISKS, SIDE EFFECTS, AND DISCOMFORTS OF THIS RESEARCH 
STUDY? 
 
This is a very low risk study, but you should be aware of risks. 
 
1. One potential risk is a breach of confidentiality, but we will do everything possible to protect your 
privacy. To protect your privacy, only Ms. Belcher (the principle investigator) and members of the 
research team will be aware of your participation in this research study. Your name will not be included on 
the questionnaires we ask you to complete or the information we collect from your medical record. Mailed 
questionnaires and information collected about you from your medical record will be kept in secure, 
locked file cabinets at the School of Nursing. All information will be identified only by a study ID number. 
The information linking these ID numbers with your identify will be kept separate from the research 
records and will be stored under lock and key. If you complete the questionnaires online, the website 
where you complete the questionnaire is secure, and your data will be safely stored and can only be 
accessed by study team members. All researchers involved in this study have been thoroughly trained to 
maintain your privacy. All information you provide will be kept by the Principle Investigator in a locked file 
cabinet within a locked office at the School of Nursing. Your identity will not be revealed in any description 
or publications of this research, and data will only be presented about groups and not individual 
participants. 
 
2. Another possible risk of this research study may include stress from having to complete the 
questionnaires. If the questions cause you stress or discomfort, you can take a break from completing the 
questionnaires. If any individual questions makes you feel distressed (anxious, sad, or nervous), you do 
not have to answer them. 
 
WHAT ARE POSSIBLE BENEFITS FROM TAKING PART IN THIS STUDY? 
 
You will likely receive no direct benefit from taking part in this research study. The results from this study 
may benefit survivors like you who experience multiple primary cancer diagnoses in the future but will 
have no direct benefit to you. 
 
WILL I BE PAID IF I TAKE PART IN THIS RESEARCH STUDY? 
 
Each participant will be provided with a $5 Amazon.com gift card code in recognition of his or her time 
and expertise after completing and returning the survey to Ms. Belcher. 
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WHO WILL KNOW ABOUT MY PARTICIPATION IN THIS RESEARCH STUDY? 
 
Any information about you obtained from this research will be kept strictly confidential (private), and any 
data that includes your identity will be stored in locked files in Research Project Office or in a password 
protected computer system.  All records related to your involvement in this research study will be stored in 
a locked file cabinet in a locked room at the School of Nursing. Your identity on these records, and in the 
corresponding data entered into the computerized system, will be indicated by an ID number rather than 
by your name. The information linking these ID numbers with your identity will be kept separate from the 
research records. You will not be identified by name in any publication of the research. All records will be 
retained by us for a minimum of seven years. 
 
It is possible that we may use the information obtained from this study to answer more research questions 
in other research studies.  This information may also be shared with other researchers here, and at other 
research centers, but those researchers will never be provided with any personal identifiers that would 
allow them to learn who you are.   
 
Why is my authorization being requested? 
 
We are also requesting your authorization, or permission, to review your medical records to 
confirm information about your cancer and medical history and treatments. The authorization to access 
your medical records will be valid for a minimum of 7 years. We will obtain the following information: 
your diagnoses and treatments, age, past medical history, and results of any tissue biopsies or blood 
tests done as part of your standard evaluation at the Cancer Center. This identifiable medical record 
information will be made available to members of the research team for an indefinite period of 
time. Your medical information, as well as information obtained during this research study, may be 
shared with other groups, possibly including authorized officials from the University of Pittsburgh 
Research Conduct and Compliance Office, for the purpose of monitoring the study. Authorized 
representatives of UPMC or affiliated health care providers may also have access to this information to 
provide services and address billing and operational issues. 
 
We will make every attempt to protect your privacy and the confidentiality of your records, as described in 
this document, but cannot guarantee the confidentiality of your research records, including 
information obtained from your medical records once your personal information is disclosed to others 
outside UPMC or the University. You can always withdraw your authorization to allow the research 
team to review your medical records by contacting the investigator listed on the first page and making 
the request in writing. If you do so, you will no longer be permitted to participate in this study. Any 
information obtained from you up to that point will continue to be used by the research team.  
 
IS MY PARTICIPATION IN THIS STUDY VOLUNTARY? 
 
Your participation in this study is completely voluntary.  You may refuse to take part in it, or you may stop 
participating at any time, even after signing this form.  Your decision will not affect your relationship or 
current or future care at a UPMC hospital or affiliated health care provider or your current or future 
relationship with a health care insurance provider. 
 
If you are eligible to participate, you will not be removed from this study without your consent. 
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HOW CAN I GET MORE INFORMATION ABOUT THIS STUDY? 
 
If you have any further questions about this research study, you may contact Ms. Belcher (412-624-8938 
or LAMPstudy@pitt.edu) or the investigators listed at the beginning of this consent form. If you have any 
questions about your rights as a research subject, please contact the Human Subjects Protection 
Advocate at the University of Pittsburgh IRB Office at 866-212-2668. 
 
 
************************************************************************************************************************ 
 
Agreement to Participate 
 
 
• I have read the consent form for this study and any questions I had, including explanation of all 
terminology, have been answered to my satisfaction. A copy of this consent form has been provided 
to me. 
 
• I understand that I am encouraged to ask questions about any aspect of this research study and that 
those questions will be answered by the researchers listed on the first page of this form. 
 
• I understand that my participation in this study is voluntary and that I am free to refuse to participate or 
to withdraw my consent and discontinue my participation in this study at any time without affecting my 
future relationship with this institution. 
 
• By signing this form, I consent to participate in this research study and provide my authorization to 
share my medical records with the research team. 
 
 
___________________________________ 
Subject’s Printed Name 
 
 
___________________________________  ________________________ _____ 
Subject’s Signature Date     Time 
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Certification of Informed Consent 
To Be Completed by Research Team 
I certify that the above-named individual(s) has been provided with information about the nature and 
purpose of this research study, and he/she has been informed of the potential benefits and possible risks 
of study participation. Contact information and encouragement to contact study personnel in case of any 
questions has been provided. We will always be available to address future questions as they arise. I 
further certify that no research component of this protocol was begun until after this consent form was 
signed. 
__________________________________________ ____________________________ 
Printed Name of Person Obtaining Informed Consent Role in Research Study 
___________________________________ ________________________ ________ 
Signature Date of Consent Receipt Time 
122 
APPENDIX D 
HUMAN SUBJECTS TRAINING 
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 1 OF 2
COURSEWORK REQUIREMENTS*
* NOTE: Scores on this Requirements Report reflect quiz completions at the time all requirements for the course were met. See list below for details.
See separate Transcript Report for more recent quiz scores, including those on optional (supplemental) course elements.
• Name: Sarah Belcher (ID: 4013572)
• Institution Affiliation: University of Pittsburgh (ID: 2074)
• Institution Email: smb208@pitt.edu
• Institution Unit: School of Nursing
• Phone: 412-624-2469
• Curriculum Group: Biomedical Human Subjects Research
• Course Learner Group: Biomedical Course
• Stage: Stage 1 - Basic Course
• Description: Choose this group to satisfy CITI training requirements for Investigators and staff involved primarily in biomedical
research with human subjects.
• Record ID: 12328541
• Completion Date: 09-Feb-2014
• Expiration Date: 09-Feb-2018
• Minimum Passing: 80
• Reported Score*: 98
REQUIRED AND ELECTIVE MODULES ONLY DATE COMPLETED SCORE
University of Pittsburgh (ID: 14517)  09-Feb-2014 No Quiz 
Belmont Report and Its Principles (ID: 1127)  09-Feb-2014 3/3 (100%) 
History and Ethics of Human Subjects Research (ID: 498)  09-Feb-2014 7/7 (100%) 
Basic Institutional Review Board (IRB) Regulations and Review Process (ID: 2)  09-Feb-2014 5/5 (100%) 
Informed Consent (ID: 3)  09-Feb-2014 4/4 (100%) 
Genetic Research in Human Populations (ID: 6)  09-Feb-2014 2/2 (100%) 
Research With Protected Populations - Vulnerable Subjects: An Overview (ID: 7)  09-Feb-2014 4/4 (100%) 
Research Involving Children (ID: 9)  09-Feb-2014 3/3 (100%) 
Conflicts of Interest in Research Involving Human Subjects (ID: 488)  09-Feb-2014 5/5 (100%) 
Research Involving Prisoners (ID: 8)  09-Feb-2014 3/4 (75%) 
Stem Cell Research Oversight (Part I) (ID: 13882)  09-Feb-2014 5/5 (100%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?ka5adbd32-73e2-4a18-96be-b270fdd39ffa-12328541
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 2 OF 2
COURSEWORK TRANSCRIPT** 
** NOTE: Scores on this Transcript Report reflect the most current quiz completions, including quizzes on optional (supplemental) elements of the
course. See list below for details. See separate Requirements Report for the reported scores at the time all requirements for the course were met.
•  Name: Sarah Belcher (ID: 4013572)
•  Institution Affiliation: University of Pittsburgh (ID: 2074)
•  Institution Email: smb208@pitt.edu
•  Institution Unit: School of Nursing
•  Phone: 412-624-2469
•  Curriculum Group: Biomedical Human Subjects Research
•  Course Learner Group: Biomedical Course
•  Stage: Stage 1 - Basic Course
•  Description: Choose this group to satisfy CITI training requirements for Investigators and staff involved primarily in biomedical
research with human subjects.
•  Record ID: 12328541
•  Report Date: 07-Jun-2018
•  Current Score**: 98
REQUIRED, ELECTIVE, AND SUPPLEMENTAL MODULES MOST RECENT SCORE
History and Ethics of Human Subjects Research (ID: 498) 09-Feb-2014  7/7 (100%) 
University of Pittsburgh (ID: 14517) 09-Feb-2014  No Quiz 
Informed Consent (ID: 3) 09-Feb-2014  4/4 (100%) 
Belmont Report and Its Principles (ID: 1127) 09-Feb-2014  3/3 (100%) 
Genetic Research in Human Populations (ID: 6) 09-Feb-2014  2/2 (100%) 
Research Involving Prisoners (ID: 8) 09-Feb-2014  3/4 (75%) 
Research Involving Children (ID: 9) 09-Feb-2014  3/3 (100%) 
Conflicts of Interest in Research Involving Human Subjects (ID: 488) 09-Feb-2014  5/5 (100%) 
Basic Institutional Review Board (IRB) Regulations and Review Process (ID: 2) 09-Feb-2014  5/5 (100%) 
Stem Cell Research Oversight (Part I) (ID: 13882) 09-Feb-2014  5/5 (100%) 
Research With Protected Populations - Vulnerable Subjects: An Overview (ID: 7) 09-Feb-2014  4/4 (100%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?ka5adbd32-73e2-4a18-96be-b270fdd39ffa-12328541
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 1 OF 2
COURSEWORK REQUIREMENTS*
* NOTE: Scores on this Requirements Report reflect quiz completions at the time all requirements for the course were met. See list below for details.
See separate Transcript Report for more recent quiz scores, including those on optional (supplemental) course elements.
• Name: Sarah Belcher (ID: 4013572)
• Institution Affiliation: University of Pittsburgh (ID: 2074)
• Institution Email: smb208@pitt.edu
• Institution Unit: School of Nursing
• Phone: 412-624-2469
• Curriculum Group: Biomedical Responsible Conduct of Research
• Course Learner Group: Same as Curriculum Group
• Stage: Stage 1 - RCR
• Description: This course is for investigators, staff and students with an interest or focus in Biomedical Research. This course
contains text, embedded case studies AND quizzes. 
• Record ID: 12328543
• Completion Date: 09-Feb-2014
• Expiration Date: 09-Feb-2018
• Minimum Passing: 80
• Reported Score*: 97
REQUIRED AND ELECTIVE MODULES ONLY DATE COMPLETED SCORE
Introduction to the Responsible Conduct of Research Archived 1248 (ID: 1248)  09-Feb-2014 No Quiz 
Research Misconduct (RCR-Biomed) (ID: 1215)  09-Feb-2014 5/5 (100%) 
Data Management (RCR-Biomed) (ID: 1308)  09-Feb-2014 5/5 (100%) 
Authorship (RCR-Biomed) (ID: 1380)  09-Feb-2014 5/5 (100%) 
Mentoring (RCR-Interdisciplinary) (ID: 1250)  09-Feb-2014 5/5 (100%) 
Collaborative Research (RCR-Biomed) (ID: 1450)  09-Feb-2014 5/5 (100%) 
Responsible Conduct of Research (RCR) Course Conclusion (ID: 1043)  09-Feb-2014 No Quiz 
Conflicts of Interest (RCR-Biomed) (ID: 1622)  09-Feb-2014 5/6 (83%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?k72260891-402f-4eda-88f0-789a6e6e5e86-12328543
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 2 OF 2
COURSEWORK TRANSCRIPT** 
** NOTE: Scores on this Transcript Report reflect the most current quiz completions, including quizzes on optional (supplemental) elements of the
course. See list below for details. See separate Requirements Report for the reported scores at the time all requirements for the course were met.
•  Name: Sarah Belcher (ID: 4013572)
•  Institution Affiliation: University of Pittsburgh (ID: 2074)
•  Institution Email: smb208@pitt.edu
•  Institution Unit: School of Nursing
•  Phone: 412-624-2469
•  Curriculum Group: Biomedical Responsible Conduct of Research
•  Course Learner Group: Same as Curriculum Group
•  Stage: Stage 1 - RCR
•  Description: This course is for investigators, staff and students with an interest or focus in Biomedical Research. This course
contains text, embedded case studies AND quizzes. 
•  Record ID: 12328543
•  Report Date: 07-Jun-2018
•  Current Score**: 97
REQUIRED, ELECTIVE, AND SUPPLEMENTAL MODULES MOST RECENT SCORE
Mentoring (RCR-Interdisciplinary) (ID: 1250) 09-Feb-2014  5/5 (100%) 
Data Management (RCR-Biomed) (ID: 1308) 09-Feb-2014  5/5 (100%) 
Authorship (RCR-Biomed) (ID: 1380) 09-Feb-2014  5/5 (100%) 
Collaborative Research (RCR-Biomed) (ID: 1450) 09-Feb-2014  5/5 (100%) 
Conflicts of Interest (RCR-Biomed) (ID: 1622) 09-Feb-2014  5/6 (83%) 
Plagiarism (RCR-Basic) (ID: 15156) 02-Mar-2018  5/5 (100%) 
Authorship (RCR-Basic) (ID: 16597) 02-Mar-2018  4/5 (80%) 
Research Misconduct (RCR-Biomed) (ID: 1215) 09-Feb-2014  5/5 (100%) 
Introduction to the Responsible Conduct of Research Archived 1248 (ID: 1248) 09-Feb-2014  No Quiz 
Collaborative Research (RCR-Basic) (ID: 16598) 02-Mar-2018  5/5 (100%) 
Data Management (RCR-Basic) (ID: 16600) 02-Mar-2018  5/5 (100%) 
Mentoring (RCR-Basic) (ID: 16602) 02-Mar-2018  5/5 (100%) 
Peer Review (RCR-Basic) (ID: 16603) 02-Mar-2018  5/5 (100%) 
Research Misconduct (RCR-Basic) (ID: 16604) 02-Mar-2018  5/5 (100%) 
Responsible Conduct of Research (RCR) Course Conclusion (ID: 1043) 09-Feb-2014  No Quiz 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?k72260891-402f-4eda-88f0-789a6e6e5e86-12328543
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 1 OF 2
COURSEWORK REQUIREMENTS*
* NOTE: Scores on this Requirements Report reflect quiz completions at the time all requirements for the course were met. See list below for details.
See separate Transcript Report for more recent quiz scores, including those on optional (supplemental) course elements.
• Name: Sarah Belcher (ID: 4013572)
• Institution Affiliation: University of Pittsburgh (ID: 2074)
• Institution Email: smb208@pitt.edu
• Institution Unit: School of Nursing
• Phone: 412-624-2469
• Curriculum Group: CITI Conflicts of Interest
• Course Learner Group: Conflicts of Interest
• Stage: Stage 1 - Basic Course
• Record ID: 14006386
• Completion Date: 11-Sep-2014
• Expiration Date: 11-Sep-2018
• Minimum Passing: 80
• Reported Score*: 80
REQUIRED AND ELECTIVE MODULES ONLY DATE COMPLETED SCORE
CITI Conflict of Interest Course - Introduction (COI-Basic) (ID: 15177)  11-Sep-2014 No Quiz 
Financial Conflicts of Interest: Overview, Investigator Responsibilities, and COI Rules (COI-Basic) (ID: 15070)  11-Sep-2014 4/5 (80%) 
Institutional Responsibilities as They Affect Investigators (COI-Basic) (ID: 15072)  11-Sep-2014 3/5 (60%) 
Conflicts of Interest Institution-Specific Policies (ID: 15179)  11-Sep-2014 10/10 (100%) 
Conflicts of Commitment and Conscience (COI-Basic) (ID: 15073)  11-Sep-2014 3/5 (60%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?kb4a7be0c-d537-4dd2-80cf-b18ff50a2c3f-14006386
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 2 OF 2
COURSEWORK TRANSCRIPT** 
** NOTE: Scores on this Transcript Report reflect the most current quiz completions, including quizzes on optional (supplemental) elements of the
course. See list below for details. See separate Requirements Report for the reported scores at the time all requirements for the course were met.
•  Name: Sarah Belcher (ID: 4013572)
•  Institution Affiliation: University of Pittsburgh (ID: 2074)
•  Institution Email: smb208@pitt.edu
•  Institution Unit: School of Nursing
•  Phone: 412-624-2469
•  Curriculum Group: CITI Conflicts of Interest
•  Course Learner Group: Conflicts of Interest
•  Stage: Stage 1 - Basic Course
•  Record ID: 14006386
•  Report Date: 07-Jun-2018
•  Current Score**: 80
REQUIRED, ELECTIVE, AND SUPPLEMENTAL MODULES MOST RECENT SCORE
CITI Conflict of Interest Course - Introduction (COI-Basic) (ID: 15177) 11-Sep-2014  No Quiz 
Conflicts of Interest Institution-Specific Policies (ID: 15179) 11-Sep-2014  10/10 (100%) 
Financial Conflicts of Interest: Overview, Investigator Responsibilities, and COI Rules (COI-Basic) (ID: 15070) 11-Sep-2014  4/5 (80%) 
Institutional Responsibilities as They Affect Investigators (COI-Basic) (ID: 15072) 11-Sep-2014  3/5 (60%) 
Conflicts of Commitment and Conscience (COI-Basic) (ID: 15073) 11-Sep-2014  3/5 (60%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?kb4a7be0c-d537-4dd2-80cf-b18ff50a2c3f-14006386
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 1 OF 2
COURSEWORK REQUIREMENTS*
* NOTE: Scores on this Requirements Report reflect quiz completions at the time all requirements for the course were met. See list below for details.
See separate Transcript Report for more recent quiz scores, including those on optional (supplemental) course elements.
• Name: Sarah Belcher (ID: 4013572)
• Institution Affiliation: University of Pittsburgh (ID: 2074)
• Institution Email: smb208@pitt.edu
• Institution Unit: School of Nursing
• Phone: 412-624-2469
• Curriculum Group: Information Privacy & Security
• Course Learner Group: Privacy & Information Security
• Stage: Stage 1 - Basic Course
• Record ID: 23759774
• Completion Date: 03-Jul-2017
• Expiration Date: 03-Jul-2021
• Minimum Passing: 80
• Reported Score*: 95
REQUIRED AND ELECTIVE MODULES ONLY DATE COMPLETED SCORE
Basics of Health Privacy (ID: 1417)  03-Jul-2017 5/5 (100%) 
Health Privacy Issues for Researchers (ID: 1419)  03-Jul-2017 5/5 (100%) 
Basics of Information Security, Part 1 (ID: 1423)  03-Jul-2017 4/5 (80%) 
Basics of Information Security, Part 2 (ID: 1424)  03-Jul-2017 5/5 (100%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?kf0084fa7-f6c2-44c0-95c4-20f8ab361f30-23759774
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 2 OF 2
COURSEWORK TRANSCRIPT** 
** NOTE: Scores on this Transcript Report reflect the most current quiz completions, including quizzes on optional (supplemental) elements of the
course. See list below for details. See separate Requirements Report for the reported scores at the time all requirements for the course were met.
• Name: Sarah Belcher (ID: 4013572)
• Institution Affiliation: University of Pittsburgh (ID: 2074)
• Institution Email: smb208@pitt.edu
• Institution Unit: School of Nursing
• Phone: 412-624-2469
• Curriculum Group: Information Privacy & Security
• Course Learner Group: Privacy & Information Security
• Stage: Stage 1 - Basic Course
• Record ID: 23759774
• Report Date: 07-Jun-2018
• Current Score**: 95
REQUIRED, ELECTIVE, AND SUPPLEMENTAL MODULES MOST RECENT SCORE
Basics of Health Privacy (ID: 1417) 03-Jul-2017 5/5 (100%) 
Health Privacy Issues for Researchers (ID: 1419) 03-Jul-2017 5/5 (100%) 
Basics of Information Security, Part 1 (ID: 1423) 03-Jul-2017 4/5 (80%) 
Basics of Information Security, Part 2 (ID: 1424) 03-Jul-2017 5/5 (100%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?kf0084fa7-f6c2-44c0-95c4-20f8ab361f30-23759774
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 1 OF 2
COURSEWORK REQUIREMENTS*
* NOTE: Scores on this Requirements Report reflect quiz completions at the time all requirements for the course were met. See list below for details.
See separate Transcript Report for more recent quiz scores, including those on optional (supplemental) course elements.
• Name: Sarah Belcher (ID: 4013572)
• Institution Affiliation: University of Pittsburgh (ID: 2074)
• Institution Email: smb208@pitt.edu
• Institution Unit: School of Nursing
• Phone: 412-624-2469
• Curriculum Group: Responsible Conduct of Research
• Course Learner Group: Same as Curriculum Group
• Stage: Stage 1 - Basic Course
• Record ID: 26362482
• Completion Date: 02-Mar-2018
• Expiration Date: 01-Mar-2022
• Minimum Passing: 80
• Reported Score*: 97
REQUIRED AND ELECTIVE MODULES ONLY DATE COMPLETED SCORE
Authorship (RCR-Basic) (ID: 16597)  02-Mar-2018 4/5 (80%) 
Collaborative Research (RCR-Basic) (ID: 16598)  02-Mar-2018 5/5 (100%) 
Data Management (RCR-Basic) (ID: 16600)  02-Mar-2018 5/5 (100%) 
Mentoring (RCR-Basic) (ID: 16602)  02-Mar-2018 5/5 (100%) 
Peer Review (RCR-Basic) (ID: 16603)  02-Mar-2018 5/5 (100%) 
Research Misconduct (RCR-Basic) (ID: 16604)  02-Mar-2018 5/5 (100%) 
Plagiarism (RCR-Basic) (ID: 15156)  02-Mar-2018 5/5 (100%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?kaafd1274-d1eb-4f06-ad49-07dc88e728af-26362482
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 2 OF 2
COURSEWORK TRANSCRIPT** 
** NOTE: Scores on this Transcript Report reflect the most current quiz completions, including quizzes on optional (supplemental) elements of the
course. See list below for details. See separate Requirements Report for the reported scores at the time all requirements for the course were met.
• Name: Sarah Belcher (ID: 4013572)
• Institution Affiliation: University of Pittsburgh (ID: 2074)
• Institution Email: smb208@pitt.edu
• Institution Unit: School of Nursing
• Phone: 412-624-2469
• Curriculum Group: Responsible Conduct of Research
• Course Learner Group: Same as Curriculum Group
• Stage: Stage 1 - Basic Course
• Record ID: 26362482
• Report Date: 07-Jun-2018
• Current Score**: 97
REQUIRED, ELECTIVE, AND SUPPLEMENTAL MODULES MOST RECENT SCORE
Plagiarism (RCR-Basic) (ID: 15156) 02-Mar-2018 5/5 (100%) 
Authorship (RCR-Basic) (ID: 16597) 02-Mar-2018 4/5 (80%) 
Collaborative Research (RCR-Basic) (ID: 16598) 02-Mar-2018 5/5 (100%) 
Data Management (RCR-Basic) (ID: 16600) 02-Mar-2018 5/5 (100%) 
Mentoring (RCR-Basic) (ID: 16602) 02-Mar-2018 5/5 (100%) 
Peer Review (RCR-Basic) (ID: 16603) 02-Mar-2018 5/5 (100%) 
Research Misconduct (RCR-Basic) (ID: 16604) 02-Mar-2018 5/5 (100%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?kaafd1274-d1eb-4f06-ad49-07dc88e728af-26362482
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 1 OF 2
COURSEWORK REQUIREMENTS*
* NOTE: Scores on this Requirements Report reflect quiz completions at the time all requirements for the course were met. See list below for details.
See separate Transcript Report for more recent quiz scores, including those on optional (supplemental) course elements.
• Name: Sarah Belcher (ID: 4013572)
• Institution Affiliation: University of Pittsburgh (ID: 2074)
• Institution Email: smb208@pitt.edu
• Institution Unit: School of Nursing
• Phone: 412-624-2469
• Curriculum Group: Social and Behavioral Science Human Subjects
• Course Learner Group: Social-Behavioral-Educational Course
• Stage: Stage 2 - Refresher Course
• Description: Choose this group to satisfy CITI training requirements for Investigators and staff involved primarily in
Social/Behavioral Research with human subjects.
• Record ID: 14006384
• Completion Date: 29-Jul-2016
• Expiration Date: 29-Jul-2020
• Minimum Passing: 80
• Reported Score*: 94
REQUIRED AND ELECTIVE MODULES ONLY DATE COMPLETED SCORE
SBE Refresher 1 – Instructions (ID: 943)  29-Jul-2016 No Quiz 
SBE Refresher 1 – History and Ethical Principles (ID: 936)  29-Jul-2016 2/2 (100%) 
SBE Refresher 1 – Federal Regulations for Protecting Research Subjects (ID: 937)  29-Jul-2016 2/2 (100%) 
SBE Refresher 1 – Informed Consent (ID: 938)  29-Jul-2016 2/2 (100%) 
SBE Refresher 1 – Defining Research with Human Subjects (ID: 15029)  29-Jul-2016 2/2 (100%) 
SBE Refresher 1 – Assessing Risk (ID: 15034)  29-Jul-2016 2/2 (100%) 
SBE Refresher 1 – Privacy and Confidentiality (ID: 15035)  29-Jul-2016 2/2 (100%) 
SBE Refresher 1 – International Research (ID: 15028)  29-Jul-2016 1/2 (50%) 
SBE Refresher 1 – Research in Educational Settings (ID: 940)  29-Jul-2016 2/2 (100%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
Verify at: www.citiprogram.org/verify/?k039bda8f-3133-4de8-8031-a3a8c22bae5e-14006384
Collaborative Institutional Training Initiative (CITI Program)
Email: support@citiprogram.org
Phone: 888-529-5929
Web: https://www.citiprogram.org
COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
COMPLETION REPORT - PART 2 OF 2
COURSEWORK TRANSCRIPT** 
** NOTE: Scores on this Transcript Report reflect the most current quiz completions, including quizzes on optional (supplemental) elements of the
course. See list below for details. See separate Requirements Report for the reported scores at the time all requirements for the course were met.
•  Name: Sarah Belcher (ID: 4013572)
•  Institution Affiliation: University of Pittsburgh (ID: 2074)
•  Institution Email: smb208@pitt.edu
•  Institution Unit: School of Nursing
•  Phone: 412-624-2469
•  Curriculum Group: Social and Behavioral Science Human Subjects
•  Course Learner Group: Social-Behavioral-Educational Course
•  Stage: Stage 2 - Refresher Course
•  Description: Choose this group to satisfy CITI training requirements for Investigators and staff involved primarily in
Social/Behavioral Research with human subjects.
•  Record ID: 14006384
•  Report Date: 07-Jun-2018
•  Current Score**: 94
REQUIRED, ELECTIVE, AND SUPPLEMENTAL MODULES MOST RECENT SCORE
SBE Refresher 1 – History and Ethical Principles (ID: 936) 29-Jul-2016  2/2 (100%) 
SBE Refresher 1 – Federal Regulations for Protecting Research Subjects (ID: 937) 29-Jul-2016  2/2 (100%) 
SBE Refresher 1 – Informed Consent (ID: 938) 29-Jul-2016  2/2 (100%) 
SBE Refresher 1 – Research in Educational Settings (ID: 940) 29-Jul-2016  2/2 (100%) 
SBE Refresher 1 – Instructions (ID: 943) 29-Jul-2016  No Quiz 
SBE Refresher 1 – International Research (ID: 15028) 29-Jul-2016  1/2 (50%) 
SBE Refresher 1 – Defining Research with Human Subjects (ID: 15029) 29-Jul-2016  2/2 (100%) 
SBE Refresher 1 – Assessing Risk (ID: 15034) 29-Jul-2016  2/2 (100%) 
SBE Refresher 1 – Privacy and Confidentiality (ID: 15035) 29-Jul-2016  2/2 (100%) 
For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institution
identified above or have been a paid Independent Learner.
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Abstract
Objective The incidence of multiple primary cancers (MPCs) is increasing, but little is known
about psychological distress in this population. The purpose of this study is to review and synthe-
size the literature regarding what is known about psychological distress in adults who have
experienced MPC diagnoses.
Methods All potentially eligible studies identified in PubMed and CINAHL were reviewed
by 2 independent evaluators, and each relevant article was assessed for methodological
quality. Data were extracted, organized, and recorded using a coding log, PRISMA flow
diagram, and a standardized table of evidence. Effect size (ES) values were calculated using
Cohen's d.
Results Five of the 562 potentially relevant articles were selected for final analysis. MPC
survivors, when compared with single cancer survivors, had lower global quality of life
(d = 0.32–0.37), poorer emotional role function and stress (d = 0.08–0.20), greater and more
frequent distress (d = 0.11–0.37), and greater subclinical anxiety (d = 0.15). Depressive symptoms
were variable (d = 0.01–0.22), and no differences between MPC and single cancer groups were
identified for sleep and suicidal ideation.
Conclusion There is a substantial lack of evidence focused on psychological distress among
the growing MPC survivor population. ES noted in the 5 studies reflect small but potentially
significant increases in psychological distress in survivors of MPC compared with survivors of a
single cancer. Clinicians should be aware of this at‐risk population when screening for distress
in cancer survivors. Suggestions for future research are provided.
KEYWORDS
cancer survivorship, cancer‐related distress, multiple primary cancers, oncology, psychological
distress, subsequent malignancies
1 | BACKGROUND
Improved cancer treatments and screening have contributed to a
growing and aging cancer survivor population, and, by 2026, the
number of Americans living with a history of cancer is predicted to rise
to 20.3 million people.1–3 However, aging and other risk factors
contribute to a 14% higher risk for cancer survivors to develop new
primary cancers, when compared with the general population. Even
greater risk may occur depending on the individual's site of first
primary cancer, age at first cancer diagnosis, causative exposures,
genetic factors, and carcinogenic effects due to cancer treatment.3,4
Cancers specifically linked to the development of subsequent malig-
nancies, or multiple primary cancers (MPCs), include Hodgkin disease,
non‐Hodgkin lymphoma, and certain solid tumor (ie, prostate, testicular,
ovarian, breast, and cervical) and childhood cancers.5,6 Nearly 1 in 5
cancers occurs in an individual with a previous cancer diagnosis, and
MPCs are a significant cause of morbidity and mortality among
cancer survivors.7–9
All of those faced with cancer experience varying levels of distress
related to diagnoses, disease‐ and treatment‐related effects, and care
transition points,10 and 20% to 47% of those with newly diagnosed
and recurrent cancer experience significant distress.11 A 2011 meta‐
Received: 31 March 2016 Revised: 4 October 2016 Accepted: 13 October 2016
DOI: 10.1002/pon.4299
2030 Copyright © 2016 John Wiley & Sons, Ltd. Psycho‐Oncology. 2017;26 :2030–2039.wileyonlinelibrary.com/journal/pon
analysis of studies conducted in varying countries estimated that 30%
to 40% of cancer patients in hospital settings have some combination
of mood disorders.12 Anxiety and depression are common causes of
distress in individuals with cancer with estimated prevalence of
10.3% and 14.9%, respectively, both of which are higher rates than
are seen in the general population.11,13 These patterns are especially
concerning, considering that distress is a risk factor for nonadherence
to cancer therapy, increased difficulty of treatment decision making,
and is associated with poorer quality of life (QOL), poorer adherence
with surveillance screening recommendations, and poorer health
behaviors, such as inactivity and smoking.11
Most research examining psychological distress in cancer patients
has been conducted without attention to number of primary cancers.
Despite epidemiological data acknowledging the growing number of
individuals with MPC, little is known regarding the relationship
between MPC and psychological distress and if this distress is similar
to individuals with 1 primary cancer. Lack of knowledge about the
prevalence and types of psychological distress experienced by this
population is an impediment to supporting their potentially unique
needs. Clinically, providers need to be able to identify and target
MPC survivors most at risk for psychological distress and resulting
behavioral and health response sequelae.
The purpose of this study is to review and synthesize the literature
regarding what is known about psychological distress in adults who
have experienced MPC diagnoses. The research question being exam-
ined is: What is the relationship between experience of MPC diagno-
ses and psychological distress in adult cancer survivors? We
hypothesized that adults who had experienced MPC diagnoses would
report increased psychological distress as compared with survivors of
single cancer diagnoses.
2 | METHODS
2.1 | Selection criteria
Criteria used to select studies for inclusion were established a priori
and were as follows: (1) study participants were ≥18 years old at time
of the study with any type of initial primary cancer diagnosis, at least 1
additional subsequent type of primary cancer diagnosis, and in any
phase of the cancer trajectory; (2) study reported on results evaluating
the relationships between the presence of ≥2 primary cancer diagno-
ses (independent variable) and psychological distress variables (depen-
dent variable); and (3) study was published in English. No study designs
were excluded.
2.2 | Search procedures
With expert health science librarian consultation, electronic literature
searches were constructed and implemented in PubMed (which also
includes Medline)14 and CINAHL15 databases, including articles from
inception of databases to February 2016. Searches were built to
account for variant terminology and indexing variations identified dur-
ing phases of search term harvesting and testing. Searches included
results for both MPC diagnoses and the responses of stress, anxiety,
and/or depression. Synonyms and modified versions of terms related
to MPC (eg, neoplasm, malignancy, cancer; second, multiple,
metachronous; and treatment associated) and psychological distress
(eg, depression, anxiety, psychological stress, and trauma) were
searched to achieve the largest possible sample (search strings avail-
able online as supporting information).
2.3 | Relevant study identification
The resulting searches yielded 562 potentially relevant articles.
Articles were reviewed for eligibility prior to analysis. In addition to
the first author (S.B.), a second independent reviewer (E.H.) selected
and coded articles. If article selection and/or data extraction differed
between reviewers, a process of consensus‐based decision making
was exercised until agreement was met.16 One hundred five articles
were not published in English and were therefore excluded. Initial title
and abstract review was conducted on the remaining 457 articles.
The 394 articles that did not meet basic selection criteria were
excluded. An electronic log was created to record article details of
interest and included a coding system to note rationale for each
excluded article.
The remaining 63 articles received full text review. During this
phase, the 2 primary reasons for exclusion were as follows: (1) MPC
was discussed only as a part of post‐treatment surveillance and (2) psy-
chological distress was not evaluated separately for the MPC and sin-
gle cancer diagnosis groups. No studies were identified that examined
distress only within those with MPC, and no qualitative or literature
synthesis studies were identified. Despite inclusion criteria that were
quite broad and employment of strategic search strategies, only 3 of
the 63 articles that received full review met criteria for inclusion. Hand
searches of reference lists and forward citation searches of the 3
selected articles yielded 2 additional articles for analysis. See
Figure 1 for a detailed description of search and article extraction pro-
cesses and reasons for article exclusion.
2.4 | Data extraction and analyses
The 5 selected articles were reviewed and assessed for methodological
quality based on the Newcastle‐Ottawa Quality Assessment Scale
criteria for assessing nonrandomized studies.17–19 A standardized table
of evidence was created to extract, record, and appraise data from the
5 articles based on criteria relevant to this study. Effect size (ES) and
95% confidence intervals were calculated using Cohen's d to measure
relationship direction and magnitude between MPC and psychological
distress.20 For the articles that presented results as odds ratios, results
were converted to Cohen's d to allow for comparison of results
between studies 21,22 (Table 1). Study methodologies were compared,
and results were synthesized across studies.
3 | RESULTS
Five studies met inclusion criteria for this review. Results of those
studies are presented in chronological order to facilitate evaluation of
the progression of scientific findings in this area.
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3.1 | Gotay et al (2007)
Gotay et al23 conducted a cross‐sectional, correlational study using
mailed surveys to evaluate global QOL, depressive symptoms, and can-
cer‐specific stress after a single versus MPC diagnosis. The population‐
based convenience sample of 1076 subjects was selected from the
Hawaii Tumor Registry (HTR), which does not record basal and squa-
mous cell cancers, and included 487 subjects with MPC diagnoses
and 589 single cancer controls, matched on initial disease site, age,
sex, race/ethnicity, time since initial diagnosis, and disease stage at
initial diagnosis. Two‐tailed independent sample t tests were used to
compare groups.
Time since first cancer diagnosis was significantly longer for MPC
survivors (13.6 ± 6.1 years) compared with those with a single cancer
(9.9 ± 4.0 years; P < .05). Despite this difference, when compared with
those with single cancers, those with MPC were still found to have sig-
nificantly lower global QOL (d = −0.37) as measured by a single item on
the European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30) and higher
total cancer‐specific stress (d = 0.14) measured by the Revised Impact
FIGURE 1 Summary of evidence search and selection
2032 BELCHER ET AL.
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of Event Scale (IES‐R). Although neither stress subscale was deter-
mined to be statistically significant (p ≤ .07), trends toward higher
stress subscale scores for both avoidance (d = 0.13) and intrusiveness
(d = 0.14) were noted. No between‐group differences were identified
for depressive symptomatology (d = 0.01) on the Center for Epidemio-
logic Studies–Depression (CES‐D) scale.
Both the use of the HTR to identify and confirm cancer diagnoses
and the use of matching for key factors between groups were strengths
of this study. Limitations of this study included differences in response
rates between MPC (55.8%) and single cancer groups (41.1%). Nonre-
sponders differed from responders, in that responders were younger,
more likely tohave apartner, andmore likely to report JapaneseandChi-
nese ethnicity. In addition, individuals livingwith active diseasewerenot
included in this study, and prognosis was not included as a covariate in
the analysis. Both of these factors could be important to understanding
the impact of MPC on psychological distress. Although geographical
location (Hawaii) and a large percentage of Pacific Islander participants
could lead to decreased generalizability to other populations, it is a
strength to focus on a relatively understudied population such as this.
3.2 | Recklitis et al (2010)
Recklitis et al24 published a cross‐sectional, correlational study to deter-
mine the prevalence of suicidal ideation (SI) and identify correlates of SI
in an adult cohort of childhood cancer survivors (n = 9126) compared
with their noncancer sibling controls (n = 2986). The population‐based
convenience sample of 12,112 adult subjects was selected from the
Childhood Cancer Survivor Study (CCSS) from participating institutions
across the United States and parts of Canada. The self‐reported pres-
ence of a secondmalignant neoplasm in 292 cancer survivorswas exam-
ined as a covariate of SI. Participants who endorsed any SI on a single
item on the Brief Symptom Inventory‐18 (BSI‐18) about thoughts of
ending one's life (“not at all” to “extremely”) were considered to have SI.
Although the proportion of those endorsing SI was significantly
greater in childhood cancer survivors (7.8%), as compared with sibling
controls (4.5%; d = 0.32), hierarchical logistical regression modeling,
adjusted for demographic factors, cancer diagnosis, cancer treatment,
and health outcomes, did not find MPC to be a significant predictor
of SI in childhood cancer survivors (d = <.01).
The inclusion of survivors from 2 countries is a strength of this
study as is the focus on childhood cancer survivors, a group known
to be at high risk for MPC development.3,6,25 Statistical regression
models predicting SI were also theoretically based. Methodological
concerns in this study included reliance on a single item to assess SI
and self‐reported health data outcomes including health and cancer
history. In addition, as MPC is treated as a covariate rather than
primary outcome in this study, demographic information for those with
MPC is not reported separately.
3.3 | Burris and Andrykowski (2011)
Burris and Andrykowski 26 published a cross‐sectional, case‐control
study aimed at assessing the physical and psychological health status
and health behaviors of survivors ofMPC. The population‐based conve-
nience sample of 404,525 subjects was selected from the 2009TA
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Behavioral Risk Factor Surveillance System survey, which used a
computer‐assisted, random‐digit dialingmethodand included8734 sub-
jects with 2 or more primary cancer diagnoses, 47,562 subjects with a
single cancer diagnosis, and 348,229 controls with no cancer history.
The survey was conducted throughout the continental United States,
District of Columbia, Puerto Rico, Guam, and Virgin Islands. Cancer sur-
vivorswhose first canceroccurredduring childhood (<18yearsold)were
excluded. Participants were asked to report the number of days in the
past month when their mental health was “not good” as well as number
of days in the pastmonth they did not get enough rest or sleep (bothon a
0–30 scale). Responses for unhealthy days and days of sleep problems
were also dichotomized into infrequent (0–13) or frequent (14–30).
Analyses of covariance (ANCOVA) and binomial logistic regression
analyses were used to compare differences among groups on continu-
ous and categorical outcomes, respectively, controlling for significant
covariates.
Those with MPC differed from single cancer survivors by age at
first cancer diagnosis (50.9 ± 15.9 years vs 52.0 ± 16.0; P < .001) and
time since original cancer diagnosis (16.9 ± 12.4 vs 11.1 ± 10.2 years;
P < .001). Analyses of categorical outcomes, adjusted for age, sex,
race/ethnicity, marital/partner status, body mass index (BMI), and
education, found that those with MPC, compared with those with sin-
gle cancers, were more likely to experience frequent mental distress
(d = 0.11) but were no more likely to experience frequent days of sleep
problems (d = <.01). Result patterns reported for number of days of
mental distress and sleep problems were the same when analyzed
continuously.
The large international sample, rigorous recruitment strategies (eg,
including unlisted numbers), and controlling for significant covariates
were strengths of the study. However, cancer diagnoses were
obtained via self‐report, and no information was provided regarding
treatment history and disease staging. Individuals with a pediatric can-
cer history were excluded despite having similar risks for MPC, limiting
generalizability to adult pediatric cancer survivors with MPC. The
inclusion of nonmelanoma skin cancers may also bias data, as psycho-
social problems in individuals with these types of cancers have not
been shown to differ from those in the general population.27
3.4 | Andrykowski (2012)
Andrykowski's 201228 cross‐sectional, population‐based correla-
tional study utilized data from the 2009 National Health Informa-
tion Survey to compare health status of individuals with MPC,
single cancers, and no previous cancers. Multistage sampling,
including oversampling for minorities, was conducted in the United
States via personal household interviews. The number of cancer
diagnoses was obtained via self‐report. The sample included 154
respondents with 2 or more primary cancer diagnoses, 1427
respondents with a single cancer diagnosis, and 25,004 respon-
dents with no previous cancer history. Exclusion criteria in cancer
survivors included data obtained via proxy interview, being less
than 1 year since initial cancer diagnosis, and being <18 years
old at initial cancer diagnosis. Nonmelanoma skin cancer diagnoses
were also excluded from this study. Participants were asked to
recall feelings during the previous 30 days (sad, nervous, restless
or fidgety, hopeless, everything was an effort, and worthless) and
rate the 6 items on a 5‐point scale, “none of the time” to “all of
the time.” The researchers summed the items to create a 0 to 24
total distress score. A cutoff score of ≥13 was selected to indicate
serious psychological distress. Participants who endorsed responses
of at least “a little of the time” for at least 1 of the 6 items were
asked, “How much did these feelings interfere with your life or
activities,” with choices on a 4‐point scale from “not at all” to “a
lot.” Demographic variables that differed by group were included
as covariates in subsequent analyses. ANCOVA and binary logistic
regression were used to compare groups, controlling for difference
between groups in time since initial cancer diagnosis.
MPC survivors differed from single cancer survivors in age at ini-
tial diagnosis (48.8 vs 52.5 years; P < .01) and time since initial cancer
diagnosis (16.2 vs 11.2 years; P < .001). When comparing MPC with
single cancers, those with MPC had greater total distress index scores
(d = 0.21) and were more likely to meet criteria for serious psycholog-
ical distress (d = 0.37). No difference was found for symptom interfer-
ence of psychological distress between groups (d = 0.03).
Sample size, sampling procedures to increase inclusion of minori-
ties, and exclusion of nonmelanoma skin cancers were study strengths.
Again, however, cancer diagnosis was obtained via self‐report, no
information was provided regarding treatment history and disease
staging, and individuals with a pediatric cancer history were excluded.
In addition, the distress score measure generated for this study limits
ability to compare it with other studies.
3.5 | Thong et al (2013)
To evaluate health status and psychosocial well‐being of MPC versus
single cancer survivors, Thong et al29 conducted a cross‐sectional sec-
ondary data analysis of 5 large cancer survivorship studies. Parent
studies were conducted through the Patient Reported Outcomes Fol-
lowing Initial treatment and Long‐term Evaluation of Survivorship
(PROFILES) Eindhoven Cancer Registry in the Netherlands30 and
began mailed survey data collection between 2008 and 2009. The
sample for the MPC study included 3637 subjects either diagnosed
with melanoma, endometrial, or colorectal cancer between 1998 and
2007 or lymphoma or multiple myeloma between 1999 and 2008.
The MPC group was comprised of individuals with other primary can-
cers (excluding basal cell cancer) that existed in this group of cancer
survivors, either before or after the cancer for which they were origi-
nally included in parent studies. The final sample included 560 subjects
with MPC diagnoses and 3077 controls with a single cancer diagnosis.
Chi‐square tests were used to compare demographic and clinical char-
acteristics between groups. ANCOVA, controlling for a priori deter-
mined confounding variables (age at survey, years since last
diagnosis, sex, marital status, comorbidity at survey, last type of
received treatment, BMI, and MPC versus single cancer × years since
last diagnosis interaction term), was used to compare MPC and single
cancer group scores on the Dutch Short Form‐36 (SF‐36), EORTC
QLQ‐C30, and Hospital Anxiety and Depression Scale (HADS). Associ-
ations between sociodemographic, clinical, and psychological variables
on SF‐36 and EORTC QLQ‐C30 scores were investigated using multi-
variate linear regression modeling.
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There were no statistically significant group differences in per-
centage of responders, nonresponders, and those with nonverified
mailing addresses for presence of MPC at the time of the survey, but
those with nonverified addresses were younger, had experienced more
years since last diagnosis, and differed by type of last diagnosed pri-
mary cancer. In the participant groups, compared with those with 1
cancer, those with MPC were more likely to be older at time of survey
(69.4 ± 10.1 years vs 63.9 ± 12.5; P < .0001), have had fewer mean
years since last cancer diagnosis (3.6 ± 2.4 vs 4.7 ± 2.5; P < .0001),
be retired or not working (87% vs 75%; P < .0001), and report signifi-
cantly higher rates of heart disease (19% vs 13%; P = .0001), diabetes
mellitus (14% vs 9%; P = .0004), and stomach disease (2% vs 1%;
P = .008). In the melanoma, endometrial, and colorectal group, mean
scores for individuals with MPC did not differ significantly from those
with single cancer on the Dutch SF‐36 subscales of emotional role
function (d = −0.08) or mental health (d = −0.08). As in the Gotay et al23
study, individuals with MPC in the lymphoma and multiple myeloma
group had lower EORTC QLQ‐C30 mean scores for global QOL
(d = −0.32). Those with MPC also had lower mean scores for emotional
function (d = −0.20) than those in the single cancer group. Similar to
the Burris and Andrykowski study,26 the groups in this study did not
differ in regard to insomnia (d = 0.02). The HADS was used to measure
anxiety and depression for endometrial and colorectal cancer, Hodgkin
and non‐Hodgkin lymphoma, and multiple myeloma survivors. MPC
and single cancer groups did not differ on mean anxiety scores
(d = 0.10). Survivors of MPC, compared with single cancer survivors
had higher depressive symptom scores (d = 0.22), and significantly
more survivors of MPC met the established cutoff scores of ≥8 both
for anxiety (d = 0.15) and subclinical depressive symptoms (d = 0.25)
compared with those with single cancers, again with small but poten-
tially important ES noted.
High respondent survey response rate (70%) and ability to rely on
tumor registry information for disease and treatment variables are
major strengths of this study. The use of different instruments to
measure health status variables limits interpretation across disease
types and potentially allows for underestimation of psychological dis-
tress in this study. This study also does not report on whether partici-
pants were undergoing active treatment at the time of the survey.
3.6 | Synthesis across studies
In summary, varying measures were used to capture cross‐sectional
data on 10,227 MPC survivors across the 5 studies. Work by
Andrykowski et al26,28,29 has provided most of the scientific literature
evaluating the relationship between MPC and psychological distress,
and, aside from one,23 all of the studies reviewed were conducted
using large, preexisting data sets. MPC survivors, when compared with
single cancer survivors, had lower global QOL (d = 0.32–0.37), poorer
emotional role function and stress (d = 0.08–0.20), greater and more
frequent distress (d = 0.11–0.37), and greater subclinical anxiety
(d = 0.15). Depressive symptoms were variable (d = 0.01–0.22), and
no differences between MPC and single cancer groups were identified
for sleep and suicidal ideation. Using Cohen's conventions for ES,20,22
the 5 studies reviewed support a small (d = 0.10 to 0.37) increase in
psychological distress in survivors of MPC, as compared with survivors
of a single cancer. Questions remains as to whether this effect goes
beyond theoretical interest and has clinical importance for cancer
survivors, who within the MPC survivor population is most at risk for
psychological distress, how the trajectory may vary over time, and
long‐term implications of distress in this population.
Strengths of these 5 studies include being large, population‐based
studies with strong designs and inclusion of a broad range of cancer
types with participants residing in various locations. Consistent findings
across studies despite the use of different psychological distress mea-
sures increase the generalizability of and confidence in these findings.
Limitations in this body of literature are noted. First, the inclusion
of a diverse range of cancer diagnoses may make the aggregation of
findings across different types of cancer problematic. Studies also dif-
fered as to whether they included subjects with histories of childhood
and nonmelanoma skin cancers and participants undergoing active
treatment. A primary limitation of these studies includes an overem-
phasis on cross‐sectional survey studies, preventing ability to both
establish causality of psychological distress and to determine how and
under what conditions psychological distress changes. Additional major
limitations are (1) a reliance on self‐reporting of cancer diagnoses (reli-
ability of self‐reported cancer diagnosis has been found to vary by age,
race, education, disease types/sites, and culture)31–34 and (2) lack of
racial and ethnic diversity. Given that prevalence of psychological dis-
tress and access to support services differs across racial and ethnic
groups, the homogeneity of the samples in the majority of studies
examined in this review limits generalizability of the findings.35,36 Aside
from the Gotay study conducted in Hawaii,23 participants of non‐White
race and ethnicity are not well represented in the MPC literature.
4 | CONCLUSIONS
Although this search yielded too few articles to draw strong conclu-
sions, the identified patterns across studies support the original
hypothesis that those with MPC appear to experience greater
amounts of psychological distress than those with a single primary
cancer. Important too was the critical lack of MPC literature identi-
fied. Despite the large sample of MPC survivors represented in this
analysis, there remains a striking paucity of research describing psy-
chological distress and the experiences of those in the growing
MPC survivor population. Current Commission on Cancer guidelines
on psychosocial distress screening37 are aimed at addressing cancer
patients' psychosocial issues and include distress and psychosocial
health needs screening as a standard of high‐quality cancer care.
The current knowledge gap in MPC science prevents clinicians and
researchers from being able to adequately identify MPC survivors
most at risk for distress and from developing targeted interventions
to reduce distress and promote well‐being for those most vulnerable
to distress and resulting negative health sequelae. However, the use
of National Comprehensive Cancer Network guidelines for distress
screening, with special attention to previous cancer history, can allow
for early identification of distress by clinicians and improvements in
medical management.11,38 Systematic screening for previous primary
cancers at time of new primary cancer diagnosis can be an additional
cue to monitor for distress.
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Researchers can build upon the findings in these preliminary stud-
ies to move the science forward to develop more robust, high‐quality
studies. Future work in this area should include recruitment of diverse
samples with particular emphasis on multiple racial and ethnic groups,
verification of the number of primary cancer diagnoses via medical
record review, use of uniform measurements of psychological distress
that have demonstrated validity and reliability in diverse popula-
tions,39,40 exclusion of nonmelanoma skin cancers from primary cancer
count, and exploration of differences within the MPC survivor popula-
tion. Another important gap in the literature is whether MPC survivors
who experienced initial cancer during childhood have different psy-
chological risks compared with MPC survivors who experience cancer
diagnoses only as adults. Moreover, future work should include longi-
tudinal designs to determine if and under what conditions these find-
ings may change over time. Despite modest ES in the identified
studies, MPC survivors appear to represent a group at risk for addi-
tional psychological distress associated with MPC development. Next
steps to move the science forward should include studies that discern
why and under what conditions those with MPC are at increased risk
and implications for distress on health outcomes. Being able to identify
those within this population who are most vulnerable to negative out-
comes will allow for targeted intervention work aimed at improving
outcomes.
Strengths of this review include systematic research methodol-
ogy consisting of a priori hypotheses and inclusion/ exclusion
criteria, construction of a robust literature search in reputable data-
bases, hand searches and forward citation searches of selected arti-
cles (resulting yield of only 2 additional relevant articles increases
confidence that the 5 highly recognized, highly cited articles selected
represent the current body of literature in this area), and use of 2
independent reviewers with consensus‐based decision making.
Systematic record keeping, data extraction, and analysis; inclusion
of a PRISMA flow diagram; methodological study quality assessment;
and ES calculations to allow for estimates of relationship direction
and magnitude also add strength to this study. A potential limitation
of this review is exclusion of articles not published in English. This
analysis will hopefully spur additional research to understand and
address the psychological needs of this growing population of MPC
survivors. Further research should address the scientific and clinical
need to understand the experiences of the expanding population
of individuals with MPC.
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Shelley Blozis, PhD 
Senior Statistical Editor 
Health Psychology 
American Psychological Association 
750 First St. NE 
Washington, DC  20002-4242 
August 2018 
Dear Dr. Blozis, 
As advances are made in early detection and cancer treatment and the cancer survivor 
population ages, the number of individuals diagnosed with two or more, or multiple, primary 
cancers is also increasing. While data is known regarding risk for and prevalence of second 
order or higher cancer diagnoses, little is known regarding the factors linking MPC to poor 
health outcomes in this population and the sociodemographic and clinical factors that place 
individuals at risk. Previous studies have also lacked theoretical grounding. By testing a 
psychobehavioral stress response model, this study, entitled, “Characterizing Psychobehavioral 
Risks in Survivors of Multiple Primary Cancers,” addresses these gaps. 
This manuscript addresses a critical cancer survivorship research gap by identifying key 
pathways associated with health outcomes in a growing yet understudied cancer survivorship 
population. We also identify individual characteristics associated with these pathways to guide 
early identification of at risk survivors and provide guidance for advancing the science, clinical 
care, and policies related to patients with MPC. We believe that this manuscript is a valuable 
addition to the scientific literature and would fit well within the scope of Health Psychology. This 
manuscript addresses current research gaps, provides data on concepts and challenges for 
future study, and is applicable to a wide variety of researchers and clinicians alike, providing 
insight into the unique needs of people in the growing population of multiple primary cancer 
survivors. 
We have followed Health Psychology’s Instructions for Authors. All authors have read and 
approved the manuscript. This manuscript is part of the first author’s dissertation research 
study. It is not under review elsewhere, nor does it contain data that are under review or 
published elsewhere, aside from the aforementioned dissertation documents. Please feel free to 
contact me with any questions regarding this submission. 
Sincerely, 
Sarah Belcher, BSN, RN, OCNÒ 
Doctoral Candidate 
Robert Wood Johnson Foundation Future of Nursing Scholar 
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